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General introduction and outline of the thesis
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Cancer is one of the leading causes of death in developed countries, responsible for 
about 25% of all deaths. On a yearly basis, 0.5% of the population is diagnosed with 
cancer. Treatment options include surgery, radiotherapy and systemic therapies such 
as chemotherapy, endocrine therapy and targeted agents. These targeted anti cancer 
therapies include monoclonal antibodies and small molecules, for example tyrosine ki-
nase inhibitors.
 Conventional chemotherapeutical agents act by creating toxic effects on all dividing 
cells. This frequently results in in severe damage of normal tissues leading to side effects 
like myelosuppression, alopecia, and gastrointestinal problems. The optimum goal is to 
find a treatment modality that specifically kills malignant cells and causes little or no side 
effects. 
 This thesis focuses on targeted anticancer agents. An important class of these agents 
are the tyrosine kinase inhibitors (TKIs). One of the first steps in TKI treatment develop-
ment is defining whether a specific type of cancer, for example the sarcomas in chap-
ter 3 of this thesis, express the receptors that are targeted. Once a TKI is developed, 
phase I studies are conducted to characterize the safety and side effects of the drug 
when administered to patients. When relevant side effects emerge, studies investigating 
the underlying mechanisms leading to these side effects are called for. Also pharmaco-
genetic studies can be performed to investigate whether certain heritable genetic varia-
tions influence efficacy or safety of the drug. After the phase I studies have proven the 
drug to be safe, the drug can be further developed. This includes the investigation of the 
TKI when combined with other anticancer agents. Items of all the described steps in TKI 
development are described in this thesis.
In Chapter 2, recent developments of small molecule TKIs in the treatment of solid 
tumors are reviewed. These therapies were developed to target key elements that play 
a role in tumor development and tumor growth. Hormonal therapy in breast cancer is 
probably the oldest targeted therapy known in oncology. A more recent discovery is 
the class of drugs designated as tyrosine kinase inhibitors, developed to block intracel-
lular signaling pathways in tumor cells, leading to dysregulation of key cell functions 
such as proliferation and differentiation. 
 In this chapter the following TKIs are reviewed: imatinib (Gleevec®/Glivec®), gefi-
tinib (Iressa®), erlotinib (OSI-774, Tarceva®), lapatinib (GW-572016, Tykerb®, Tyverb®), 
canertinib (CI-1033), sunitinib (SU 11248, Sutent®), vandetanib (ZD6474, Zactima®), 
vatalanib (PTK787/ZK 222584), sorafenib (Bay 43-9006, Nexavar®), and Leflunomide 
(SU101, Arava®). Clinical studies with these new targeted agents in a wide range of 
tumor types and their future role in anticancer treatment is discussed. 
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Overexpression of the epidermal growth factor receptors EGFR and ERBB2 (Her2neu) is 
a negative prognostic factor in a variety of malignancies, including breast cancer, ovar-
ian cancer, and lung cancer. These receptors constitute interesting drug targets. Indeed, 
drugs such as erlotinib, cetuximab and trastuzumab were developed specifically to in-
hibit these targets. In various subtypes of sarcomas, EGFR and ERBB2 overexpression has 
been reported and therefore drugs targeting these receptors may potentially be useful 
in the treatment of sarcomas. This is important because most sarcomas are relatively 
resistant to chemotherapy and novel treatments are urgently called for. Therefore, in 
Chapter 3 we describe the construction of a tissue micro-array with 18 different types 
of soft tissue tumors to evaluate EGFR and ERBB2 expression. 
The development and registration of new small molecule kinase inhibitors is proceed-
ing remarkably fast. In this thesis, 2 phase I studies of new agents and 1 combination 
study of a new agent with a registered agent are described. The main objective of 
these studies is to evaluate the safety and tolerability of the new drug, with additional 
pharmacokinetic, pharmacodynamic and efficacy assessments. In Chapter 4, a phase I 
dose escalation study of telatinib (BAY 57-9352), a tyrosine kinase inhibitor of VEGFR-2, 
VEGFR-3, PDGFR-β and c-Kit, in patients with advanced or metastatic solid tumors is 
discussed. In Chapter 9, a phase I pharmacokinetic and pharmacodynamic study of 
the aurora kinase inhibitor danusertib (PHA-739358) in similar patients is discussed. 
In Chapter 8 the use of a targeted agent in combination with a conventional chemo-
therapeutic drug is investigated. This study aims at enhancing the efficacy of the com-
bination compared to monotherapy with each of these drugs, without causing more 
toxicity. In this phase I dose escalation study, treatment with sunitinib in combination 
with ifosfamide is studied. 
With the development of new drugs new side effects may emerge. Vascular endothelial 
growth factor (VEGF) inhibitors induce hypertension as a common side effect. The 
mechanisms leading to the increase in blood pressure during this anti-angiogenic 
therapy are not clear. We hypothesized that systemic inhibition of VEGF impairs vascular 
function and causes rarefaction, which then leads to the development of hypertension 
in patients treated with anti-angiogenic agents. Functional rarefaction (a decrease in 
perfused microvessels) or anatomic rarefaction (a reduction in capillary density) may be 
the underlying mechanism.
 We performed blood pressure and vascular structure and function studies in patients 
treated with VEGF inhibitors in order to clarify the mechanism by which small molecule 
angiogenesis inhibitors cause an increase in blood pressure. In Chapter 6 the blood 
pressure and vascular studies during treatment with telatinib, a small molecule VEGF in-
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hibitor, are described. In Chapter 7, the underlying mechanisms of hypertension related 
to bevacizumab (Avastin®), a VEGF antibody, are investigated.
Many studies have been performed to individualize anticancer drug treatment aiming 
at decreasing side effects or optimizing efficacy. Pharmacogenomics is a very exciting 
and new field of today’s medicine, promising a personalized, tailor-made medication 
strategy to improve drug response and decrease harmful adverse reactions. Pharma-
cogenomics, often used synonymously with pharmacogenetics, is defined as: ’the indi-
vidualization of drug therapy through medication selection or dose adjustment based 
upon direct (e.g., genotyping) or indirect (e.g., phenotyping) assessment of a person’s 
genetic constitution for drug response.’ 
The development of tailor-made pharmaceutics is especially useful in the field of oncol-
ogy, since most anticancer agents have a very narrow therapeutic index. This sometimes 
leads to lack of any anti-tumor response or a high level of side effects. Heritable genetic 
variations (germline polymorphisms) in genes encoding for drug transporters, drug me-
tabolizing enzymes or drug targets have been shown to influence the pharmacokinetics 
and pharmacodynamics of many drugs including drugs used in cancer therapy. There 
is a rapid development in the field of targeted anti-cancer agents, whereas the neces-
sary accompanying pharmacogenetic research during drug development is lacking. It is 
important to conduct these studies for new anticancer agents to increase knowledge of 
variants in genes encoding for both drug metabolizing enzymes and drug targets, and 
to understand interindividual variability in pharmacokinetics and pharmacodynamics. 
Ultimately, this may lead to a better, tailor-made anticancer therapy with less side effects 
and more effective use of novel drugs in the future. 
In Chapter 5 the pharmacogenetics of telatinib (BAY 57-9352), a tyrosine kinase in-
hibitor of VEGFR-2, and VEGFR-3, used in patients with advanced or metastatic solid tu-
mors is studied. Chapter 10 describes the pharmacogenetic investigations of danusertib 
(PHA-739358), a small-molecule pan-aurora kinase inhibitor, used in similar patients.
A general discussion of the reported studies described in this thesis is presented in Chap-
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Small molecule tyrosine kinase inhibitors (TKIs) are developed to block intracellular sig-
naling pathways in tumor cells, leading to deregulation of key cell functions such as pro-
liferation and differentiation. Over 25 years ago, tyrosine kinases were found to function 
as oncogenes in animal carcinogenesis; however, only recently TKIs were introduced as 
anti cancer drugs in human cancer treatment. Tyrosine kinase inhibitors have numer-
ous good qualities. First, in many tumor types they tend to stabilize tumor progression 
and may create a chronic disease state which is no longer immediately life threatening. 
Second, side effects are minimal when compared to conventional chemotherapeutic 
agents. Third, synergistic effects are seen in vitro when TKIs are combined with radio-
therapy and/or conventional chemotherapeutic agents. In this article, we will give an 
update of the tyrosine kinase inhibitors that are currently registered for use or in an ad-
vanced stage of development, and we will discuss the future role of TKIs in the treatment 
of solid tumors. The following TKIs are reviewed: Imatinib (Gleevec®/Glivec®), Gefitinib 
(Iressa®), Erlotinib (OSI-774, Tarceva®), Lapatinib (GW-572016, Tykerb®), Canertinib (CI-
1033), Sunitinib (SU 11248, Sutent®), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), 
Sorafenib (Bay 43-9006, Nexavar®), and Leflunomide (SU101, Arava®). 
Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update 
15
Introduction
Conventional chemotherapeutical agents act by creating toxic effects on all dividing 
cells, frequently resulting in severe damage of normal tissues leading to side efects like 
myelosuppression, alopecia, or gastrointestinal problems. The optimum goal is to find 
a treatment modality that specifically kills malignant cells and causes little or no side 
efects. Targeted therapies were developed to target key ele ments that play a role in 
tumor development and tumor growth, with hormonal therapy in breast cancer being 
the oldest targeted therapy known in oncology. A more recent discovery are the tyrosine 
kinase inhibitors, developed to block intracellular signaling pathways in tumor cells, 
leading to dereg ulation of key cell functions such as proliferation and diferentiation. 
Over 25 years ago, tyrosine kinases were found to function as oncogenes in animal car-
cinogenesis. However, only recently, tyrosine kinase inhibitors were introduced as anti 
cancer drugs in human cancer treatment.1–3 
 Tyrosine kinases (TKs) are enzymes that catalyze the phosphorylation of tyrosine resi-
dues. There are two main classes of TKs: receptor TKs and cellular TKs. Receptor TKs have 
an extracellular ligand binding domain, a transmembrane domain, and an intracellular 
catalytic domain. The kinase is activated by binding of a ligand (mostly growth factors) 
to the extracellular domain, leading to dimerization of the receptors and autophosphor-
ylation of the tyrosine residues of the intracellular catalytic domain. This results in an 
active receptor conformation and acti vation of signal transduction within the cell. Cel-
lular TKs are located in the cytoplasm, nucleus, or at the intracellular side of the plasma 
membrane. Tyrosine kinases are involved in cellular signaling pathways and regulate key 
cell functions such as proliferation, diferentiation, anti-apoptotic signaling, and neurite 
outgrowth (Fig. 1).4 
 Unregulated activation of TKs, through mecha nisms such as point mutations or over-
expression, can lead to various forms of cancer as well as benign proliferative condi-
tions.5 These findings lead to the hypothesis that inhibitors of TKs could have antitu mor 
effects, and many tyrosine kinase inhibitors (TKIs) were subsequently developed.1,5 To-
day, there are two main mechanisms to block the activation of a tyrosine kinase. First, 
the TKI can block the ATP-binding side and prohibit the autophosphorylation of the 
tyrosine residues, and therefore prohibit the activation of the intracellular signal-trans-
duction pathways. These drugs are usually referred to as small molecule tyrosine kinase 
inhibitors. Second, a monoclonal antibody can occupy the extracellular ligand domain 
of the receptor tyrosine kinase and prohibit binding of the actual ligand and, therefore, 
prohibit activation of the intracellular signal-trans duction pathways. 
 In this article, we will focus on the small molecule tyrosine kinase inhibitors. The 
development and registration of new small molecule tyrosine kinase inhibitors is pro-
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ceeding remarkably fast. Therefore, frequent new updates of small molecule tyrosine 
ki nase inhibitors are very relevant for physicians treating cancer patients. In this article, 
we will give an update of the tyrosine kinase inhibitors that are currently registered for 
use or in an advanced stage of development, and we will discuss the future role of TKIs 
in the treatment of solid tumors. 
c-KIT Tyrosine Kinase Inhibitors
Imatinib (STI-571, Gleevec® (in US), Glivec® (in Europe)) 
Imatinib is a small molecule that reversibly com petes with ATP for binding to the kinase 
domain of the c-KIT, c-Abl, and platelet-derived growth factor receptor-β (PDGFR-β) ty-




Figure 1:  Tyrosine kinase activation and the MAPK/Erk intracellular signaling pathway; 
mechanism of action of tyrosine kinase inhibitors (TKIs). The MAPK/Erk intracellular 
signaling pathway is an example of one of the pathways that can be activated by binding of a 
ligand (mostly growth factors) to the receptor tyrosine kinase. ATP binds to the tyrosine 
kinase and auto-phosphorylation takes place, resulting in activation of the MAPK/Erk 
intracellular signaling pathway. An activated Erk dimer can translocate to the nucleus where it 
phosphorylates a variety of transcription factors regulating gene expression.  
Tyrosine kinase inhibitors block the ATP-binding side of the tyrosine kinase and therefore 
inhibit the activation of the intracellular signaling pathway, resulting in blockage of protein 
synthesis necessary for proliferation and differentiation of the tumor cell. 
FIG. 1. Tyrosine kinase activation and the MAPK/Erk intracellular signaling pathway; mechanism of 
action of tyrosine kinase inhibitors (TKIs). The MAPK/Erk intracell ular signaling pathway is an exam-
ple of one of the pathways that can be activated by binding of a ligand (mostly growth factors) to 
the receptor tyrosine kinase. ATP binds to the tyrosine kinase and auto-phosphorylation takes place, 
resulting in activation of the MAPK/Erk intracellular signaling pathway. An activated Erk dimer can 
translocate to the nucleus where it phosphorylates a variety of transcription factors regulating gene 
expres sion. Tyrosine kinase inhibitors block the ATP-binding site of the tyrosine kinase and therefore 
inhibit the activation of the intra cellular signaling pathway, re ulting in blockag  of protein synthe-
sis necessary for proliferation and differentiation of the tumor cells. 
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kinase inhibitor, giving astonishing results in patients with chronic myelogenous leuke-
mia (CML) by inhibiting the phosphorylation of the Bcr-Abl TK, and thereby suppressing 
the prolifera tion of Bcr-Abl expressing leukemic cells. A phase II study was performed 
in approximately 1000 patients with CML, with patients in the chronic phase receiving 
400 mg of imatinib orally a day, and pa tients in accelerated phase or blast crisis receiv-
ing 600 mg/day. Complete hematological responses were seen in 91% of the patients 
in chronic phase CML, 53% of patients in accelerated phase CML, and 26% of pa tients 
in blast crisis. However, in the late-stages dis ease, the efects were short lasting, with a 
recurrence of imatinib-resistant cells within months.6 In this article, we will focus on the 
results in solid tumors. 
 In gastrointestinal stromal tumors (GISTs), imati nib also showed remarkable re-
sults.7,8 Imatinib blocks the c-KIT tyrosine kinase, which is constantly activated in 90% 
of GISTs by a gain-of-function mutation in the c-KIT proto-oncogene.9 Approxi mately 
30–50% of GISTs that harbour no c-KIT mutation do have PDGF mutations, and depend-
ing on the subtype of the PDGF mutation these GISTs are also sensitive to imatinib. The 
highest responses were seen in GISTs with exon 11 mutations and, the more rare, PDGF 
mutations.9,10 Approximately 5–10% of GISTs are negative for both c-KIT and PDGF mu-
tations. In a phase III trial reported in 2004, 946 patients were randomized for treatment 
with 400 mg imatinib once daily or 400 mg twice daily.11 Complete responses were 
seen in 5 vs. 6%, partial responses in 45 vs. 48%, and stable disease in 32 vs. 32% of 
patients. At median follow-up of 760 days, 56% in the group receiving imatinib 400 mg 
once daily showed progression of the disease, com pared with 50% of patients receiving 
400 mg twice daily. Side effects were frequent but mostly mild. Anemia, edema, fatigue, 
nausea, pleuritic pain, diar rhea, granulocytopenia, and rash were the most common side 
effects. These were impressive results for a tumor type that, until recently, was poorly 
af fected by chemo-or radiotherapy and for small molecule TKIs in general. Therefore, 
studies were initiated to explore the role of imatinib in the adju vant setting in high risk 
patients with GISTs. Cur rently, the results of these studies with adjuvant imatinib in high 
and intermediate risk GIST are awaited. Resistance to imatinib in GISTs is a well known 
problem and can be caused by secondary mutations or c-KIT amplification. Therefore, 
other therapies for GISTs are being explored, like sunitinib (see chapter on sunitinib).12 
 Imatinib is also designated as orphan drug for the treatment of dermatofibrosarcoma 
protuberans (DFSP), based on case reports of this rare tumor type, in cases that can 
not be managed with surgery alone.13,14 The cutaneous malignant mesenchymal tumor 
dermatofibrosarcoma protuberans is typically associated with a translocation between 
chromo somes 17 and 22, involving the platelet-derived growth factor-β (PDGF-β) gene, 
forming a ring chromosome. Imatinib inhibits the growth of these tumor cells by inhibit-
ing PDGFR tyrosine kinase. 
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 Imatinib’s activity in advanced aggressive fibro matosis (desmoid tumor) and, to a 
lesser extent, in advanced chordoma may also be based on PDGFR-β inhibition. In a re-
cently published article, 3 out of 19 desmoid patients demonstrated a partial response, 
with 4 additional patients showing stable disease for more than one year.15 In a mul-
ticenter phase II trial, 51 patients with advanced aggressive fibromatosis were treated 
with imatinib 300 mg po BID. At the time of analysis, 45 patients were evaluable. Me-
dian time to treatment failure was 6.8 months. Remark ably, in only 1 of 22 available 
tumor specimens a PDGFR mutation was found.16 In chordoma pa tients, the effect was 
often less clear on CT-scan, but in some cases clearly by subjective improvement of 
complaints.17 Recent clinical studies suggest that there might also be an effect of ima-
tinib in glioblas toma multiforme and malignant gliomas by inhibit ing PDGFR tyrosine 
kinase.18–21 
 Imatinib inhibited growth of small-cell lung cancer (SCLC) cells in vitro by inhibiting 
c-KIT; however, there was no objective tumor response in SCLC pa tients in vivo. This was 
probably caused by the fact that there was no c-KIT mutation detectable in most of the 
patients.22,23 This was also seen in other tumor types, like uterine leiomyosarcomas.24 
EGFR/Her1 and Her2 Tyrosine Kinase Inhibitors 
The Her-family of tyrosine kinases consists of four members: Her1 (Human Epidermal 
Growth Factor Receptor: EGFR, erbB1), Her2 (erbB2), Her3 (erbB3), and Her4 (erbB4). 
After binding of a receptor-specific ligand homodimeric or heterodi meric complexes are 
formed. Her-kinase activation deregulates growth, desensitises cells to apoptotic stim-
uli, and regulates angiogenesis.25 Overexpression of EGFR and Her2 is a factor of poor 
prognosis in a variety of malignancies, including breast cancer, ovarian cancer, and lung 
cancer.26,27 
Gefitinib (Iressa®) 
Gefitinib was the first commercially available EGFR TKI and is now registered for use in 
Asia and the United States in second-or third line therapy for advanced non-small-cell 
lung cancer (NSCLC). Two phase II trials evaluated the efficacy of gefitinib in patients 
with advanced NSCLC: IDEAL (Iressa® Dose Evaluation in Advanced Lung Cancer)-1 and 
IDEAL-2. IDEAL-1 included 210 patients in Europe, Australia, South Africa, and Japan 
who had previ ously received one or two chemotherapy regimens, with at least one con-
taining platinum. IDEAL-2 in cluded 216 patients in the United States who had failed two 
or more prior chemotherapy regimens containing platinum and docetaxel. Patients were 
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randomized for continuous treatment with 250 or 500 mg gefitinib monotherapy once 
daily orally. 
 IDEAL-1 showed that gefitinib dosage of 250 and 500 mg/day were equally efective, 
with an objective tumor response of 18% and 19% respectively.28 The objective tumor 
response rate in IDEAL-2 was 12% in the 250 mg/day gefitinib patients and 9% in the 
500 mg/day patients.29 The difference in response was most likely caused by the worse 
performance status in IDEAL-2, a higher number of previous chemother apy regimens in 
IDEAL-2, and the Japanese origin of a subset of patients in IDEAL-1 (which later be came 
correlated with an higher number of activating mutations in the EGFR gene).30 Overall 
survival was 18.5 (IDEAL-1) and 16.3 (IDEAL-2) months in pa tients with complete or 
partial response, 8.5 and 9.4 months in stable disease, and 3.8 and 4.2 months in pro-
gressive disease. Most reported side effects were cutaneous and gastrointestinal com-
plaints. Since the use of gefitinib became more widespread, a more serious side effect, 
pulmonary fibrosis, was noted in approximately 1% of patients.31,32 The recommended 
dose for use was established at 250 mg/day while this was equally effective and better 
tolerated. 
 In large phase III studies, INTACT-1 and-2, gefi tinib in combination with chemother-
apy in previ ously untreated NSCLC patients did not show improved efficacy over che-
motherapy alone.33,34 A placebo-controlled phase III trial randomizing NSCLC patients in 
second-or third-line treatment for treatment with gefitinib 250 mg/day or placebo plus 
best supportive care also did not show any sur vival benefit.35 
 In the approval of gefitinib, the EGFR status of the tumor was not included in se-
lecting patients for treatment. Patient characteristics that were associated with respon-
siveness to EGFR inhibitors were histo logic features of adenocarcinoma, female sex, no 
history of smoking, and Asian ancestry. The EGFR level in immunohistochemical stain-
ing does not pre dict response to EGFR inhibiting therapies and does not correlate with 
poor survival.36–38 Recent studies reported an activating mutation in the tyrosine kinase 
side of the EGFR gene in NSCLC that seemed pre dictive for response to gefitinib treat-
ment.39–41 For future use of gefitinib, it will be highly important to select those patients 
that are likely to benefit from this EGFR-TKI, while non-selection is probably the main 
cause of the disappointing results of gefitinib. 
 Phase II studies with gefitinib monotherapy or combination therapy have been con-
ducted in many tumor types, including esophageal carcinoma, meta static breast cancer, 
prostate cancer, head and neck cancer, colorectal cancer, renal cell carcinoma, and ovar-
ian carcinoma.42–53 In EGFR expressing colo rectal cancer (CRC), the monoclonal antibody 
ce tuximab has been proven active.54,55 Therefore, beneficial effects of EGFR TKIs were 
expected. However, recent trials showed no effect of gefitinib in CRC patients. Of the 
115 gefitinib treated patients, only one patient obtained a partial response, pro gression 
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free survival was 1.9 months, and median survival 6.3 months. No significant changes 
in bio logical indicator of EGFR pathway activation were detected.52 However, a second 
phase II trial reported partial responses in 78% of patients treated with gefitinib in com-
bination with fluorouracil and oxa liplatin (FOLFOX-4).56 Many trials with gefitinib for 
various tumor types are still ongoing. 
Erlotinib (OSI-774, Tarceva®) 
Erlotinib is an EGFR TKI with proven efficacy in monotherapy phase II trials in NSCLC, 
ovarian cancer, pancreatic cancer, head and neck squamous cell cancer, and primary 
glioblastoma.57–59 
 A survival benefit of erlotinib compared with best supportive care was reported in 
previously treated NSCLC patients.60 Patients with stage IIIB or IV NSCLC were randomly 
assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo. 
The response rate was 8.9 percent in the erlotinib group and less than 1 percent in the 
placebo group. Progression-free survival was 2.2 months and 1.8 months, respectively. 
In contrast to the trial with gefitinib,35 the study comparing erlotinib with best sup-
portive care60 did show improved survival for erlotinib treated patients. The trials were 
similarly designed; however, the strict inclusion criterion describing refractory disease in 
the gefitinib trial may have resulted in a different patient population. After the publica-
tion of these trials, clinicians favored the use of erlotinib over gefitinib. However, a trial 
di rectly comparing the two drugs was never started. 
 In phase III trials (TALENT and TRIBUTE) in NSCLC patients, there was no additional 
benefit of erlotinib in combination with chemotherapy, com pared to chemotherapy 
alone.61,62 Erlotinib is regis tered for the second-and third-line treatment of patients with 
advanced NSCLC after failure of at least one prior platinum treatment. 
 Since late 2005, erlotinib is also registered for ad vanced pancreatic cancer. A Phase III 
trial in 569 chemotherapy-naıve patients with advanced pancre atic cancer reported an 
improval in 1-year survival from 17% to 24% when erlotinib 100 mg daily was added 
to gemcitabine 1000 mg/m2/week, compared to gemcitabine alone.63 Median over-
all survival in creased from 5.9 months to 6.4 months. EGFR status was not an entry 
criterion; however, tumor samples are being evaluated for EGFR expression by immu-
nohistochemistry. Current studies in pancreatic cancer patients focus on combination 
with chemo therapy, radiotherapy, and other targeted therapies, or on maintenance 
therapy of erlotinib. 
 A phase II study of erlotinib in patients with ad vanced biliary cancer showed a po-
tentially beneficial efect of erlotinib. Progression free survival at 6 months was 17% 
and partial responses were seen in 3 of 42 patients.64 Earlier, the same author reported 
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a phase II study of erlotinib in hepatocellular cancer patients. Progression free survival 
at 6 months was 32%, and partial responses were seen in 3 of 38 pa tients.65 Phase II 
trials in metastatic colorectal car cinoma patients with erlotinib alone or in combina-
tion with chemotherapy showed promising results.66,67 Erlotinib 150 mg orally daily, in 
combi nation with bevacizumab 10 mg/kg intravenously every 2 weeks, was evaluated 
in 63 patients with metastatic clear-cell renal carcinoma, which resulted in a median 
survival of 11 months and 1-year pro-gression-free survival of 43%. Treatment was well 
tolerated; skin rash and diarrhea were the most fre quent treatment-related toxicities.68 
 The most frequent reported adverse events in erl otinib treatment are skin rash and 
diarrhea. The incidence of interstitial lung disease in patients receiving erlotinib was 
equal to that in gefitinib, approximately 1%.69,70
Lapatinib (GW-572016, Tykerb®) 
Lapatinib is an EGFR and Her2 tyrosine kinase inhibitor.71 Phase I studies in trastuzumab 
refractory breast cancer and NSCLC demonstrated clear tumor responses.72 In a phase II 
study in 86 patients with metastatic colorectal cancer, effects of lapatinib were minor, 
with 1 partial response, 5 minor responses, and 5 patients with stable disease.73 Re-
ported adverse events were diarrhea and skin rash. 
 An international, multicenter, randomized, open-label phase III trial in patients with 
documented HER2 overexpressing refractory advanced or meta static breast cancer 
treated with lapatinib in combi nation with capecitabine versus capecitabine alone was 
recently stopped after the interim analysis. At the time of interim analysis, 392 patients 
had been en rolled in the study, of which 321 were included in the analysis (161 in the 
combination arm and 160 in the monotherapy arm). Median time to progression in the 
combination arm was 8.5 months, compared with 4.5 months in the capecitabine alone 
arm.74 The addition of lapatinib to capecitabine resulted in such a striking increase in 
time to progression that this combination will probably be used by clinicians as standard 
of care in patients with advanced HER2 positive breast cancer that failed on trastuzumab. 
However lapatinib is not yet registered for use in this, or any, indication. 
 In a phase III trial, patients with advanced renal cell carcinoma (RCC) who failed 
prior cytokine therapy were randomized to receive oral lapatinib 1250 mg OD or hor-
mone therapy. At the time of the analysis, 417 patients were randomized. In the gen eral 
study-population, median time to progression and median overall survival did not difer 
between the two groups. In the EGFR overexpressing patients, median time to progres-
sion was 15.1 months in the lapatinib treated patients, vs. 10.9 weeks in the hor mone 
therapy treated patients. The reported median overall survival was 46.0 vs. 37.9 weeks.75 
 Phase II results on the use of lapatinib in breast cancer patients with brain metasta-
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ses, locally ad vanced squamous cell carcinoma of the head and neck, biliary carcinoma, 
and hepatocellular carci noma have recently been reported at the 2006 ASCO Annual 
Meeting (http://www.asco.org). 
Canertinib (CI-1033) 
Canertinib is a tyrosine kinase inhibitor that non-selectively inhibits all members of the 
Her-family. This might result in a broader spectrum of anti tumor activity. In phase I 
studies, reported adverse events were diarrhea, rash, anorexia.76 In a phase II study in 
patients with platinum-refractory or recurrent ovar ian cancer, canertinib did not show 
activity in unscreened patients.77 Studies in breast cancer and NSCLC are currently 
ongoing. 
Vascular Endothelial Growth Factor Tyrosine Kinase 
Inhibitors 
The Vascular Endothelial Growth Factor (VEGF) family belongs to the platelet-derived 
growth factor (PDGF) superfamily and consists of VEGF-A, -B, -C, -D, -E, and the pla-
centa growth factor (PIGF). VEGF-A (normally referred to as VEGF) is the most potent 
endothelial growth factor. It contributes to tumor angiogenesis and presumably to tu-
mor growth and haematogenous spread of tumor cells.78 More over, VEGF-A protects 
endothelial cells from apop tosis and contributes to the maintenance of the vascular 
system.79,80 
 Most of the VEGF Receptor (VEGFR) kinase inhibitors under investigation inhibited 
multiple kin ases not involved in angiogenesis, resulting in diverse side efects. New 
VEGFR kinase inhibitors are being developed to selectively target a small subset of pro-
tein kinases, and therefore minimalize the side-efects. 
Sunitinib (SU 11248, Sutent®) 
Sunitinib is an orally available inhibitor of VEGFR, PDGFR, c-KIT, and FLT-3 kinase activ-
ity. In a phase II study in patients with immunotherapy refractory metastatic renal cell 
carcinoma treated with sunitinib (6-week cycles: 50 mg orally once daily for 4 weeks, 
followed by 2 weeks of), 40% of patient showed a partial response and 27% stable dis-
ease.81 When the results were combined with a second study with an identical patient 
population, the total evalu able patient population was 168 patients. Objective respons-
es were seen in 42% and stable disease of 3 or more months in 24%. Median progression 
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free sur vival was 8.2 months.82 These response rates were much higher than seen with 
any other systemic treatment in RCC. The main adverse effects were fatigue, diarrhea, 
nausea, dyspepsia, stomatitis, and bone marrow abnormalities. Motzer reported the re-
sults of a phase III study comparing sunitinib (6-week cycles: 50 mg orally once daily for 
4 weeks, followed by 2 weeks off) to IFN-a (6-week cycles: subcutaneous injection 9 MU 
given three times weekly) as first line therapy for metastatic renal cell cancer patients. 
There was a statistically significant improvement in median progression free survival 
(47.3 vs. 24.9 weeks) and objective response rate (24.8% vs. 4.9%) for sunitinib over IFN-
a.83 Sunitinib might therefore now be considered the new standard first-line treatment 
for advanced kidney cancer. 
 In January 2006, sunitinib was not only approved by the FDA for advanced renal cell 
carcinoma, but also for imatinib-resistant and imatinib-intolerant GIST. This was based 
on the early results of a phase III trial in patients with documented progression of GIST 
on imatinib.84,85 Patients were treated with a starting dose of 50 mg sunitinib once daily 
for four weeks, followed by 2 weeks off treatment, in repeti tive 6-week cycles (N = 207) 
or placebo (N = 105). Due to the positive results found at a planned interim analysis, 
the trial was unblinded and all patients started treatment with sunitinib. Partial response 
was seen in 6.8% of sunitinib treated patients, compared to 0% in the placebo group. 
Stable disease for more than 22 weeks occurred in 17.4%, compared to 1.9%. Time to 
progression was significantly longer in the sunitinib treated patients, 27.3 weeks com-
pared to 6.4 weeks. The most common non-hematological adverse events were fatigue, 
diarrhea, nausea, sore mouth, and skin discoloration. 
 From a biological point of view, continuous dosing of sunitinib seems more logical. A 
study in 28 patients with advanced imatinib-resistant GIST explored the continuous daily 
37.5 mg dosing regi men, which was feasible and associated with similar tolerability as 
is seen with intermittent sunitinib dosing.86 
 Sunitinib showed a potentially beneficial efect in previously treated advanced NSCLC 
and unresec table neuroendocrine tumors in phase II studies.87,88 
Zactima (ZD6474) 
Zactima is an orally available, small molecule, dual VEGF receptor-2 (VEGFR-2) and EGFR 
tyrosine kinase inhibitor. Zactima has the potential to directly inhibit tumor cell prolif-
eration and survival by blocking EGFR and inhibit tumor angiogenesis by blocking VEGF 
activity. Zactima inhibits VEGF signaling and angiogenesis in vivo and shows broad-spec-
trum antitumor activity in a range of histologi cally diverse tumor xenograft models.89 
In phase I trials, dose limiting toxicities were diarrhea, hyper tension, thrombocytopenia, 
and prolongation of the cardiac QT interval. Phase II assessment of zactima is now in 
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progress in a variety of tumor types in single and combination regimens.90,91 In early 
reports of two phase II studies of zactima in combination with docetaxel or carboplatin 
and paclitaxel for NSCLC, zactima did not significantly increase toxicity com pared to che-
motherapy alone.92 In the study reported by Heymach, patients with locally advanced or 
met astatic (stage IIIB/IV) NSCLC after failure of first-line platinum-based chemotherapy 
were randomized to treatment with zactima 100 mg orally once daily plus docetaxel 
(75 mg/m2 i.v. infusion every 21 days) (N = 42), zactima 300 mg orally once daily plus 
docetaxel (N = 44), or docetaxel alone (N = 41). Median progression free survival was 
higher in the combination therapy treated groups (19 vs. 17 vs. 12 weeks respective-
ly).93 This resulted in the initiation of a phase III evaluation of zactima plus docetaxel in 
second-line NSCLC. 
 In a double-blind, randomized phase II trial, 168 patients with NSCLC were random-
ized for initial treatment with zactima 300 mg or gefitinib 250 mg. Zactima demon-
strated a significant prolongation of progression free survival versus gefitinib (11.0 vs. 
8.1 weeks). Overall survival was not significantly difer ent (median 6.1 and 7.4 months, 
respectively).94 
 Zactima shows also promising evidence of clinical activity in patients with hereditary 
medullary thyroid carcinoma. Of 15 evaluable patients, 3 had partial responses and 10 
stable disease.95 
Vatalanib (PTK787/ZK 222584 (PTK/ZK)) 
Vatalanib is an oral inhibitor of a number of kin ases including VEGFR-1 and VEGFR-2 
as well as the platelet-derived growth factor receptor (PDGF R). It clearly demonstrated 
an anti-tumor efect in several solid tumor types. Adverse events were lightheadedness, 
fatigue, transaminase elevation, hypertension, nausea, and vomiting.96 Dynamic 
contrast-enhanced molecular resonance imaging (DCE-MRI) in patients with advanced 
colorectal carcinoma and liver metastases showed a vatalanib dose-dependent 
reduction of vascular permeability and blood flow in the liver metastases.97 A phase III 
study (CONFIRM-1, Colorectal Oral Novel Therapy for the Inhibition of Angiogenesis and 
Retarding of Metastases in First-line) showed no beneficial effects of adding vatalanib to 
chemotherapy (oxaliplatin/5 fluorouracil/leucovorin (FOLFOX4)) in metastatic colorectal 
cancer patients.98 A second phase III study in 855 pretreated patients with metastatic 
colorectal carcinoma (CONFIRM-2, Colorectal Oral Novel Therapy for the Inhibition of 
Angiogenesis and Retarding of Metastases in Second-line) demon strated a significant 
improvement in progression free survival when vatalanib 1250 mg qd was added to 
FOLFOX. Overall survival was the same in both treatment arms.99 Combination and 
monotherapy trials are currently also conducted in other tumor types. 
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Sorafenib (Bay 43-9006, Nexavar®) 
Sorafenib is a novel oral Raf-1 kinase, platelet-de rived growth factor receptor (PDGFR) 
and VEGFR kinase inhibitor with antitumor efects in colon, pan creas and breast cancer 
cell lines and in colon, breast and non-small-cell lung cancer xenograft models.100 A 
phase I study in 69 patients with refractory solid tumors reported promising results.101 
Dose limiting toxicities were hematological toxicity, diarrhea, fati gue, hypertension, and 
skin rash. In a recent phase II randomized discontinuation trial in patients with meta-
static renal cell carcinoma, sorafenib showed anti-tumor activity and was well tolerat-
ed.102,103 An interim analysis of a phase III trial randomizing 769 patients with advanced 
RCC to sorafenib 400 mg bid or placebo reported an improvement of progression free 
survival from 12 weeks to 24 weeks in sorafenib treated patients compared to pla-
cebo.104 Updated results reported at the ASCO 2006 meeting showed a survival benefit 
for sorafenib over placebo (median overall survival of 19.3 months vs. 15.9 months).105 
Sorafenib was granted FDA fast track approval in December 2005. 
 Phase III trials in stage III or IV melanoma and in advanced hepatocellular carcinoma, 
and phase II trials in multiple tumor types are currently ongoing. 
 It has previously been suggested that rash com monly associated with EGF-pathway 
inhibitors could be predictive of treatment outcome, and that the onset of rash could 
be used for optimal dose titra tion.106 This might also be effective in treatment with 
sorafenib, as it is an inhibitor of Raf kinase, which is a downstream effector molecule 
of the EGFR sig naling pathway. A recent report combining data from four phase I trials 
supported this hypothesis. Patients receiving sorafenib dosed at or close to the recom-
mended dose of 400 mg bid, and experiencing skin toxicity and/or diarrhea, had a 
significantly increased time to progression compared with patients without such toxic-
ity.107 Blood pressure has also been re ported as a possible biomarker in patients treated 
with sorafenib and other VEGF inhibitors.108,109 
Platelet-Derived Growth Factor Tyrosine Kinase 
Inhibitors 
Platelet-derived growth factor (PDGF) and its tyrosine kinase receptor (PDGFR) have been 
impli cated in the pathogenesis of a number of tumor types and play an important role 
in various cellular func tions, including growth, proliferation, diferentiation, and angio-
genesis.110 Multiple PDGFR kinase inhib itors have been evaluated in human solid tu-
mors; many are not specific for PDGF and act on a number of tyrosine kinase receptors. 




Leflunomide (SU101, Arava®) 
Leflunomide is a small molecule inhibitor of the PDGFR tyrosine kinase and partially 
inhibits EGFR and the fibroblast growth factor receptor (FGFR). Leflunomide is an im-
munomodulatory agent that is indicated in adults for treatment of active rheumatoid 
arthritis. It has demonstrated broad-spectrum anti tumor activity in preclinical studies. A 
multicenter phase II study in hormone refractory prostate cancer patients treated with 
leflunomide showed partial re sponses in 1 of 19 patients, a prostate-specific antigen de-
cline greater than 50% in 3 of 39 patients, and improvement in pain in nine of 35 evalu-
able patients. The patients received a 4-day i.v. loading dose of SU101 at 400 mg/m2 
for 4 consecutive days, followed by 10 weekly infusions at 400 mg/m2. Despite the 
detection of PDGFR overexpression in 80% of the metastases and 88% of the primary 
tumors, these were disappointing results.112 The most frequently reported side effects 
with leflunomide were asthenia, nausea, anorexia, and anemia. 
 A phase III randomized study of leflunomide ver sus procarbazine for patients 
with glioblastoma multiforme in first relapse, and a phase II/III ran domized study of 
leflunomide with mitoxantrone and prednisone versus mitoxantrone and prednisone 
alone in patients with hormone refractory prostate cancer have just finished recruiting. 
Results have not yet been reported. 
Tyrosine Kinases As A Target: Success Or Failure? 
Imatinib (Gleevec®/Glivec®) was the first small mol ecule TKI that was successfully devel-
oped. The re sults of imatinib in GIST, a tumor that is poorly afected by chemotherapy and 
radiotherapy, were astonishing and lead to a boost in research of small molecule tyrosine ki-
nase inhibitors in solid tumors. The results of these investigations in other solid tu mors were 
not as astonishing, although substantial efects were seen in many diferent tumor types. 
 There are multiple reasons for this more modest efect in other solid tumors. First, most 
tumor cells harbor multiple genetic defects, and inhibiting one tyrosine kinase might not 
be sufficient. Second, inhibiting tyrosine kinases leads to a stop in cell division, and lack of 
further growth is therefore the maximum achieved goal. Third, inhibiting an intra cellular 
signaling pathway by a TKI can be overcome by tumor cells by redirecting the signals 
through other pathways. Fourth, tumor cells can become resistant to TKIs, mostly due to 
new mutations in the tyrosine kinase, drug efflux mechanisms, receptor down-regulation, 
and loss of TK-inhibitory path ways. 
 However, TKIs do have numerous good qualities. First, in many tumor types, they tend 
to stabilize tumor progression and may create a chronic disease state which is no longer 
immediately life threatening. Second, side efects are minimal when compared to con-
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ventional chemotherapeutic agents. Third, syner gistic efects are seen in vitro when TKIs 
are com bined with radiotherapy and/or conventional chemotherapeutic agents.113–117 If 
studies in vivo confirm these results, one should consider studying the effects of reducing 
chemotherapy dose, which might lead to fewer side effects with equal efficacy. One of the 
mechanisms of synergy between these drugs and chemotherapy is the increase of drug 
up take due to decrease of interstitial fluid pressure by PDGF inhibition.1–3 
 The TKIs that are currently registered or in ad vanced stages of clinical development are 
shown in Table 1. 
Future directions
The identification of patients who are likely to benefit from inhibition of specific tyro-
sine kinases will become highly important. An important issue is the high costs of small 
Table 1.  Tyrosine kinase inhibitors: currently registered or in clinical development for 
solid tumors 
Agent Target receptors Development stage
Imatinib (STI-571, Gleevec®) c-Abl, PDGFR-b, c-KIT Licensed for GIST, (CML) Orphan 
drug request for DFSP
Gefitinib (Iressa®) EGFR Licensed for 2d- or 3rd line NSCLC 
(Asia, United States)
Erlotinib (OSI-774, Tarceva®) EGFR Licensed for 2d- or 3rd line NSCLC, 
advanced pancreatic cancer
Lapatinib (GW-572016, Tykerb®) EGFR, Her-2 Phase I/II/III
Canertinib (CI-1033) EGFR, Her-2, Her-3, Her4 Phase I/II
Sunitinib (SU11248, Sutent®) PDGFR, VEGFR, KIT, FLT-3 Licensed for advanced RCC, and 
imatinib-resistant/-intolerant GIST
Zactima (ZD6474) VEGFR, EGFR Phase I/II/III
Vatalanib (PTK787) VEGFR, PDGFR, C-KIT Phase II/III (colorectal carcinoma)
Sorafenib (BAY43-9006, Nexavar®) c-Raf-1, B-Raf, VEGFR, 
PDGFR
Licensed for advanced RCC, Phase 
II/III (melanoma, HCC)
Leflunomide (SU101, Arava®) PDGFR (EGFR, FGFR) Phase II/III (prostate cancer, GBM)
PDGFR: platelet-derived growth factor receptor, GIST: gastrointestinal stromal cell tumor, CML: 
chronic myelogenous leukemia, DFSP: dermatofibrosarcoma protuberans, EGFR: epidermal growth 
factor receptor, NSCLC: non-small-cell lung cancer, VEGFR: vascular endothelial growth factor re-
ceptor, RCC: renal cell carcinoma, HCC: hepatocellular carcinoma, FGFR: fibroblast growth factor 
receptor, GBM: glioblastoma multiforme
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molecule tyrosine kinase inhibi tors, up to $30,000 per patient per year.1 Patients should 
be selected based on genetics of their cancer cells, as is proven to be effective in NSCLC 
patients, where only patients with a mutation in the EGFR receptor showed a favorable 
response to gefitinib. 
 Alterations should be made to the conventional phases of drug-development. Maxi-
mum tolerated dose (MTD) can no longer be the only end-point in phase I studies, since 
TKIs have limited side efects and MTD might never be reached. Instead, phase I studies 
should aim at identifying the maximum bio logical active dose, i.e. the dose that creates 
the maximum target inhibition. In phase III studies, selection of the study population 
should be made based on biogenetics of the tumor, and investigations should also in-
clude pharmacodynamic analysis of target inhibition. In previous large phase III trials in 
unselected patients, TKIs were incorrectly judged to be inefective, and research of an 
efective drug has incorrectly been stopped. Instead of response rate, other endpoints 
should be chosen, like time to pro gression, while with tyrosine kinase inhibitors it might 
take some time before stabilization of the dis ease occurs. 
 Most small molecule tyrosine kinase inhibitors lack substantial benefit when given as 
monotherapy. Therefore combination therapies based on synergy, combining multiple 
small molecule TKIs (like gefiti nib and sunitinib in RCC trials), combining a small mol-
ecule TKI with an antibody TKI (like erlotinib and bevacuzimab in CRC trials, and lapatinib 
and trastuzumab in breast cancer trials), or combining a TKI with conventional chemo-
therapy and/or radio therapy are more likely to be efective. 
 In the near future, preclinical studies will hope fully be able to identify more activated 
tyrosine kinases, as overexpression of a target is not a guarantee for treatment success. 
Molecular markers for toxicity, response and survival, such as the var ious mutations 
in GISTs are needed. Future treat ment regiments are likely to include multiple tyrosine 
kinase inhibitors, based on biogenetics of the tumor cells, in combination with che-
motherapy, radiotherapy, and other anticancer agents. Hope fully, this will improve the 
prognosis of patients with several solid tumors by giving a complete or partial tumor 
response or by creating a chronic stable state in which the disease is no longer immedi-
ately life threatening. 
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Epidermal growth factor receptor (EGFR, Her1) and human epidermal growth factor re-
ceptor 2 (ERBB2, Her2) are members of the Her-family of transmembrane receptor tyro-
sine kinases. In various subtypes of sarcomas EGFR and ERBB2 overexpression has been 
reported. We studied different subtypes of sarcomas for EGFR and ERBB2 expression to 
evaluate possible candidates likely to benefit from EGFR and ERBB2 blocking therapies. 
Methods
A tissue micro-array with 18 different types of soft tissue tumors was constructed, and 
immunohistochemical (IHC) analyzed for EGFR and ERBB2 expression. 
Results
Positive membranous staining for EGFR was seen in various sarcoma subtypes, including 
liposarcomas (3/20), leiomyosarcomas (3/8), synovial sarcomas (4/5), malignant periph-
eral nerve sheath tumors (3/7), rhabdomyosarcomas (2/3), solitary fibrous tumors (1/2), 
and angiosarcomas (1/1). IHC staining for ERBB2 was negative in all subtypes. 
Conclusions
Our results demonstrate that IHC staining for EGFR and ERBB2 shows cytoplasmatic 
staining in many subtypes of sarcomas, and membranous staining for EGFR in multiple 
subtypes of sarcomas. However, the immunohistochemical presence of growth factor 
receptors does not necessarily implicate that the subsequent pathway is activated, or 
is a potential subject to therapy. These results however open the possibility to study 
the effect of EGFR blocking therapies, and confirm previous results that ERBB2 is not a 
potential treatment target.
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Introduction
Sarcomas are rare and complex malignant tumors of mesenchymal origin, with a broad 
histopathologic spectrum.1 Sarcomas represent less than 1% of all malignancies. The over-
all prognosis of sarcomas depends on the possibility of complete surgical removal of the 
tumor, while in general the effects of radiation therapy and chemotherapy are limited. The 
search for new treatment modalities, especially in tumor types resistant to known cancer 
therapies, is focusing on identification and inhibition of molecular targets, such as growth 
factor receptors. Recent research has also focused on the Her-family of tyrosine kinases. 
 Epidermal growth factor receptor (EGFR, Her1) and human epidermal growth factor 
receptor 2 (ERBB2, Her2) are members of the Her-family of transmembrane receptor ty-
rosine kinases. Her-kinase activation deregulates growth, desensitizes cells to apoptotic 
stimuli and regulates angiogenesis. Overexpression of EGFR and ERBB2 is a factor of poor 
prognosis in a variety of malignancies, including breast cancer, ovarian cancer, and lung 
cancer.2,3 Inhibiting EGFR with a tyrosine kinase inhibitor like erlotinib (Tarceva®) in non-
small-cell lung cancer patients, with a monoclonal antibody like cetuximab (Erbitux®) in 
colorectal and head- and neck carcinoma, or blocking ERBB2 with a monoclonal antibody 
like trastuzumab (Herceptin®) in breast cancer patients are approved treatment options 
nowadays. 
 In breast cancer patients a higher level of membranous ERBB2 overexpression is a predic-
tive factor for increased response to treatment with trastuzumab.4 In normal clinical prac-
tice ERBB2 overexpression is classified as negative (0, 1+) or positive (2+, 3+) by immuno-
histochemical (IHC) staining. For EGFR the correlation between the level of EGFR expression 
with IHC staining and response to EGFR blocking therapies is not equally clear, sometimes 
demonstrating activity of EGFR inhibiting therapies in tumors that express low levels of 
EGFR.5,6 Therefore EGFR levels are described as negative (0) and positive (1+, 2+, 3+).
 In various subtypes of sarcomas EGFR and ERBB2 overexpression has been reported, 
however the number of studies are limited and sometimes contradictory.7-18 For a better 
defining of the sarcoma subtypes that are overexpressing EGFR and/or ERBB2 and are 
therefore more likely to benefit from EGFR and/or ERBB2 blocking therapy, a tissue micro-
array, with 19 different types of soft tissue tumors, was evaluated for EGFR and ERBB2 
expression by IHC staining.
Methods
A tissue micro-array (TMA) with 18 different types of soft tissue tumors, was constructed 
at the Department of Pathology of the Leiden University Medical Center, and used for the 
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immunohistochemical (IHC) analyses. Triplicate tissue cores with a diameter of 0.6 mm, 
as selected by two pathologists (SR and PCWH), were taken from each specimen using 
a tissue arrayer (Beecher Instruments, Silver Springs, MD, USA) and arrayed on a recipi-
ent paraffin block, using standard procedures.19 Table 1 shows the tumor types that are 
present on the TMA. All leiomyosarcomas were of deep soft tissue origin. Immunohisto-
chemical staining was performed on 5 µm sections of the tissue array, using a paraffin 
sectioning aid system (Instrumedics Inc, Hackensack, NJ, USA).
 Staining for EGFR was performed using the EGFR detection system (Zymed, San 
Francisco, California, USA), according to the manufacturer’s instructions. The samples 
were dewaxed, rehydrated, and washed with phosphate-buffered saline (PBS). Antigen 
retrieval with pepsine was employed before incubation with the primary antibody, anti-
EGFR (mouse monoclonal antibody, clone 31G7, 1:100). After washing with PBS, the 
samples were incubated with the biotinylated secondary antibody, followed by incuba-
tion with labeled streptavidin-biotin complex. After the final washing with PBS, staining 
was performed by means of 3,3’-diamino-benzidine (DAB), followed by counterstaining 
with Mayer–haematoxylin for 30 sec. 
 Staining for ERBB2 was performed using the ERBB2 detection system (Lab Vision 
Corporation Fremont, California, USA), according to the manufacturer’s instructions. 
Microwave citric acid antigen retrieval was employed before incubation with the primary 
antibody, anti- ERBB2 (mouse monoclonal antibody, clone 3B5 1:1000).
 As a negative control sections were stained without adding the primary antibody. 
Positive controls (placenta for EGFR and 3+ overexpressing breast carcinoma for ERBB2) 
were present on the TMA. Both EGFR and ERBB2 staining was scored as 0 (negative), 1+ 
(weak), 2+ (moderate) or 3+ (strong), according to the scoring system provided by the 
manufacturer. For EGFR levels were described as negative (0) and positive (1+, 2+, and 
3+). For ERBB2 expression was classified as negative (0, 1+) or positive (2+, 3+).
 Slides were examined and scored blind by two of the investigators (NS, SR) inde-
pendently. Conflicting assessments were reviewed until final agreement was achieved. 
Where duplicate cores gave discordant results, the higher score was used.
Results
A tissue micro-array with 18 different soft tissue tumors, including 12 types of sarcomas, 
and 6 types of benign soft tissue tumors (table 1), was immunohistochemically (IHC) 
stained for epidermal growth factor receptor (EGFR) and human epidermal growth fac-
tor receptor 2 (ERBB2, Her2). Not all cases were evaluable, because tissue cores may be 
lost from the slides. The IHC results are also shown in table 1. 
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 In all positive cases ERBB2 staining was diffusely present throughout the cell, con-
sistent with cytoplasmatic rather than membranous expression. The positive controls 
showed clear membranous staining. Positive membranous staining for EGFR was seen in 
multiple malignant soft tissue tumor types and in one of the benign soft tissue tumors.
 Figure 1 shows examples of positive cytoplasmatic staining in ERBB2 (rhabdomyo-
sarcoma) and positive membranous staining in EGFR (solitary fibrous tumor, synovial 
sarcoma, angiosarcoma).
Table 1.  Contents of the tissue micro-array (evaluable tissue samples) and results of the 
immunohistochemically (membranous) staining for epidermal growth factor re-
ceptor (EGFR) and ERBB2.











     Myxoid liposarcoma
     Pleomorphic liposarcoma
     Dedifferentiated liposarcoma
     Atypical lipomatous tumor
3/20
      2/8
      1/2
      0/2




     0/8
     0/2
     0/2
     0/7
Leiomyosarcoma 3/8 50-75 0/8
MPNST 3/7 50-75 0/6
Synovial sarcoma 4/5 75-100 0/5
Rhabdomyosarcoma 
     Pleomorphic
     Embryonal
2/3
     1/1




     0/1
     0/2
Gastrointestinal stromal tumor 0/3 0/3
Myxofibrosarcoma 0/3 0/3
Solitary fibrous tumor 1/2 25-50 0/2
Myxoinflammatory fibroblastic sarcoma 0/2 0/2
Dermatofibrosarcoma protuberans 0/2 0/2
Angiosarcoma of soft tissue 1/1 25-50 0/1
Undifferentiated high grade pleomorphica sarcoma 1/4 0-25 0/4
Lipoma 0/5 0/4
Desmoid type fibromatosis 0/4 0/4
Myxoma 0/4 0/4
Schwannoma 0/2 0/2
Synovial chondromatosis 0/1 0/1
Diffuse type giant cell tumor of soft tissue 0/1 0/1




Most sarcomas are resistant to radiotherapy and many commonly used chemotherapy 
agents, and therefore investigators are searching for other treatment options in sarcoma 
patients. In the oncology field over the last years there has been great interest in the 
growth factor receptor blocking therapies. Both the epidermal growth factor receptor 
(EGFR) inhibitors and ERBB2 inhibitors have been proven beneficial in respectively non-
small-cell lung, head- and neck, pancreatic and colorectal cancer (all EGFR) and breast 
cancer (ERBB2). In sarcoma patients EGFR or ERBB2 inhibitors have never been evaluated 
systematically. 
 Our results show positive membranous staining for EGFR in a variety of sarcoma 
subtypes, including liposarcomas (myxoid and pleomorphic), leiomyosarcomas (intra-
Figure 1.  Epidermal growth factor receptor (EGFR) and ERBB2 immunostaining results. All original 
magnification 630X.
Figure 1. A Diffuse cytoplasmic staining for ERBB2 in rhabdomyosarcoma.
Figure 1. B Membranous staining for EGFR in solitary fibrous tumor. 
Figure 1. C Membranous staining for EGFR in synovial sarcoma. 
Figure 1. D Membranous staining for EGFR in angiosarcoma.
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muscular), synovial sarcomas, malignant peripheral nerve sheath tumors (MPNST), rhab-
domyosarcomas (pleomorphic and embryonal), solitary fibrous tumors, and angiosarco-
mas (deep). Membranous IHC staining for ERBB2 was negative in all sarcoma subtypes. 
These results show that treatment of these EGFR positive subtypes of sarcomas with 
EGFR blocking therapies can theoretically be effective. 
 Published reports on EGFR and especially ERBB2 expression in sarcomas have been 
contradicting.7-18 Positive IHC staining for EGFR in soft tissue sarcomas ranges from 
50 – 100%, with the highest number of positive cases in synovial sarcoma, myxofibro-
sarcoma, MPNST, and so-called malignant fibrous histiocytoma.7-9,12,13,20,21 Yang et al 
reported EGFR positive staining in 3 out of 4 angiosarcomas, which is consisted with 
our findings. Positive IHC staining for ERBB2 ranges from 0-60%.7-12,14-16 The results of 
IHC staining depend highly on the types of antibodies used, the time-span and method 
of fixation, and the absence of a uniform scoring system leads to a high interobserver 
variability.22 This, together with the low number of sarcoma samples investigated, may 
be the reason for the previously described contradicting results.
 In our study EGFR was considered positive when membranous staining was present. 
In most cases membranous staining was focal rather than diffuse in all malignant cells. 
When IHC staining for a growth factor receptor is focal a beneficial effect of receptor 
inhibiting therapies is less likely, while staining is not present in all malignant cells of 
that patient. However in our study, EGFR and ERBB2 staining was also diffusely present 
throughout the cell, consistent with cytoplasmatic rather than membrane expression. 
Previous reports in osteosarcoma cell-lines describe that even in tumors that have no 
membrane pattern on IHC staining, EGFR and ERBB2 receptors are located on the cell 
membrane.9 The difference is that receptor levels expressed are much lower than in the 
epithelial malignancies in which the IHC staining for EGFR and ERBB2 was first used, 
which can prevent a clear immunodetection of the protein on the cell surface. Other 
possible explanations for the cytoplasmatic immunostaining are that the antibody binds 
to precursor forms of the EGFR/ ERBB2 protein in the cytoplasm or that the activated 
antibody-EGFR/ ERBB2 complex is internalized.23
 Previous reports show that EGFR expression is more frequently found in synovial 
sarcomas than in other soft tissue tumors.7,17,18 This resulted in the initiation of a phase 
II trial treating patients with synovial sarcoma with gefitinib therapy (an EGFR small 
molecule tyrosine kinase inhibitor) by the European Organization for Research and Treat-
ment of Cancer (EORTC). However in recent reports in IHC positive synovial sarcomas, 
and other soft tissue sarcomas, there was no EGFR gene amplification seen by FISH, and 
positive effects of gefitinib therefore seemed less likely.20,24 The results of this Phase II 
trial were reported recently and no substantial benefit of gefitinib monotherapy com-
pared to conventional chemotherapy was seen.25
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 Questions are still rising whether IHC staining for EGFR is the correct method to 
evaluate EGFR status.5 It is possible that other markers, like the level of activated phos-
phorylated EGFR or the presence of activating EGFR mutations, are more important. In 
non-small cell lung cancer (NSCLC) total EGFR expression does not relate to other clinical 
prognostic indicators, and does not relate to clinical response to EGFR inhibitors like er-
lotinib or gefitinib.26 Phosphorylated EGFR (p-EGFR), EGFR gene copy number, and EGFR 
activating mutations have been shown to be better markers then EGFR overexpression 
by IHC for prediction of poor prognosis in NSCLC.27,28 Future research should focus on 
the determination of markers that can predict a favorable outcome, like the association 
between activating mutations in the ATP-binding site of EGFR and response on gefitinib 
(Iressa) in non-small-cell lung cancer patients, or the association between KRAS muta-
tions and resistance to cetuximab (Erbitux®) in colorectal carcinoma patients.29,30
 In breast cancer there is a correlation between ERBB2 gene amplification and ERBB2 
protein overexpression.2,31 Studies in other tumor types, including osteosarcoma, Ew-
ing sarcoma and synovial sarcoma report a ERBB2 protein overexpression with positive, 
mainly cytoplasmatic, IHC staining without amplification of ERBB2 gene by fluorescence 
in situ hybridization (FISH) evaluation, indicating that ERBB2 overexpression can be inde-
pendent from gene amplification.16,17 There was no effect of trastuzumab (ERBB2 inhibi-
tion) in osteosarcoma and Ewing sarcoma cell-lines.15,17 Further studies are required to 
increase insight in the role of IHC and FISH evaluation of ERBB2 as predictive markers for 
response to ERBB2 inhibiting therapies in sarcomas.
 Our results demonstrate that IHC staining for EGFR and ERBB2 shows cytoplasmatic 
staining in many subtypes of sarcomas, and membranous staining for EGFR in multiple 
subtypes of sarcomas. Therefore there is a possibility that sarcoma patients may benefit 
from EGFR inhibiting therapies. Benefit from ERBB2 blocking therapies is highly unlikely. 
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Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of VEGFR-2, VEG-
FR-3, PDGFR-β, and c-Kit. This phase I dose escalation study was conducted to evaluate 
the safety and tolerability of telatinib, with additional pharmacokinetic, pharmacody-
namic and efficacy assessments.
Patients and methods 
Patients with solid tumors refractory to standard therapies or with no standard therapy 
available were enrolled. Doses of continuously administered telatinib were escalated 
from 20 mg od to 1500 mg bid. 
Results 
Fifty-three patients were enrolled. Most frequently observed drug-related adverse events 
were nausea (26.4%, grade ≥3: 0%) and hypertension (20.8%, grade 3: 11.3%, grade 
4: 0%). Two DLTs were observed: one poorly controlled hypertension (600 mg bid), and 
one grade 2 weight loss, anorexia, and fatigue (1500 mg bid). A formal MTD was not 
reached. Telatinib was rapidly absorbed, with median tmax <3 hours post-dose. Nearly 
dose proportional increase in exposure was observed with substantial variability. Telati-
nib half-life averaged 5.5 hours. Biomarker analyses showed dose-dependent increase in 
VEGF levels and decrease in sVEGFR-2 levels, with a plateau at 900 mg bid. A decrease in 
tumor blood flow (Ktrans and IAUC60) was observed with DCE-MRI. Best tumor response 
was stable disease, observed in 50.9% of patients.
Conclusions 
Telatinib was safe and well tolerated up to 1500 mg bid. Based upon pharmacodynamic 
and pharmacokinetic endpoints, telatinib 900 mg bid is the recommended dose for sub-
sequent phase II studies.
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Introduction
The vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) play a pivotal 
role in tumor-related angiogenesis, and the VEGF/VEGFR pathway is an important target 
for anti-angiogenic drug development and tumor therapy.1-8  
 Telatinib (BAY 57-9352) is an orally available, potent inhibitor of VEGFR-2, VEGFR-3, 
platelet-derived growth factor receptor (PDGFR-β), and c-Kit tyrosine kinases. Telatinib 
inhibits VEGFR-2 autophosphorylation in a whole-cell assay of receptor autophosphory-
lation with an IC50 of 19 nM. Telatinib also inhibits VEGF-dependent proliferation of 
human umbilical vein endothelial cells (HUVECs) with an IC50 of 26 nM and PDGF-stim-
ulated growth of human aortic smooth muscle cells with an IC50 of 249 nM. Telatinib 
demonstrates anti-tumor activity in various cancer models. Formation of the N-glucuro-
nides of telatinib is identified as the major biotransformation pathway in man. Telatinib 
is metabolized by various CYP isoforms and UGT1A4.9,10
 We performed a phase I, pharmacological, and biomarker study of telatinib. Objec-
tives were to (1) determine maximum tolerated dose (MTD) and define dose-limiting 
toxicities (DLT), (2) characterize safety, (3) pharmacokinetics, and (4) biomarkers of bio-
logical activity, including serum markers and dynamic contrast-enhanced magnetic reso-
nance imaging (DCE-MRI) results, and (5) evaluate anti tumor activity.
Patients and Methods
Eligibility criteria
Patients with histologically or cytologically confirmed advanced or metastatic solid tu-
mors for whom no standard therapy was available, with an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ≤2 were eligible. Other inclusion criteria were: 
evaluable or measurable disease by RECIST; age ≥18 years; life expectancy ≥12 weeks; 
adequate bone marrow, liver, and renal function (hemoglobin ≥9.0 g/dl; absolute neu-
trophil count ≥1,500/mm3; platelet count ≥100,000/mm3; total bilirubin ≤1.5x the upper 
limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) ≤2.5x ULN, (liver metastases AST/ALT <5x ULN); alkaline phosphatase ≤ 4x ULN; 
PT-INR and PTT <1.5x ULN; serum creatinine ≤1.5x ULN). Exclusion criteria were: history 
of cardiac disease; HIV, hepatitis B or C infection; active infection; serious non-healing 
wound, ulcer, or bone fracture; symptomatic metastatic brain or meningeal tumors un-
less >6 months from definitive therapy without evidence of tumor growth, and clinically 
stable; seizure disorder requiring anticonvulsant medication; history of organ allograft; 
pregnancy or breast-feeding; history of any condition that could endanger the safety of 
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the patient; anticancer treatment <4 weeks before the first dose; previous anti-angio-
genic therapies/VEGFR-2 inhibitors. 
 Written informed consent from all patients and approval from the institutional re-
view boards was obtained.
Drug Administration and Dose Escalation Procedure
Telatinib was administered orally, once daily (od) or twice daily (bid), on a continuous 
basis. Based upon toxicological data, pharmacokinetic data, and a parallel phase I 
study with telatinib administered in a “14 days on / 7 days off” schedule, the starting 
dose was 20 mg od. The formulations used in this study were: solution formulation 
(20 mg od cohort), 25 mg telatinib mesylate tablet formulation (75 mg od cohort), and 
150 mg telatinib mesylate tablet formulation (bid dosing cohorts). For the purpose of 
analysis, one cycle was defined as 21 days of administration.  
 Doses were doubled for subsequent cohorts if no drug-related toxicity in cycle 1 
was observed. When DLT had been observed or following toxicity ≥grade 2 in ≥2 pa-
tients, subsequent dose increments were 33-66%. 
 DLT was defined as grade 4 neutropenia ≥7 days, febrile neutropenia, grade 4 
thrombocytopenia, grade 3 thrombocytopenic bleeding, and any drug-related grade 
3 or 4 non-hematological toxicity excluding alopecia, nausea and vomiting not refrac-
tory to anti-emetics, and hypertension not refractory to anti-hypertensive medication 
during the first cycle.
 If DLT was observed in one patient, three additional patients were recruited at that 
dose level, with dose escalation proceeding if <2 of 6 patients exhibited DLT. Because 
pharmacokinetic results of the initial 2 cohorts showed significant inter patient vari-
ability, all subsequent cohorts were expanded to a minimum of six patients. If DLT was 
observed in ≥2 of 3 or ≥2 of 6 patients, the maximum-tolerated dose (MTD) had been 
exceeded, and additional patients were recruited at the next lower dose level. The MTD 
was defined as the highest dose level that could be given to 6 patients with <1 patient 
experiencing DLT. If a patient experienced a drug related DLT, telatinib was withheld 
for up to 3 weeks. If toxicity resolved to .grade 1, the dose of telatinib was reduced 
to the next lower dose level. Otherwise, the patient was withdrawn from the study. 
Administration of telatinib was continued until disease progression or unacceptable 
toxicity.
 One additional cohort of 4 patients was enrolled (as part of a larger group in a 
companion study) to evaluate the bioavailability of a new 300 mg mesylate tablet for-
mulation in comparison to the 150 mg mesylate tablet formulation. Patients received 
a single dose of 900 mg using the 300 mg tablet and continued with 150 mg tablets.
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Pre-treatment Evaluation and Safety Assessment
Pre-treatment evaluation consisted of a complete medical history, physical examination, 
ECOG performance status assessment, vital signs, baseline 12 lead ECG, blood sample 
for complete blood count (CBC), coagulation analysis, biochemistry analysis, sample for 
urinalysis, serum pregnancy test, plasma and urine sampling for biomarkers, baseline 
tumor measurements, and DCE-MRI.
 On days 1 and 14 of each cycle evaluation consisted of a brief history and physical 
examination, vital signs, blood samples for CBC, biochemistry, and coagulation analy-
sis, urinalysis, 12-lead ECG. Response evaluation was performed every 2 cycles and was 
assessed according to RECIST.11 Patients were evaluated weekly in the first cycle and 
every 1 or 2 weeks in additional cycles for adverse events and toxicity according to the 
National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 3.0. 
Pharmacokinetic Evaluation
Pharmacokinetic (PK) evaluation was performed by collecting blood samples on 
days 1 and 14 of cycle 1, and day 14 of cycles 2 and 4 via an indwelling intravenous 
catheter. In cycle 1, a 5 mL sample was collected pre-dose and at 0.5, 1, 2, 3, 4, 6, 
8, 12 hours post-dose. An additional sample was collected at 24 hours post-dose for 
once daily regimen. In cycles 2 and 4, an abbreviated sampling schedule was used. 
Pharmacokinetic parameters Cmax, tmax, AUC0-tn, AUC0-24 (for od regimen), AUC0-12 (for 
bid regimen) and half-life for telatinib and its metabolite (BAY 60-8246) were calculated 
by non-compartmental analysis using WinNonlin (version 4.1.a).
Pharmacodynamic Analysis
Urine samples and 20 ml blood samples for pharmacodynamic (PD) analysis were col-
lected at baseline, pre-dose and 8 hours post-dose on days 1 and 14 of cycles 1 and 2 
and on day 1 of cycle 3, and pre-dose on day 1 of each subsequent cycle. The following 
parameters were measured: plasma soluble VEGFR-2 (sVEGFR-2), plasma VEGF, plasma 
basic fibroblast growth factor (bFGF), plasma IL-8, urinary VEGF. Samples were analyzed 
using the relevant quantitative enzyme linked immunosorbent assay (ELISA; R&D Sys-
tems Europe, Oxford, UK) according to the manufacturer’s instructions. 
 DCE-MRI scans were performed at baseline, on day 2 of cycle 1, and on day 14 of 
cycles 2 and 3. We used a 1.5-T MR imaging system (Philips Medical Systems, Best, The 
Netherlands) using a body coil in retroperitoneal and abdominal lesions. . The tumors 
were localized using standard T1- and T2- fat-saturated fast spin echo sequences. 
Subsequently, dynamic MR imaging was performed using T1-weighted turbo field-
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echo sequence with TR 5.4/TE 1.4, flip angle of 20°, nonselective inversion preparatory 
pulse, with delay time of 165 msec, and section thickness of 5–8 mm, with a temporal 
resolution, of 3 seconds during at least the first 84 seconds. Total acquisition time lasted 
5 min. A power injector (Spectris; Medrad, Indianola, Pa) with injection flow rate of 
2 mL/sec was used to start intravenous administration of gadopentetate dimeglumine 
(Magnevist, Bayer-Schering, Berlin, Germany), which was followed by a 20-mL saline 
flush. Bolus injection was initiated 5 seconds after the start of data acquisition.12 
 Assessed parameter was Ktrans, describing the volume transfer coefficient of con-
trast between blood plasma and the tumor. Empirical quantitative methods were used 
to quantify the signal-intensity time curve using the initial area under the contrast-agent 
concentration-time curve after 60 seconds (iAUC60) and time to peak enhancement 
(TTPE; time period between arterial enhancement and the enhancement of the index le-
sions).13,14 The second pre-contrast dynamic images were automatically subtracted from 
all dynamic contrast-enhanced MR images using software of the MR system.
Statistical analysis
Continuous variables are presented as mean values ± standard deviation and categorical 
variables as frequencies (percentages), unless otherwise stated. Comparison between 
variables at baseline and post-dose was performed with paired samples t-test or Wil-
coxon signed rank test as appropriate. Correlations with drug exposure were assessed 
by Spearmans Rank correlation coefficient. All analyses were performed using SPSS ver-
sion 12.01 (SPSS, Chicago, Ill, USA) and were two-sided, with a level of significance of 
a=0.05.
Results
Between July 2004 and October 2006, 53 patients were enrolled. Patient characteristics 
are summarized in Table 1.
Safety and Tolerability
All treatment-related adverse events are summarized in Table 2. Most frequently report-
ed treatment-related adverse events were nausea (26.4%) and hypertension (20.8%). Six 
episodes of grade three drug-related hypertension were observed. There was no appar-
ent dose relationship. Grade 4 drug-related hypertension was not observed. Hyperten-
sion was easily manageable with anti-hypertensive medication in most cases. 
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Table 1. Baseline demographics and patient characteristics
Baseline characteristics Patients (n (%))
Gender
     Male 29  (55)
     Female 24  (45)
Age, years
     Median (range) 55  (17-76)
ECOG performance status
     0 15  (28)
     1 32  (60)
     2  3  (6)
     Not reported  3  (6)
Prior anticancer therapies
     Surgery 51  (96)
     Systemic anticancer therapy 45  (85)
     Number of previous treatments (range)  2.5 (0-13)
     0-1 20  (38)
     2-5 29  (55)
     >5  4  (8)
     Radiation therapy 19  (36)
Tumor type
     Soft tissue sarcoma 11  (21)
     Colorectal cancer 10  (19)
     Renal cell cancer  5  (9)
     Esophageal cancer  5  (9)
     Other 22  (42)
          Ovarian cancer  3  (6)
          Osteosarcoma  3  (6)
          Adrenal cancer  3  (6)
          Cholangiocarcinoma  3  (6)
          Melanoma  3  (6)
          Pancreatic cancer  2  (4)
          Bladder cancer  1  (2)
          Chordoma  1  (2)
          Anal cancer  1  (2)
          Neuroendocrine carcinoma  1  (2)
          Prostate cancer  1  (2)
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 Two DLTs were observed. At 600 mg bid one episode of poorly controlled hyper-
tension in a patient with metastatic renal cell carcinoma, prior nephrectomy and pre-
existing hypertension was observed. Despite addition of a third antihypertensive agent 
and two dose reductions, grade 3 hypertension persisted and telatinib was permanently 
discontinued. At 1500 mg bid one episode of the combination of persistent grade 2 
weight loss, grade 2 anorexia, and grade 2 fatigue was felt to be intolerable by the 
patient and therefore was considered DLT. Despite two dose reductions, this patient did 
not tolerate telatinib. Four additional patients experienced possible drug-related adverse 
events requiring dose reduction, interruption or discontinuation. One patient at 300 mg 
bid reported grade 2 diarrhea requiring permanent discontinuation of telatinib. One 
patient at 600 mg bid experienced grade 3 AST and ALT elevation, normalizing after 
dose reduction. One patient at 900 mg bid with well-controlled pre-existing hyperten-
sion reported grade 3 headache requiring two dose reductions of telatinib. One patient 
at 1500 mg bid discontinued telatinib following an episode of otherwise uncomplicated 
grade 3 esophageal varices bleeding. Due to the low incidence of treatment-related DLT, 
a formal MTD could not be defined.
Pharmacokinetics
Telatinib pharmacokinetic parameters are summarized in Table 3. Telatinib was rapidly 
absorbed, with tmax values observed less than 3 hours post-dose.
 Although an overall dose proportional increase in exposure was observed in the 150-
1500 mg bid dose range, high interpatient variability was observed, similar to that ob-
served with other VEGF-R or EGF-R tyrosine kinase inhibitors.15-20 In the intermediate dose 
levels (e.g. 300 mg BID and 600 mg BID) deviation from dose proportionality was observed 
likely due to pharmacokinetic variability.  Plasma half-life of telatinib averaged 5.5 hours 
and is consistent with the observation that steady-state is achieved within the first 14 days 
of telatinib administration. A limited number of patients provided cycle 4 pharmacoki-
netic samples, yielding comparable results at cycle 2 day 14 and cycle 4 day 14.
 There was no correlation between telatinib exposure and toxicity or time to progres-
sion.  This is partly due to the low incidence of some of the toxicities and the relatively 
small number of patients per cohort.
 Comparison of geometric mean AUC of telatinib and its metabolite BAY 60-8246 
indicate that exposure to the metabolite is less than 20% of exposure to parent com-
pound.
 In a cohort of four patients in whom bioavailability of the 300 mg mesylate tablet 
was compared to that of the 150 mg mesylate tablet, high interpatient variability in the 




SVEGFR-2 and VEGF plasma levels
Changes in plasma levels of VEGF and sVEGFR-2 in relation to telatinib dose are summa-
rized in figure 1A and 1B. Over the dose range studied, increasing exposure to telatinib 
resulted in lower plasma sVEGFR-2 levels (both pre-dose and post-dose) after 14 con-
Table 3.  Geometric mean (% coefficient of variation) of telatinib pharmacokinetic pa-
















































































































































































































a: Median [range], b: For once daily cohorts AUC(0-24), mg×h/L is reported, c: Sample size reduced by 1, 
d: Sample size reduced by 2

































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Biomarker results: plasma VEGF (fig 1A) and sVEGFR-2 (fig 1B) levels; individual 
patient’s ratios over baseline value for cycle 1 day 1 through cycle 2 day 14, pre-dose (PRE-D) 
and post-dose (POST-D). Plasma sVEGFR-2 ratio over baseline value versus telatinib AUC0-24 on 
cycle 1 day 14 (fig 1C) and versus telatinib Cmax on cycle 1 day 14 (fig 1D)  
 
















     1C             1D 
      
 16
Figure 1: Biomarker results: plasma VEGF (fig 1A) and sVEGFR-2 (fig 1B) levels; individual 
patient’s ratios over baseline value for cycle 1 day 1 through cycle 2 day 14, pre-dose (PRE-D) 
and post-dose (POST-D). Plasma sVEGFR-2 ratio over baseline value versus telatinib AUC0-24 on 
cycle 1 day 14 (fig 1C) and versus telatinib Cmax on cycle 1 day 14 (fig 1D)  
 
















     1C             1D 
      
 16
Figure 1: Biomarker results: plasma VEGF (fig 1A) and sVEGFR-2 (fig 1B) levels; individual 
patient’s ratios over baseline value for cycle 1 day 1 through cycle 2 day 14, pre-dose (PRE-D) 
and post-dose (POST-D). Plasma sVEGFR-2 ratio over baseline value versus telatinib AUC0-24 on 
cycle 1 day 14 (fig 1C) and versus telatinib Cmax on cycle 1 day 14 (fig 1D)  
 
















     1C             1D 
      
Fig 1.  Biomarker results: plasma VEGF (fig 1A) and sVEGFR-2 (fig 1B) levels; individual patient’s 
ratios over baseline value for cycle 1 day 1 through cycle 2 day 14, pre-dose (PRE-D) and post-
dose (POST-D). Plasma sVEGFR-2 ratio over baseline value versus telatinib AUC0-24 on cycle 1 




A phase I dose escalation study of telatinib, an inhibitor of VEGFR-2, VEGFR-3, PDGFR-β and c-Kit
57
tinuous days of dosing (Figures 1C and 1D, table 4) There was no statistical correlation 
between dose of telatinib and plasma levels of VEGF and sVEGFR-2. Changes in plasma 
levels of VEGF and sVEGFR-2 plateaued at 900 mg bid, suggesting a saturable effect. 
There were no consistent changes in plasma levels of bFGF, and IL-8 and urinary levels 
of VEGF. 
DCE-MRI
Reproducible DCE-MRI results for screening and at least for one post screening assess-
ment were available from 16 subjects for evaluation of Ktrans and iAUC60, and from 
32 patients for evaluation of TTPE. DCE-MRI data for evaluation of Ktrans and iAUC60 
Table 5. Best Tumor Response
Cohort N Best Tumor Response
Stable disease Progressive disease Unknown
20 mg od 4 2 2 –
75 mg od 6 2 4 –
150 mg bid 6 2 4 –
300 mg bid 6 3 3 –
600 mg bid 6 4 1 1
900 mg once, bid later 4 2 2 –
900 mg bid 15 8 7 – 
1500 mg bid 6 4 2 –
 16
Figure 1: Biomarker results: plasma VEGF (fig 1A) and sVEGFR-2 (fig 1B) levels; individual 
patient’s ratios over baseline value for cycle 1 day 1 through cycle 2 day 14, pre-dose (PRE-D) 
and post-dose (POST-D). Plasma sVEGFR-2 ratio over baseline value versus telatinib AUC0-24 on 
cycle 1 day 14 (fig 1C) and versus telatinib Cmax on cycle 1 day 14 (fig 1D)  
 
















     1C             1D 




were missing from 37 patients for several reasons: no DCE-MRI performed (n=17), 
analysis unreliable due to poor quality, i.e. low signal-to-noise ratio, interference arti-
facts (n=14), only one scan performed (n=4), no contrast agent given (n=1), unknown 
(n=1). DCE-MRI data for evaluation of TTPE were missing from 21 patients for the fol-
lowing reasons: no DCE-MRI performed (n=17), only one scan performed (n=1), no 
contrast agent given (n=1), unknown (n=2). 
 DCE-MRI results are summarized in Table 4. For TTPE, a clear dose-response relation-
ship was seen. TTPE changes from baseline were positively correlated to telatinib AUC.
Anti tumor activity
A disease control rate (DCR) of 50.9% was observed with 27 of 53 patients having stable 
disease as best tumor response (Table 5). Disease control for 6-12 months was seen in 
3 patients, 12-18 months in 2, and >18 months in 4 patients. There were no complete 
or partial responses, however, some degree of tumor shrinkage was observed in 16 pa-
tients (30.2%). 
Discussion
In this phase I dose escalation study we explored tolerability, safety and biological activ-
ity of the selective VEGFR tyrosine kinase inhibitor telatinib (BAY 57-9352).
 With regard to safety, the most frequently reported treatment-related adverse 
events were nausea (26.4%) and hypertension (20.8%). Nausea occurred throughout 
all dose levels and was mild. Hypertension was easily managed with a maximum of 
two anti-hypertensive agents in all but one patient. Based upon previous experience 
and considering the potential underlying mechanisms of the observed hypertension, 
angiotensine converting enzyme inhibitors and calcium antagonists were most frequently 
prescribed. It is conceivable that hypertension should be considered an indication of 
biological activity of VEGF inhibitors rather than as side-effect.1,3,15,21-25
 As only one out of 6 patients at 1500 mg bid experienced DLT (combination of 
grade 2 weight loss, anorexia, and fatigue), we formally could not define the MTD of 
telatinib based upon clinical toxicity. Eventhough grade 2 toxicity formally did not define 
DLT in this study, on ongoing (combination of) grade 2 toxicity induced by continuous 
drug administration must be considered to be cumbersome and therefore can define as 
intolerable.
 In our study, pharmacokinetics of telatinib were dose proportional in the overall dose 
range studied, albeit with substantial interpatient variability and deviation from dose 
proportionality in the intermediate dose levels. This observation may be attributed to in-
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herent variability in absorption and/or metabolism of telatinib, as well as various patient 
and tumor characteristics. In a parallel study with telatinib, a markedly less than dose 
proportional increase in exposure was observed at dose levels exceeding 900 mg bid.26
 Telatinib induced changes in plasma levels of VEGF and sVEGFR-2 that are consis-
tent with findings in trials with telatinib and other VEGFR inhibitors.15,16,19,26,27 These 
changes plateaued at 900 mg bid suggesting a saturable effect. 
 Based upon the combined analysis of pharmacokinetic and pharmacodynamic results 
observed in the two dose escalation studies with telatinib, and based upon practical is-
sues such as number of tablets to be taken, we defined 900 mg bid as the dose recom-
mended for phase II studies. Based upon the mechanism of action of VEGFR-2 tyrosine 
kinase inhibitors, a continuous dosing schedule may prove to have optimal activity, and 
therefore studies exploring continuous administration of telatinib in combination with 
various anticancer therapies have been initiated.28
 DCE-MRI analysis revealed changes in TTPE that are correlated to telatinib exposure. 
Similar studies with other angiogenesis inhibitors support our results.29-31 A trend to 
a dose-effect relationship was seen, but no significant correlation could be assessed. 
We could not determine a statistical correlation between DCE-MRI results and clinical 
outcome such as disease control rate (data not shown separately). Eventhough DCE-MRI 
analyses should be considered a non-validated technique, results obtained in our study 
indicate an antiangiogenic effect of telatinib and seem to support the results of ad-
ditional analyses of changes in flow mediated dilatation (FMD), nitroglycerin-mediated 
dilatation (NMD), and capillary density that were done in this study and are reported 
separately.32 
Determining antitumor activity of telatinib was a secondary endpoint of this study. Com-
plete or partial responses were not observed in this study, but some minor tumor regres-
sions and prolonged periods of disease stabilization are indicative of anti-tumor activity 
and merit confirmation in a phase II study program. Among cases of prolonged disease 
stabilization is a young patient with an epitheloid hemangio-endothelioma of the scalp 
who is now on medication for more than three years.
Two VEGF tyrosine kinase inhibitors (sunitinib and sorafenib) have gained regulatory 
approval. Telatinib may have some theoretical advantages over sunitinib and sorafenib. 
Theoretically, side effects like thyroid dysfunction, cardiac function impairment, and re-
versible posterior leukoencephalopathy syndrome observed with sunitinib or sorafenib 
may be caused by blocking pathways not described in the pre-clinical or clinical stud-
ies or by the redirection of signals through other pathways.33-38 These side effects can 
therefore by agent-specific and to date, albeit in a relatively small number of patients, 
telatinib has not induced any of these side effects. 
Chapter 4
60
 Compared to telatinib, vatalanib (PTK787/ZK222584) seems to have some similari-
ties. In our opinion, telatinib has potential benefit over vatalanib. The IC50 of vatalanib 
for VEGFR-3, c-Kit, and PDGFRβ are respectively 18, 20, and 16 times higher than the IC50 
for VEGFR-2. For telatinib these IC50’s are 0.66, 0.17 and 2.5 times higher, respectively. 
Activation of VEGFR-3 in lymphatic endothelial cells can facilitate lymphangiogenesis 
and lymphatic spread of tumor cells.39 Therefore, theoretically, the superior potency of 
telatinib compared to vatalanib with regard to VEGFR-3 inhibition will hopefully trans-
late into increased clinical efficacy. Future studies will have to prove this optimism.
 In conclusion, telatinib (BAY 57-9352) administered as continuous treatment is safe 
and well tolerated. Based upon the combined analysis of clinical, pharmacodynamic, 
and pharmacokinetic endpoints, 900 mg bid is the dose recommended for future phase 
II studies.
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Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert do-
main receptor (KDR; VEGFR-2) and fms-related tyrosine kinase 4 (FLT4; VEGFR-3). This 
study aims at the identification of relationships between single-nucleotide polymor-
phisms (SNPs) in genes encoding for transporter proteins and pharmacokinetic param-
eters in order to clarify the significant interpatient variability in drug exposure. In addi-
tion, the potential relationship between target receptor polymorphisms and toxicity of 
telatinib is explored.
Methods
Blood samples from 33 patients enrolled in a phase I dose-escalation study of telati-
nib were analyzed. For correlation with dose normalized AUC(0-12), ATP-binding cassette 
(ABC) B1 (ABCB1), ABCC1, and ABCG2 were the genes selected. For correlation with 
telatinib toxicity, selected genes were the drug target genes KDR and FLT4.
Results
No association between dose normalized AUC(0-12) and drug transporter protein poly-
morphisms was observed. In addition, no association between toxicity and KDR or FLT4 
genotype or haplotype was seen.
Conclusions
Our pharmacogenetic analysis could not reveal a correlation between relevant gene 
polymorphisms and clinical and pharmacokinetic observations of telatinib. 
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Introduction
Single nucleotide polymorphisms (SNPs) in genes encoding for drug transporters and 
drug targets contribute to interindividual heterogeneity of drug efficacy and toxicity in 
cancer therapy.1,18 This type of research is referred to as pharmacogenetics. In our cur-
rent study we analyze pharmacogenetic factors likely to be involved in telatinib disposi-
tion and mechanism of action. 
 Telatinib (BAY 57-9352) is an orally active, small-molecule tyrosine kinase inhibitor 
of kinase insert domain receptor (KDR; vascular endothelial growth factor receptor 
(VEGFR)-2) and fms-related tyrosine kinase 4 (FLT4; VEGFR-3). Telatinib is metabolized 
by various cytochrome P450 (CYP) isoforms including CYP3A4/3A5, CYP2C8, CYP2C9, 
and CYP2C19 as well as by uridine diphosphate glucuronosyltransferase 1A4 (UGT1A4), 
with the formation of the N-glucuronides of telatinib as the major biotransformation 
pathway in man. In vitro studies showed telatinib to be a weak substrate of the adenosine 
triphosphate binding cassette (ABC) B1 (ABCB1) transporter.
 In a phase I and pharmacological study we showed that pharmacokinetics (PK) of 
telatinib were dose proportional (manuscript accepted by JCO, see Chapter 4). How-
ever, substantial interpatient variability was observed (Cmax and AUC(0-12) % coefficient 
of variation 20-150%) and no clear association between telatinib exposure and toxicity 
could be established. However, in this class of agents an increase in toxicity is generally 
observed with increasing dose.3,17 Although in general limited information on drug me-
tabolism and toxicity is available in early stages of drug development, pharmacogenetic 
research may be valuable. For example, if significant side effects could be linked to a 
certain drug transporter polymorphism, this could influence further drug development 
or could become an important issue in patient selection.
 The current study examines the potential relationships between SNPs in genes 
coding for transporter proteins and pharmacokinetic parameters of telatinib in order to 
identify factors contributing to the significant interpatient variability in drug exposure. 
In addition, this study explores the potential relationship between target receptor 
polymorphisms and toxicity of telatinib. 
Methods
This study was conducted in a subset of patients enrolled into a two-centre, phase I 
dose-escalating study of telatinib (manuscript accepted by JCO, see Chapter 4). The aim 
of this exploratory pharmacogenetic study was to identify possible relationships be-
tween SNPs in genes coding for drug transporters and PK parameters; and drug target 
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related SNPs and side effects of telatinib. From 33 of the 53 patients treated in the 
phase I study residual blood samples were available for pharmacogenetic analyses. De-
mographic, toxicity and pharmacokinetic characteristics were comparable for included 
and excluded patients (data not shown). Four of these 33 patients were treated with 
telatinib oral solution or 25 mg tablets, the remaining patients with 150 mg tablets. 
 Since bioavailability of the telatinib formulations differ, a decision was made to 
restrict the current analysis to one telatinib formulation. Therefore, in the association 
analysis with PK, only the 29 patients treated with the 150 mg tablets were included.
Patients and samples
Eligibility criteria, drug administration procedures and clinical and pharmacokinetic re-
sults are described in detail elsewhere (manuscript accepted by JCO, see Chapter 4). 
Briefly, patients with histologically or cytologically confirmed advanced or metastatic 
solid tumors for whom no standard therapy was available, with an Eastern Cooperative 
Oncology Group (ECOG) performance status ≤2 were eligible. Telatinib was administered 
orally, once daily (od) or twice daily (bid), on a continuous basis. The clinical trial had 
a standard 3+3 phase I dose escalation study design. Because of significant interpa-
tient variability in pharmacokinetics the decision was made to expand all cohorts to a 
minimum of six patients from the second cohort onwards. Response evaluation was 
performed every 2 cycles and was assessed according to RECIST.19
 Residual blood samples taken for the routine patient care were stored at -20ºC at the 
local hospital laboratories. One frozen blood sample for each patient was collected from 
the two participating hospitals (Leiden University Medical Center, Leiden and Erasmus 
Medical Center, Rotterdam). All samples were anonymized by a third party, according to 
the instructions given in the “Code of Conduct for the use of data in Health Research” 
and “Code for Proper Secondary Use of Human Tissue” (www.federa.org). Approval 
from the institutional medical ethical review boards was obtained.
Pharmacokinetic and toxicity parameters
PK evaluation was performed by collecting blood samples on days 1 and 14 of cycle 1, 
and day 14 of cycles 2 and 4. Pharmacokinetic parameters were calculated by non-
compartmental analysis using WinNonlin (version 4.1.a). 
 In this study cycle 1 day 14 (representing steady-state) dose normalized AUC(0-12), 
calculated as AUC(0-12)/actual dose administered, was selected as the PK parameter to 
associate with transporter genetic polymorphisms. 
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 Patients were evaluated for adverse events and toxicity according to the National 
Cancer Institute Common Toxicity Criteria (NCI-CTC), version 3.0. In general, the NCI-
CTC toxicity score distinguishes between mild (grade 1), moderate (grade 2), severe 
(grade 3), life-threatening or disabling toxicity (grade 4) and death related to adverse 
events (grade 5). Telatinib administration resulted in limited toxicity. Grade 3-4 toxicity 
was only seen in 3 patients. Therefore, despite the fact that grade 3-4 toxicity is more 
clinically relevant, the occurrence of any grade 1-4 toxicity was considered to be the 
best candidate parameter for association analyses with drug target receptor genetic 
polymorphisms. Since toxicity observed in the first cycle was limited we decided to use 
overall toxicity observed in all treatment cycles for statistical association studies. In addi-
tion, hypertension is considered to be one of the more serious telatinib side effects, and 
grade 1-4 hypertension was also selected for association analyses. 
Selection of candidate genes 
Candidate genes were selected based on the information of preclinical pharmacology 
studies as reported in the Investigator’s brochure (Bayer Pharmaceutical Corporation, 
data on file). For association with PK parameters ABCB1, ABCC1, and ABCG2 were the 
genes selected. For correlation with telatinib toxicity selected genes were the drug target 
genes encoding KDR and FLT4. For the major biotransformation pathway in man, the 
formation of the N-glucuronides through UGT1A4, no SNP met the criteria for selection 
described below.
 The SNPs were selected, taking into consideration one or more of the following cri-
teria: validated SNP assay, SNP causes preferably non-synonymous amino acid change, 
indications for clinical relevance from previous publications, and a preferred minor gen-
otype frequency of ~10%.
DNA extraction and SNP analysis methods
DNA was isolated from whole blood samples with MagNA Pure DNA Isolation kit (Roche 
Diagnostics, Almere, The Netherlands). DNA concentrations were quantified using a 
NanoDrop spectrophotometer (Isogen, IJsselstein, The Netherlands). Taqman assays 
were obtained from Applied Biosystems (Applied Biosystems, Nieuwerkerk aan den IJs-
sel, The Netherlands). As a quality control, 4 samples were genotyped in duplicate for all 
assays and 2 assays were tested in duplicate on all samples. As negative controls water 
was used. Overall, no inconsistencies were observed in the results.
 The following SNPs were analyzed: ABCB1 3435C>T (rs1045642), ABCB1 1236C>T 
(rs1128503), ABCB1 2677G>A/T (rs2032582), ABCB1 -129T>C, ABCC1 C>G (rs129081), 
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ABCC1 825T>C (rs246221), ABCC1 1062T>C (rs35587), ABCC1 2012G>T (rs45511401), 
ABCG2 346G>A (rs2231137), ABCG2 421C>A (rs2231142), FLT4 1480A>G (rs307826), 
FLT4 2670C>G (rs448012), KDR 1719A>T (rs1870377), KDR -604T>C (rs2071559), and 
KDR 1192G>A (rs2305948).
 SNP genotyping was performed with BIOMARK 48.48 dynamic array (Fluidigm Cor-
poration, South San Francisco, CA, USA). All assays were performed according to proto-
cols provided by the manufacturer.
Statistical analysis
Differences in pharmacokinetic and toxicity parameters among genotypes were analyzed 
by Student’s t-test, ANOVA or Kruskal-Wallis test for continuous variables or chi-square 
test for dichotomous variables where appropriate. For toxicity, differences in genotype 
distribution were tested by 3 x 2 cross-tabulations for each genotype, and by 2 x 2 cross-
tabulations for carriers versus noncarriers, with analysis by 2-sided chi-square test. 
 Polymorphisms within a gene were tested with the chi-square test (P-value < 0.05) 
to detect linkage disequilibrium (LD). If LD between SNPs was detected, haplotypes 
were determined for each individual with gPLINK (http://pngu.mgh.harvard.edu/purcell/
plink/).11 No phase uncertainty in the defined haploblocks and haplotypes (Rh^2> 0.98) 
was seen. 
 Associations between the number of copies of a haplotype and clinical parameters 
were performed using a chi-square test for dichotomous variables and Student’s t-test, 
ANOVA or Kruskal-Wallis test for continuous variables.
 All statistical analyses were performed using SPSS 16.0 software (SPSS, Chicago, IL) 
and were two-sided, with a level of significance of a=0.05.
Results
Baseline patient characteristics, observed treatment-related toxicities, pharmacokinet-
ics and treatment duration are presented in Table 1. Telatinib doses used were 20 mg 
od (n=2), 75 mg od (n=2), 150 mg bid (n=4), 300 mg bid (n=4), 600 mg bid (n=3), 
900 mg bid (n=16), and 1500 mg bid (n=2). Our population comprised 100% Cauca-
sians with 45% males and 55% females. Most frequent tumor types were soft tissue 
sarcomas (27%) next to colorectal cancer (15%) together with a high number of other 
tumor types (58%) consistent with the phase I nature of the clinical study. Median num-
ber of treatment courses was 5.5, ranging from 1 to 30, with one course being 3 weeks 
of telatinib administration.
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 Telatinib toxicity was generally mild, with any grade 1-4 toxicity during all treatment 
cycles occurring in 23 out of 33 patients (70%). Grade 3-4 toxicity was only observed in 
3 patients. Hypertension was the most frequently observed side-effect (n=7) and was 
unrelated to dose.16 
Table 1.  Patient characteristics, overall telatinib-induced toxicity, pharmacokinetic results 
and outcome data of telatinib treated patients. 
Characteristics Patients (n (%))
Gender
     Male 15 (45)
     Female 18 (55)
Age, years
     Mean (range) 53 (22-77)
Tumor type
     Soft tissue sarcoma  9 (27)
     Colorectal cancer  5 (15)
     Adrenal cancer  3 (9)
     Ovarian cancer  3 (9)
     Cholangiocarcinoma  2 (6)
     Esophageal cancer  2 (6)
     Melanoma  2 (6)
     Miscellaneous  7 (21)
ECOG performance score
    0  9 (27)
    1 24 (73)
Nr of previous treatment lines
    Mean (range)  3 (0-13)
Toxicity
     Any toxicity grade 1-4 23 (70)
     Any toxicity grade 3 or 4  3 (9)
     Hypertension grade 1-4  7 (21)
     Hypertension grade 3 or 4  2 (6)
Pharmacokinetic parameters 
  Mean (range)
     Dose normalized AUC(0-12) 
     (µg.hr/L per mg of dose)  9.26 (0.98-34.60)
Number of treatment courses
     Mean (range)  5.5 (1-30)
ECOG: Eastern Cooperative Oncology Group
Dose normalized AUC: area under the curve/dose
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 The success rates for all genotyping assays were 100%. Genotype frequencies for 13 
of 15 SNPs were in Hardy-Weinberg equilibrium (P >0.05). ABCB1 -129T>C and ABCC1 
2012G>T did not adhere Hardy-Weinberg equilibrium, which was most likely caused by 
the limited population size. Genotype frequencies for both SNPs were in line with previ-
ous publications and frequencies reported in the NCBI database (www.ncbi.nlm.nih.gov). 
 There was no association between telatinib dose normalized AUC(0-12) and genetic 
polymorphisms in ABCB1, ABCC1, or ABCG2 (Table 2). Haploblock for ABCB1 included 
3435C>T, 1236C>T, and 2677G>A/T; haploblock for ABCC1 included 825T>C, and 
1062T>C. Haplotype frequencies for ABCB1 were TTT 0.392, CTT 0.017, TCG 0.093, and 
CCG 0.498, and for ABCC1 CC 0.197, TC 0.061, and TT 0.724. Also ABCB1 and ABCC1 
haplotypes did not show an association with telatinib dose normalized AUC(0-12). 
 The number of telatinib treatment courses was not related to any of the genetic 
polymorphisms and haplotypes analyzed. Since this was an exploratory study with a 
relatively small number of patients, different dose levels, different tumor types, and vari-
able previous treatment lines association analyses between polymorphisms and treat-
ment outcome were not performed. 
 No association between any grade 1-4 toxicity and KDR or FLT4 genotype or haplo-
type was observed (Table 3). 
Discussion
The development of tailor-made pharmaceutics is especially useful in the field of oncol-
ogy, as most standard anticancer agents have a very narrow therapeutic index, leading 
to nonspecific anti-tumor response in combination with a high level of side effects. For 
example, in 3-5% of patients with severe 5-FU-related toxicity. dihydropyrimidine dehy-
drogenase (DPD) deficiencies are described.2,13 In addition, the genetic variant of the 
gene encoding UDP glucuronosyltransferase (UGT) 1A1 polymorphism, UGT1A1*28, is 
associated with a higher incidence of toxicity, mostly hematological toxicity, in irinote-
can treatment.4,5,7 
 Most research to improve cancer treatment through genetics has focused on poly-
morphisms in genes encoding the drug transporters and drug metabolizing enzymes but 
less is known about genetic variation in drug targets. Directing treatment on the vascu-
lar endothelial growth factor (VEGF) pathway, one of the key players in angiogenesis, is 
a focus of more recent research. VEGF inhibitors have only become available for clinical 
use in the last few years and consequently, very little is known regarding the influence 
of polymorphisms in VEGF or its receptor, VEGFR.8,10 One CA repeat polymorphism in 
the KDR (VEGFR2)) gene is described previously, with a higher promoter activity in the 
Pharmacogenetics of telatinib used in patients with solid tumors 
71
Table 2.  Association between genetic polymorphisms and telatinib pharmacokinetic 
data.
Dose normalized AUC
Gene Polymorphism Genotype No. Mean SD
ABCB1 3435C>T CC  7 7.30 3.35
CT 16 11.10 9.10
TT  6 6.65 4.76
P-value 0.343
1236C>T CC  9 7.84 3.26
CT 15 11.60 9.44
TT  5 4.82 1.81
P-value 0.167
2677G>A/T GG  9 7.84 3.26
TG 15 11.60 9.44
TT  5 4.82 1.81
P-value 0.167
-129T>C TT 26 8.67 7.51
TC  2 15.65 6.06
CC  1 11.79 n.a.
P-value 0.430
ABCC1 # (rs129081) CC  5 10.22 7.57
GC 15 10.44 9.07
GG  9 6.77 3.16
P-value 0.494
825T>C TT 18 8.26 6.54
TC 11 10.90 8.76
P-value 0.362
1062T>C TT 17 8.36 6.73
TC 10 9.95 9.15
CC  2 13.45 3.30
P-value 0.631
2012G>T GG 24 8.80 5.89
GT  4 13.46 14.57
TT  1 3.63 n.a.
P-value 0.391
ABCG2 346G>A GG 25 9.78 7.83
AG  4 6.00 2.69
P-value 0.353
421C>A CC 23 8.95 7.96
CA  6 10.48 5.26
P-value 0.661
#=*801 number from termination codon TGA (5397). 3UTR
Chapter 5
72
11-repeat polymorphism compared to the 12-repeat polymorphism.6 Four SNPs in the 
KDR gene were identified by Park et al (-92G>A, 54A>G, 889G>A, and 1416T>A) and 
associated with atopy.9 Recently, Schneider et al reported that KDR genotypes were not 
associated with toxicity or efficacy of paclitaxel with or without bevacizumab treatment 
in advanced breast cancer patients.15 
 VEGF inhibitors can induce very specific side effects which are hard to predict. This is 
even more relevant while in future use these angiogenesis inhibitors most likely will be 
combined with various chemotherapeutic agents. Pharmacogenetic research might help 
to identify the patients at risk for specific side effects and select patients or doses needed 
for optimal treatment without adding potentially harmful side effects. 
 In this exploratory study we could not find an association between polymorphisms 
in genes encoding transporter proteins and telatinib pharmacokinetics or between drug 
target gene polymorphisms and telatinib induced toxicity. This lack of association might 
be explained by, for example, the limited number of patients, the relatively limited toxic-
ity, and the variability in tumor types, number of previous treatment lines, and perfor-
mance scores. Since toxicity was limited we used toxicity reported over all treatment 
cycles. This may have caused bias, and therefore number of treatment cycles was used 
as a covariate in the multivariate analysis. Since different telatinib doses were used, we 
corrected by associating polymorphisms with dose normalized AUC(0-12).
Table 3. Association between genetic polymorphisms and telatinib-induced toxicity.
Toxicity: any toxicity grade 1-4 
all cycles
Gene Polymorphism Genotype No Yes P-value
FLT4 1480A>G AA 7 20 0.336
AG 3 3
2670C>G CC 6 11 0.813
CG 3 9
GG 1 3
KDR 1719A>T AA 1 1 0.809
TA 4 9
TT 5 13
-604T>C CC 3 7 0.870
CT 5 13
TT 2 3
1192G>A CC 5 19 0.091
TC 4 4
TT 1 0
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 Pharmacogenetic testing is important for all new drug applications. Knowledge on 
pharmacokinetics and pharmacodynamics of both registered and new developing drugs 
is increasing far more rapidly than the knowledge on genetic variants in metabolizing 
enzymes, transporters and drug target genes.1,12,14 Therefore, DNA collection for future 
genetic studies, retrospective and prospective, is required and all patients in clinical tri-
als should be asked to consent for DNA collection for future studies. Often side effects 
are based on single gene polymorphisms affecting drug metabolism, interaction with 
cellular targets or transport. Therefore, hypothesis based pharmacogenetic research of 
candidate genes is important in phase I and II studies to limit the number of patients un-
necessarily exposed to a toxic dose or drug. This information may reduce the size, costs 
and duration of subsequent phase III studies. 
 In general, in the preclinical and phase I setting little is known about drug pharma-
cokinetics and pharmacodynamics. With this exploratory study we tried to increase 
that knowledge, because, despite of the rapidly increasing use of VEGF inhibitors, the 
knowledge of determinants that predict response and toxicity in the individual patient 
is still lacking. Therefore, it remains highly important to conduct pharmacogenetic 
association studies in early drug development in order to increase knowledge on 
interpatient variability of drug response. 
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Hypertension is a commonly reported side effect in antiangiogenic therapy. We inves-
tigated the hypothesis that telatinib, a small molecule angiogenesis inhibitor, impairs 
vascular function, induces rarefaction, and causes hypertension.
Experimental Design
A side-study was done in a phase I trial of telatinib, a small molecule tyrosine kinase in-
hibitor of vascular endothelial growth factor receptors 2 and 3, platelet-derived growth 
factor receptor, and c-KIT in patientswith advanced solid tumors. Measurements of blood 
pressure, flow-mediated dilation, nitroglycerin-mediated dilation, aortic pulse wave ve-
locity, skin blood flux with laser Doppler flow, and capillary density with sidestream dark 
field imaging were done at baseline and after 5 weeks of treatment. Blood pressure and 
proteinuria were measured weekly.
Results
Mean systolic and diastolic blood pressure values increased significantly at +6.6 mm Hg 
(P = 0.009) and +4.7 mm Hg (P = 0.016), respectively. Mean flow-mediated dilation 
and mean nitroglycerin-mediated dilation values significantly decreased by -2.1% (P = 
0.003) and -5.1% (P = 0.001), respectively. After 5 weeks of treatment, mean pulse wave 
velocity significantly increased by 1.2 m/s (P = 0.001). A statistically significant reduc-
tion of mean skin blood flux of 532.8% arbitrary units was seen (P = 0.015). Capillary 
density statistically significantly decreased from 20.8 to 16.7 capillary loops (P = 0.015). 
Proteinuria developed or increased in six patients during telatinib treatment.
Conclusion
The increase in blood pressure observed in the treatment with telatinib, an angiogenesis 
inhibitor, may be caused by functional or structural rarefaction. 
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Introduction
Dysregulated signaling through the vascular endothelial growth factor (VEGF)/VEGF re-
ceptor-2 (VEGFR-2) pathway mediates neoangiogenesis and thereby promotes tumor 
development and metastasis.1,2 Overexpression of VEGF is common in solid tumors and 
has been associated with poor prognosis3. Furthermore, the overexpression or increased 
activation of VEGFR-2 has been associated with a poor prognosis in solid tumors.4,5 In 
preclinical models, inhibition of the tyrosine kinase activity of the VEGFR-2 blocks angio-
genesis and inhibits the growth of tumors.6
 Hypertension is a commonly reported side effect in trials with inhibitors of VEGF/
VEGFR-2 signaling, like bevacizumab and sunitinib.7–12 The mechanisms leading to this 
increase in blood pressure during antiangiogenic therapy have not been elucidated. Pro-
posed mechanisms include reduced formation of nitric oxide (NO) by endothelial cells, a 
reduced responsiveness of vascular smooth muscle cells to NO, an increased production 
of or reaction to vasoconstricting stimuli, a reduced compliance and distensibility of the 
vascular wall, and microvascular rarefaction.13–15 Because microvessels (arterioles and 
capillaries) are a major contributor to total peripheral vascular resistance, functional 
rarefaction (a decrease in perfused microvessels) or anatomic rarefaction (a reduction in 
capillary density) may play an important role in the development of hypertension. 
 We hypothesized that systemic inhibition of VEGF impairs vascular function and 
causes rarefaction, which then leads to the development of hypertension in patients 
treated with antiangiogenic agents. 
Materials and methods
This study was conducted on a subset of patients enrolled into an open-label, nonran-
domized, two-center, phase I dose-escalating study of oral telatinib (Bay 57-9352).16 The 
purpose of this study was to search for possible mechanisms that cause hypertension 
in patients treated with antiangiogenic therapy and to confirm our hypothesis that sys-
temic inhibition of VEGF inhibits vascular function and causes rarefaction. 
Patients 
Patients with advanced solid tumors with no standard treatment available were eligible 
for study participation. Inclusion criteria were age of 18 y or older; WHO performance 
status of 0 to 2; life expectancy of at least 12 wk; and adequate bone marrow, liver, 
and renal function. Exclusion criteria were history of cardiac disease; history of HIV, 
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hepatitis B, or hepatitis C infection; active clinically serious infection; serious nonheal-
ing wound, ulcer, or bone fracture; symptomatic metastatic brain or meningeal tumors; 
pregnancy or breast feeding; treatment with any anticancer agent or investigational 
drug 4 wk before the first dose; antiangiogenic therapies/VEGFR-2 inhibitors before en-
rollment. 
 The side-study was conducted on patients that were treated in the Leiden University 
Medical Center. The study protocol was approved by the Medical Ethical Committee of 
the Leiden University Medical Center. All patients gave written informed consent. 
Intervention 
Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of the VEGFR-2 (IC50 
in biochemical assay, 6 nmol/L), VEGFR-3 (IC50, 4 nmol/L) tyrosine kinases, and the 
growth factors receptors platelet-derived growth factor receptor-a (IC50, 15 nmol/L) 
and c-Kit (IC50, 1 nmol/L). Telatinib was continuously given once daily or twice daily in an 
oral formulation as solution or tablet. Patients were divided into cohorts with escalating 
doses. Therapy continued until progressive disease, unacceptable toxicity, death, con-
sent withdrawal, or withdrawal from study at the discretion of the investigator. Telatinib 
was provided by Bayer Pharmaceuticals Corporation. 
 We assessed blood pressure, vascular function, and structure variables at baseline, 
and after 5 wk of treatment, in addition to regular evaluation of variables for safety, 
pharmacokinetics, and efficacy. 
Hemodynamic, vascular function, and vascular structure variables 
and proteinuria 
Blood pressure, flow-mediated dilation (FMD), nitroglycerin-mediated dilation (NMD), 
aortic pulse wave velocity (PWV), skin blood flux with laser doppler flow, and capillary 
density with sidestream dark field (SDF) imaging were assessed at baseline and after 
5 wk of treatment with telatinib. All measurements were done by the same experienced 
investigator, in the morning, in a quiet, temperature-controlled room. 




Peripheral blood pressure measurements at baseline and at the 5-wk visit were done 
after 15 min rest, measuring thrice in a supine position with 5-min intervals, using an 
automatic device (Datex-Ohmeda S/5 Light Monitor, Datex-Ohmeda, Inc.) with the cuff 
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor 
79
placed at the brachial artery. For statistical analysis, we used the mean of three consecu-
tive measurements. Peripheral blood pressure measurements at the weekly visit to the 
outpatient clinic were done by the treating physician, using an aneroid sphygmoma-
nometer (Maxi-Stabil 3, Speidel & Keller, Welch Allyn) with the auscultatory method. 
Central blood pressure
Application tonometry of the brachial and external carotid artery (SphygmoCor SCOR-
PVx device, AtCor) was done. The mean of the three peripheral blood pressure measure-
ments was used to calculate central aortic pressure.17 
Aortic pulse wave velocity
Measurements were done at the right carotid and femoral arteries using standard blood 
pressure transducers (SphygmoCor SCOR-PVx device, AtCor) with simultaneous electro-
graphic gating. This enabled the base of the pressure wave to be recorded and the time 
delay between the carotid and femoral waves to be calculated. The distance between 
the two sites was measured. PWV was defined as the distance traveled by the pressure 
waves divided by the time delay. 
Flow mediated dilation
The FMD measurements were done in a quiet, temperature-controlled room. Postisch-
emic vasodilator responses in the brachial artery were measured using a Wall Track 
System (WTS 2, Pie Medical). This system consists of a standard 7.5-MHz linear array 
ultrasound transducer connected to a PC equipped with a data acquisition board and 
software. Subjects were investigated in a supine position, and three ECG leads were 
attached. Ischemia was induced in the forearm by inflation of a blood pressure cuff 
just below the elbow of the right arm for 5 min. After deflation of the cuff, changes in 
brachial artery wall diameter were measured every 20 s for 4 min. WTS measurements 
were stored and analyzed off line using WTS software. FMD was expressed as percent-
age change in brachial artery diameter after ischemia. 
NMD
NMD was assessed in the same way as FMD, with the exception that 0.4 mg of nitro-
glycerin were given sublingually, instead of cuff inflation and deflation, before measure-
ments were started. 
Laser Doppler flowmetry
Forearm skin blood flux was measured using laser Doppler flowmetry (Periflux PF4001, 
Perimed; wavelength, 782 nm) before and during forearm postischemic hyperemia.18 
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Flows were recorded by the Perisoft program, with the time constant set at 3 s down-
stream from a broadband filter (12 MHz). Results were reported as arbitrary flow units 
(10 mV). The percentage of change in arbitrary units from baseline (before ischemia) to 
maximal flow in the postischemic hyperemic phase was reported. 
Capillary density measurements with SDF imaging
Patients were situated in a supine position with the investigator at the head side of the 
bed. An SDF hand-held device (MicroScan Video Microscope System, MicroVision Medi-
cal) was introduced into the open mouth and gently pushed to the mucosal surface of 
the inner lip. SDF imaging consists of a light guide surrounded by light-emitting diodes 
that emit green light (540 F 50 nm) which penetrates the tissue and directly illuminates 
the tissue microcirculation. The SDF technique and the technique of its precessor orthog-
onal spectral polarization imaging are described in detail in previous publications.19,20 
 Images of the mucosal microcirculation were projected on a computer screen. The 
final on-screen magnification of the images obtained with the SDF imaging device was 
325 times original. When images of satisfying quality were seen, video images of at least 
30 s were obtained. Images were obtained from four different lip quadrants (mucosal 
readings of the left and right upper inner lip quadrant and the left and right lower inner 
lip quadrant) using the SDF probe. From every quadrant, at least three 30-s video images 
were obtained. Video images were stored on digital videotape in .avi format. 
 Off line, at least five still frames of each quadrant were captured from these video 
images. The number of capillary loops per frame was counted. Capillary density for each 
frame was expressed as the mean number of capillary loops per mm2. The mean capillary 
density per lip quadrant and total lip was calculated. 
 All measurements were done by one technician, not blinded to the time point in 
treatment of the patients. Off-line analysis (counting of the number of capillary loops) 
was done by two observers, who were blinded to the time point in treatment of the 
patients. 
 Whereas the technique has not been used very frequently in the measurement of mi-
crocirculation of the mucosal surface of the inner lip, additional quality measurements 
were done. In 10 healthy volunteers, no difference in capillary density was observed be-
tween the different lip quadrants. The reproducibility of the SDF technique to determine 
capillary density was moderate to high, showing a coefficient of variation of 4.6%. 
Proteinuria
Urinalysis, measured by dipstick, was done weekly in all patients to monitor proteinuria. 
Proteinuria was recorded according to the National Cancer Institute Common Toxicity Cri-
teria version 3.0. Grade 1 is defined as 1+ by dipstick, grade 2 as 2+ or 3+ by dipstick, 
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grade 3 as 4+ by dipstick, and grade 4 as nephrotic syndrome. We report the development 
of proteinuria (grade 0 before treatment increasing to grade >0 during treatment) and 
the worsening of proteinuria (increase of proteinuria by z1 grade compared with baseline). 
Pharmacokinetic analysis 
Serial blood samples were collected for pharmacokinetic analysis on days 1 and 14 of 
cycle 1. Telatinib plasma concentrations were analyzed by a noncompartmental method 
using the KINCALC software package, Bayer AG, version 2.33 or higher. Peak plasma level 
(Cmax), area under the concentration-time curve [AUC(0-tn)], were calculated. 
Statistical analysis 
Continuous variables are presented as mean values ± SD and categorical variables as 
frequencies (percentages), unless otherwise stated. Comparisons between variables at 
baseline and after 5 wk were done with paired Student’s t-tests and were two-sided, 
with a level of significance of a = 0.05. For skin blood flux and capillary density, the 
Wilcoxon signed-rank test was used. The relationship between blood pressure, vascular 
function and structure variables, and telatinib daily dose and telatinib pharmacokinetic 
variables [Cmax and AUC(0-tn)] was investigated by correlation analysis. Correlation analy-
sis was done using Pearson’s and Spearman’s correlation coefficients where appropriate. 
Correlations with proteinuria were done using an armitage test for trend. For correlation 
purposes proteinuria was reported as presence of new proteinuria or increase in existing 
proteinuria (yes or no). All analyses were done using SPSS version 12.01 (SPSS). 
Results
Eighteen of 33 patients treated in our hospital were included in this side study. Reasons 
for exclusion were vaso-active hormone producing adrenal carcinoma (n = 3), absence 
of measurements for logistics reasons between June and December 2005 (n = 7), ab-
sence of measurements at 5 weeks due to early drop out for early progressive disease 
(n = 2), anatomic anomaly of the arm (n = 1), absence of appropriate drug compliance 
(supported by pharmacokinetic data; n = 1), and failure to upheld appointment baseline 
visit (n = 1). NMD measurements were not done in two patients; both had a preexisting 
headache and refused sublingual nitroglycerin administration. 
 Baseline demographics and patient characteristics of the 18 patients included in this 
study are listed in Table 1. Patients received the following starting doses of Bay 57-9352: 
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patient 1, 20 mg solution once daily; patients 2 to 3, 75 mg (25 mg tablets) once daily; 
patients 4 to 5, 150 mg (150 mg tablets) twice daily; patients 6 to 9, 300 mg (150 mg 
tablets) twice daily; patient 10, 600 mg (150 mg tablets) twice daily; and patients 11 to 
18, 900 mg (150 mg tablets) twice daily. 
Blood pressure results
Both peripheral systolic blood pressure and peripheral diastolic blood pressure increased 
in 14 of 18 patients (78%) after 5 weeks treatment with telatinib compared with baseline 




  Male gender  9 (50) 
  Age, y (range) 55 (22-76) 
Additional cardiovascular risk factors 
  Body mass index, kg/m2 (range) 24.7 (20.5-29.7) 
  Nicotine abuse, in past or present  5 (28) 
  History of cardiovascular disease  0 (0) 
  History of hypertension  1 (6) 
  Renal impairment (creatinine > ULN)  5 (28) 
WHO performance scale 
  0  4 (22) 
  1 14 (78) 
Prior treatment 
  Surgery 13 (72) 
  Chemotherapy 17 (94) 
  Radiotherapy  8 (44) 
   Blood pressure lowering drugs at entry  2 (11) 
Tumor type 
  Anal carcinoma  1 (6) 
  Carcinoid tumor  1 (6) 
  Cholangiocarcinoma  1 (6) 
  Colorectal carcinoma  3 (17) 
  Esophageal carcinoma  1 (6) 
  Ovarian carcinoma  3 (17) 
  Prostatic carcinoma  1 (6) 
  Renal cell carcinoma  1 (6) 
  Soft tissue sarcoma  5 (28) 
  Urothelial cell carcinoma  1 (6) 
NOTE: Data are presented as n (%) unless otherwise specified. Abbreviation: ULN, upper limit of normal. 
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Fig. 1. Blood pressure (A), skin blood flux (C), and capillary density (D) results at baseline and after 5 
wk of treatment with telatinib. B, mean systolic blood pressure (continuous line) and mean diastolic 
blood pressure (dashed line) before treatment, weekly during treatment, and after discontinuation 
of telatinib treatment. A horizontal dashed line was added at baseline systolic blood pressure and 
baseline diastolic blood pressure for facilitation of reading. Left from the vertical line blood pres-
sures measured in the first 84 d of treatment. Right from the vertical line blood pressures measured 
7 and 28 d after discontinuation of treatment. pSBP, peripheral systolic blood pressure; pDBP, pe-
ripheral diastolic blood pressure; cSBP, central systolic blood pressure; cDBP, central diastolic blood 
















































































Baseline After 5 weeks




































































































Baseline After 5 weeks






















values. The mean peripheral systolic blood pressure significantly increased from 132.2 
to 138.8 mm Hg (P = 0.009), and the mean peripheral diastolic blood pressure values 
increased from 83.1 to 87.8 mm Hg (P = 0.016; Table 2; Fig. 1A). The increase in central 
systolic blood pressure (4.3 mm Hg) was not statistically significant (P = 0.106). Both 
peripheral and central pulse pressure showed no change after 5 weeks of treatment. 
 Mean peripheral blood pressures measured at the weekly visits showed a similar 




A.  Hemodynamic and vascular function/structure variables at baseline and after 5 wk of 
treatment with telatinib 
Baseline 
values 
After 5 wk 
treatment 
Change ± SD 95% Confidence 
interval
P 
pSBP (mm Hg) 132.2 138.8   +6.6 ± 9.5 (1.9 to 11.3) 0.009*
pDBP (mm Hg) 83.1 87.8   +4.7 ± 7.4 (1.0 to 8.4) 0.016*
cSBP (mm Hg) 129.9 134.2   +4.3 ± 10.9 (-1.0 to 9.8) 0.106 
cDBP (mm Hg) 82.9 87.5   +4.6 ± 7.8 (0.7 to 8.4) 0.024*
MAP (mm Hg) 102.5 107.6   +5.1 ± 7.2 (1.5 to 8.7) 0.008* 
pPP (mm Hg) 54.3 57.1   +2.8 ± 12.9 (-3.6 to 9.2) 0.369 
cPP (mm Hg) 47.0 46.8    –0.2 ± 10.2 (-5.2 to 4.9) 0.946 
FMD (%) 6.0 3.9    –2.1 ± 2.6 (0.8 to 3.5) 0.003* 
NMD (%) 17.0 11.9    –5.1 ± 4.1 (2.9 to 7.3) 0.001* 
PWV (m/s) 8.5 9.7   +1.2 ± 0.8 (0.8 to 1.7) 0.001* 
Skin blood flow (%AU) 1091.5 558.7  –532.8 ± 362.0 (-912.7 to -152.9) 0.015* 
Capillary density (n) 20.8 16.7    –4.1 ± 3.3 (-7.2 to -1.1) 0.015*
B.  Individual blood pressure data before treatment, during treatment, and after discon-
tinuation of telatinib treatment 
Pt Systolic blood pressure, d 
0 7 14 21 28 35 42 49 56 63 70 77 84 +7 +28 
 1 110 105 110 115 115 110 130 120 115 120 115 110 
 2 115 115 120 120 125 120 115 130 120 
 3 130 160a 135 140 150 128 150 180a 145 145 135 
 4 130 125 120 138 120 125 125
 5 115 120 125 120 120 125 130 110 
 6 145 150 145 155a 140 140 135 130 160a 150 120 
 7 110 100 120 125 110 110 120 125 105 110 
 8 130 140 150 150 160 160 130 130 125 140 110 
 9 105 130 130 140 125 130 110
10 130 120 126 140 135 120 140 130 135 130 140 100 
11 120 120 130 130 135 120
12 140 130 135 130 125 170a 130 160 149 163 150 110 
13 120 125 150 140 156a 140 150 130 130 130 
14 125 143 130 130 112 120 
15 120 125 110 120 120 135 120 120 
16 135 130 150 145 130 110 118 
17 130 125 130 135 120 128 125
18 125 140 145 150 125 130 125 140 135 105 130 ongoing 
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the individual patients are reported in Table 2B. Results for the first 84 days on treatment 
are reported. The number of patients on telatinib treatment after 84 days was too small 
for reliable results to be reported (n = 7). None of the seven patients remaining on study 
medication after 84 days developed a new increase in blood pressure. In all patients, the 
blood pressure values returned to baseline within 4 weeks after the discontinuation of 
the telatinib. 
 One patient received antihypertensive medication before start of treatment (thia-
zide diuretic). Four additional patients were started on antihypertensive treatment: one 
patient receiving 600 mg telatinib daily and three patients receiving 1800 mg daily. 
Antihypertensive medication consisted of a thiazide diuretic in one patient, a calcium 
antagonist in one patient, and an ACE inhibitor in two patients. 
Pt Diastolic blood pressure, d 
0 7 14 21 28 35 42 49 56 63 70 77 84 +7 +28 
 1 60 60 55 70 55 70 65 60 60 70 55 70 
 2 70 80 80 80 80 80 80 80 80 
 3 75 80 75 80 70 72 70  80 80 70 75 
 4 85 90 90 85 65 60 70
 5 75 80 75 85 80 75 80 70 
 6 85 85 85 85 80 90 85 85 90 90 80 
 7 70 70 75 85 85  80 80 80 70 70 
 8 75 70 80 90 90 89 85 75 80 80 60 
 9 70 90 85 90 80 80 70
10 75 80 81 85 80 85 70 85 80 75 65 70 
11 75 75 80 85 85 80
12 80 80 85 80 80 102a 90 100 100 98 85 75 
13 70 80 89 85 97 90 90 80 80 75 
14 80 79 85 80 78 75 
15 75 80 70 70 80 80 80 80 
16 85 90 110 90 75 70 77 
17 85 80 85 90 80 74 80
18 80 85 85 90 85 85 80 90 90 70 80 ongoing 
NOTE: Data in italics indicate antihypertensive medication started.
Abbreviations: pSBP, peripheral systolic blood pressure; pDBP, peripheral diastolic blood pressure; cSBP, central 
systolic blood pressure; cDBP, central diastolic blood pressure; MAP, mean arterial pressure; pPP, peripheral pulse 
pressure; cPP, carotid pulse pressure; %AU, percentage of change from baseline in arbitrary units; n, number. 
*P < 0.05. 
aNo antihypertensive treatment started, regardless of protocol.
B.  Individual blood pressure data before treatment, during treatment, and after discon-
tinuation of telatinib treatment
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Vascular function and vascular structure assessments
FMD decreased from baseline in 15 of 18 patients (83%) after 5 weeks treatment with 
telatinib. At 5 weeks, the mean decrease in FMD, compared with baseline, was statisti-
cally significant, from 6.0% to 3.9% (P = 0.003; Table 2). After 5 weeks of treatment, 
NMD decreased in 94% of patients. The mean change in NMD from 17.0% at baseline to 
11.9% after 5 weeks was statistically significant (P = 0.001; Table 2). An increase in PWV 
was seen in 17 of 18 patients (94%). Mean PWV significantly increased from 8.5 m/s at 
baseline to 9.7 m/s after 5 weeks treatment (P = 0.001; Table 2). Mean forearm skin blood 
Fig. 2. SDF images demonstrating visible capillary loops of a representative patient. A, at baseline. 
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flux decreased significantly (-532.8 %AU, P = 0.015; Table 2). SDF imaging was done in 
seven patients. In all of the patients, the number of capillary loops markedly decreased 
after 5 weeks of treatment (Figs. 1 and 2; Table 2). Capillary density, the mean number of 
capillary loops per image, decreased from 20.8 at baseline to 16.7 after 5 weeks treat-
ment with telatinib (P = 0.015). 
 
Proteinuria
In four patients, proteinuria was reported at baseline, grade 1 proteinuria in one patient, 
and grade proteinuria in three patients. Proteinuria increased in one of those patients 
from grade 1 to grade 2. Five patients developed new onset proteinuria during telati-
nib treatment: grade 1 in three patients and grade 2 in two patients. Five of these six 
patients with new onset or increasing proteinuria were receiving the highest dose of 
telatinib at 1,800 mg daily. After discontinuation of treatment in three of six patients, 
the proteinuria returned to normal. For the other three patients, no data for proteinuria 
after discontinuation of telatinib were available. In two of the six patients with new 
Table 3. Telatinib daily dose and pharmacokinetic variables [Cmax and AUC(0-tn)]
Patient Daily dose 
(mg) 
Cycle 1, day 1 Cycle 1, day 14 
Cmax, mg/L AUC(0-tn), mg h/L Cmax, mg/L AUC(0-tn), mg h/L
 1 20 0.2061 0.5284 0.1658 0.9628 
 2 75 0.2927 1.7464 0.1888 1.8779 
 3 75 0.3734 1.4246 0.4526 1.6941 
 4 300 0.0675 0.4141 0.1822 1.7680 
 5 300 0.0935 0.7527 0.1355 1.0164 
 6 600 1.2678 3.4588 1.1915 5.9823 
 7 600 0.1250 0.4504 0.6493 3.3407 
 8 600 0.1888 1.1649 0.2897 2.3776 
 9 600 1.2809 8.7848 1.4486 10.3795 
10 1200 2.1691 16.7094 1.6995 16.4708 
11 1800 0.4298 2.4610 1.7637 5.2292 
12 1800 1.0484 7.0520 1.1216 7.3369 
13 1800 0.2856 3.0094 0.2229 1.9701 
14 1800 0.0552 0.8416 0.0969 0.8832 
15 1800 0.2918 2.7700 0.8145 6.7397 
16 1800 1.2599 3.4356 0.5728 3.1803 
17 1800 1.6730 9.7474 2.6011 12.2049 
18 1800 0.4515 2.9511 0.7626 6.2329 
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or increasing proteinuria, an increase in blood pressure above 150 mm Hg systolic or 
above 100 mm Hg diastolic was reported. These two patients were treated with an ACE 
inhibitor, resulting in disappearance of the proteinuria. The other four patients were not 
treated for the proteinuria. 
Pharmacokinetic analysis and correlations
Telatinib pharmacokinetic variables [Cmax and AUC(0-tn)] are shown in Table 3. There was 
no correlation between either blood pressures or vascular function/structure variables 
and daily dose of telatinib or telatinib pharmacokinetic variables [Cmax and AUC(0-tn)]. No 
correlation between development or increase of proteinuria and blood pressure mea-
surements or any of the other variables was seen. However, there was positive correla-
tion between daily dose of telatinib and proteinuria (linear-by-linear association, 5.0; 
P = 0.025). All patients with SDF measurements done received 1,800 mg of telatinib a 
day. No correlation between SDF results and daily dose could therefore be calculated. 
Discussion
We studied the effects of telatinib, a tyrosine kinase inhibitor and potent inhibitor of 
angiogenesis, on the vasculature to determine a mechanism by which small molecule 
angiogenesis inhibitors cause an increase in blood pressure. The rarefaction (reduction 
in capillary density) and change in microvascular characteristics observed in this study 
provide a plausible mechanism for the increase in systolic and diastolic blood pressure. 
Telatinib caused a significant decrease in endothelium-dependent and endothelium-
independent vasodilation. VEGF inhibition by itself decreases NO synthesis, which pro-
motes vasoconstriction, increases peripheral resistance, and therefore can induce an 
increase in blood pressure.21–24 It remains unclear whether the key problem is impaired 
NO synthesis, the change in capillary structure leading to impaired NO vascular smooth 
muscle cell responsiveness, or a combination of both. Aortic pulse wave velocity is a vari-
able for vascular stiffness, a which is known to increase with age, and is an independent 
predictor of cardiovascular risk and all-cause mortality in renal disease, hypertensive 
patients, and patients with diabetes mellitus.25–27 We observed a significant increase in 
PWV, which correlated with the increase in mean arterial pressure. Although blood pres-
sure is a known independent determinant of pulse wave velocity, it cannot be excluded 
that inhibition of angiogenesis has a direct effect on stiffness of the arterial tree.28 In a 
subgroup of patients, we did SDF imaging to visualize a the microvessels in the buccal 
mucosa. All patients showed a reduction in the number of mucosal capillaries (rarefac-
tion) during antiangiogenic treatment. Vessels smaller than 150 mm in diameter are the 
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most important segment of the vascular bed to regulate blood flow and blood pres-
sure.29,30 A reduction in the number of (functional) arterioles and capillaries leads to 
increased peripheral vascular resistance and blood pressure. Rarefaction is a consistent 
finding in patients with hypertension,30–32 and it is also reported in normotensive young 
adults with a genetic predisposition to high blood pressure.33 Blocking the growth of 
capillaries by VEGFR inhibitors and other angiogenesis inhibitors might lead to the same 
results even in subjects that are not predisposed to the development of hypertension. 
Whether the observed rarefaction is structural (disappearance of capillaries) or func-
tional (i.e., nonperfused existing capillaries) is unclear, as visualization of microvessels 
based upon the SDF technique depends on perfusion of these vessels. Although the 
rapid normalization of blood pressure within weeks and reversal in proteinuria in some 
patients after discontinuation of telatinib may indicate improvement in functional rar-
efaction, this is more likely in functional then structural rarefaction. It remains uncertain 
whether the changes in microvessel architecture are reversible upon discontinuation of 
the treatment. While capillary density measurements were done in only seven patients, 
one should be careful with the interpretation of these results. These results have to be 
confirmed in a larger patient sample. 
 The exact mechanism by which telatinib leads to rarefaction and hypertension is 
unclear. Telatinib is a small molecule tyrosine kinase inhibitor, blocking the ATP-binding 
site of the VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-a, and c-Kit re-
ceptors. Platelet-derived growth factor and c-Kit receptor activation result in activation 
of pathways that, for a large part, are also activated by VEGFR-2. However, hyperten-
sion is rarely seen in the treatment with platelet-derived growth factor and c-Kit inhibi-
tors, such as imatinib and nilotinib.34,35 In contrast, selective inhibitors of VEGF/VEG-
FR-2 signaling, such as sunitinib or bevacizumab, frequently cause hypertension.7–10 
The increase in blood pressure is therefore most likely caused by the inhibition of the 
VEGFR signaling. However, we cannot rule out that c-KIT or platelet-derived growth 
factor inhibition has a role in mediating the blood pressure changes or changes in any 
of the other measured variables. A recently published preclinical observation suggests 
that VEGF signaling is required for vascular homeostasis.36 Our findings could be the 
clinical proof of that concept. 
 Our study has several limitations. First, the study was set up as a side-study of a 
phase I dose-finding study. Therefore, different dosages of telatinib were used by our 
patients. However, there was no correlation between changes on blood pressure, vascu-
lar structure/function variables, capillary density, and daily dose of telatinib or telatinib 
exposure. Even in the patients with lower doses of telatinib, significant changes in all 
measured variables were seen. Second, due to the small number of patients it was not 
possible to reliably quantitate capillary characteristics, such as length, diameter size, and 
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tortuosity. Third, no control group was measured and distinction between treatment 
and placebo effects is therefore not clear. Fourth, no vascular measurements were done 
after discontinuation of treatment. Whereas all patients had advanced tumors with a 
low life expectancy, we chose not to burden these patients with additional measure-
ments after cessation of the study drug. Finally, the temporal relationship between rar-
efaction and hypertension is unclear. Therefore, future studies, in larger patient samples, 
with measurements before, during, and after treatment are necessary. 
 In the most extensively studied VEGF inhibitor bevacizumab, the increase in blood 
pressure is dose dependent.13 We did not observe this in our study. This could have been 
due to the small study size. In addition, the start of antihypertensive medication may 
have masked a correlation between blood pressure and daily dose of telatinib. However, 
the development or increase of proteinuria was dose dependent. Another explanation 
for the sole dose dependency for proteinuria is that telatinib may have an effect on 
glomerular endothelial cells, which is independent of blood pressure and independently 
caused by the VEGF blockade.37–40 
 In conclusion, we report that 5 weeks of treatment with a small molecule tyrosine 
kinase inhibitor, blocking VEGFR-2 and VEGFR-3, results in a significant increase in both 
systolic and diastolic blood pressure. The reduction in capillary density and microvascu-
lar flow, associated with a reduced vasodilatory capacity, may suggest that rarefaction is 
a mechanism that underlies the increase in blood pressure induced by telatinib and pos-
sibly other antiangiogenic agents. Further research in larger patient samples is needed 
to confirm this hypothesis. 
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VEGF inhibition is known to decrease capillary density. Decreased capillary density may 
be the basis for VEGF inhibitor related side effects. We investigated whether the effects 
of bevacizumab on capillary density are reversible. 
Patients and methods
Capillary density, assessed by sidestream dark field imaging of the mucosal surface of 
the lip, was measured at baseline, after 6 weeks of bevacizumab treatment and >3 
months after discontinuation. Additional measurements included blood pressure (BP) 
measurements, flow-mediated dilation (FMD), nitroglycerin-mediated dilation (NMD), 
and aortic pulse wave velocity (PWV). 
Results 
Fourteen patients were included. Seven patients completed measurements at all 3 pre-
defined timepoints. Capillary density significantly decreased after 6 weeks of bevacizum-
ab treatment and was reversible after discontinuation of the bevacizumab (p=0.00001 
using a general linear model repeated measures test). Blood pressure, FMD and NMD 
remained unchanged. Mean PWV increased after 6 weeks treatment (p=0.027) and 
decreased after bevacizumab discontinuation. Amongst the 6 patients with the best 
response were the 3 patients showing the clearest decrease in capillary density after 
6 weeks of bevacizumab treatment.
Conclusions 
Bevacizumab induced decrease in capillary density is reversible. Non-invasive assessment 
of capillary density during treatment with anti-angiogenic drugs may be useful as a 
marker of treatment efficacy. 
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Introduction
Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor 
(VEGF), is currently being used in the treatment of various types of cancer, including 
colorectal, breast, renal cell and non-small-cell lung cancer.1-6  
 A clear decrease in capillary density has been reported in the treatment with two 
VEGF inhibitors, telatinib and bevacizumab.7,8 Decreased vasculary density, or rarefac-
tion, may be a possible mechanism for various side effects seen in the treatment with 
VEGF inhibitors. One of these side effects is hypertension, with grade 3-4 hyperten-
sion, using the common toxicity criteria, developing in 9-16% of bevacizumab-treat-
ed patients develops.9,10 Research in rats also showed that vascular rarefaction may 
be the cause of sunitinib-induced hypothyroidism and bevacizumab-induced enteric 
perforations.11 Since bevacizumab-treated patients may have a prognosis of several 
years in palliative setting and many years when adjuvant schedules will prove to be 
beneficial, the patient group is relatively large. Increased knowledge on bevacizum-
ab-induced vascular changes may help to identify patients at risk for complications, 
stimulate the sense of urgency to monitor patients and to start early treatment in case 
of hypertension, hypothyroidism, encephalopathy or other vascular-related complica-
tions.12 
 The aim of this study is to investigate whether the bevacizumab-associated vas-
cular and blood pressure effects are reversible after discontinuation of bevacizumab 
treatment. An additional goal is to provide more information on the mechanisms in 
the development of bevacizumab-associated side effects.
Patients and Methods
Eligibility Criteria and study outline
Patients receiving bevacizumab monotherapy or combination therapy for breast or 
colorectal cancer were eligible for participation. Patients with previous bevacizumab 
treatment, major surgery within the last 4 weeks, or clinical significant cardiovascular 
disease in the previous year were excluded. Written informed consent was obtained 
from all patients before any study related procedure was performed, and approval 
from the institutional medical ethical review boards was obtained before study initia-
tion. 
 Blood pressure measurements and vascular assessments were performed at base-
line (<7 days before first bevacizumab administration), after 6 weeks (before third 
3-weekly bevacizumab administration) and >3 months after last bevacizumab admin-
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istration. All measurements were performed by the same experienced investigator, in 
a quiet, temperature-controlled room.
Assessments
Capillary density measurements with SDF imaging 
Patients were situated in a supine position with the investigator at the head side of the 
bed. An SDF hand-held device (MicroScan Video Microscope System, MicroVision Med-
ical) was introduced into the open mouth and gently pushed to the mucosal surface of 
the inner lip. SDF imaging consists of a light guide surrounded by light-emitting diodes 
that emit green light (540 F 50 nm) which penetrates the tissue and directly illuminates 
the tissue microcirculation. The SDF technique is described in detail in previous pub-
lications.7,13,14 Images of the mucosal microcirculation were projected on a computer 
screen. The final on-screen magnification of the images obtained with the SDF imag-
ing device was 325 times original. When images of satisfying quality were seen, video 
images of at least 30 s were obtained. Images were obtained from four different lip 
quadrants (mucosal readings of the left and right upper inner lip quadrant and the left 
and right lower inner lip quadrant) using the SDF probe. From every quadrant, at least 
three 30-s video images were obtained. Video images were stored on digital videotape 
in avi format. Off line, at least five still frames of each quadrant were captured from 
these video images. The number of capillary loops per frame was counted. Capillary 
density for each frame was expressed as the mean number of capillary loops per mm2. 
The mean capillary density per lip quadrant and total lip was calculated. Using offline 
computer analysis, capillary diameter was measured. The mean diameter of at least 80 
capillaries per visit of each patient was calculated. All measurements were done by one 
technician, not blinded to the time point in treatment of the patients. Off-line analysis 
(counting of the number of capillary loops and measurement of capillary diameter) 
was done by two observers (JR and NS), who were blinded to the time point in treat-
ment of the patients. The reproducibility of the SDF technique to determine capillary 
density in healthy volunteers was moderate to high, showing a coefficient of variation 
of 4.6%.7
Peripheral blood pressure measurements
Brachial blood pressure was measured at home, 4 times a day for at least three con-
secutive days, after 15 min rest, measuring thrice in a supine position with 5-min in-
tervals, using an automatic device (Datex-Ohmeda S/5 Light Monitor, Datex-Ohmeda, 
Inc.) with appropriate cuff size. For statistical analysis, we used the mean of the mea-
surements. 
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Central blood pressure measurements
Application tonometry of the radial and external carotid artery (SphygmoCor SCOR-PVx 
device, AtCor) was done. The mean of the three peripheral blood pressure measure-
ments was used to calculate central aortic pressure.15
Flow mediated dilation
The FMD measurements were done in a quiet, temperature-controlled room. Postisch-
emic vasodilator responses in the brachial artery were measured using a Wall Track 
System (WTS 2, Pie Medical). This system consists of a standard 7.5-MHz linear array 
ultrasound transducer connected to a PC equipped with a data acquisition board and 
software. Subjects were investigated in a supine position, and three ECG leads were 
attached. Ischemia was induced in the forearm by inflation of a blood pressure cuff 
just below the elbow of the right arm for 5 min. After deflation of the cuff, changes in 
brachial artery wall diameter were measured every 20 s for 4 min. WTS measurements 
were stored and analyzed off line using WTS software. FMD was expressed as percent-
age change in brachial artery diameter after ischemia. 
Nitroglycerin-mediated dilation
NMD was assessed in the same way as FMD, with the exception that 0.4 mg of nitroglyc-
erin was given sublingually, instead of cuff inflation and deflation, before measurements 
were started. 
Aortic pulse wave velocity 
Measurements were done at the right carotid and femoral arteries using standard blood 
pressure transducers (SphygmoCor SCOR-PVx device, AtCor) with simultaneous electro-
graphic gating. This enabled the base of the pressure wave to be recorded and the time 
delay between the carotid and femoral waves to be calculated. The distance between 
the two sites was measured. PWV was defined as the distance traveled by the pressure 
waves divided by the time delay. 
Statistical analysis
Continuous variables are presented as mean values and categorical variables as frequencies 
(percentages), unless otherwise stated. Comparisons between variables at baseline, after 
6 weeks, and after discontinuation of bevacizumab treatment, were made with a general 
linear model repeated measures test or with a paired Student’s t-test were appropriate, 
and were two-sided, with a level of significance of a = 0.05. All calculations were made by 




Between March 2007 and July 2008, a total of 14 patients were enrolled in the study. 
In 8 patients measurements could be performed after discontinuation of bevacizumab 
treatment. Baseline patient and treatment characteristics of both groups are listed in 
Table 1.
 Patients received bevacizumab for colorectal cancer (12 patients) or breast cancer (2 pa-
tients). All patients had metastasized disease. Bevacizumab dose was 7.5 mg/kg/3weeks 
for the patients with colorectal cancer and 10 mg/kg/2weeks for the breast cancer pa-
tients. Bevacizumab was combined with various chemotherapy schedules; capecitabine 
plus oxaliplatin (7 patients), capecitabine (3 patients), irinotecan (2 patients), paclitaxel 
and capecitabine (1 patient), paclitaxel (1 patient). 
Reversibility of vascular changes
Measurements after discontinuation of bevacizumab treatment could be performed in 
8 patients. In one of these patients SDF data were not available due to technical reasons. 
Capillary density measurements with SDF imaging 
Using a general linear model repeated measures test on the 7 patients with 3 evalu-
able SDF measurements, before, during and after bevacizumab treatment, the change 
in capillary density due to bevacizumab treatment was significant, with a p-value of 
0.00001 (Fig 1). More importantly, after discontinuation of the bevacizumab treatment 
the changes in capillary density showed to be reversible, with a p-value of 0.001 (Fig 1). 
 Figure 2 shows the SDF images of a representative patient, demonstrating visible capil-
lary loops at baseline, decreased capillary density after 6 weeks of bevacizumab treatment, 
and normalization of capillary density >3 months after bevacizumab discontinuation.
Of the 7 patients, 6 patients were without any systemic anticancer therapy in the three 
months before the third visit. One patient was still treated with capecitabine plus oxali-
platin, however without bevacizumab. 
At baseline, 2 patients received a single blood pressure lowering agent (thiazide di-
uretic or angiotensin-II receptor antagonist), 3 patients received two agents (β-blocker 
plus thiazide diuretic, β-blocker plus angiotensin converting enzyme (ACE) inhibitor, 
and β-blocker plus angiotensin-II receptor antagonist, all in 1 patient respectively), and 
1 patient received 3 blood pressure lowering agents (β-blocker plus loop diuretic plus 
angiotensin-II receptor antagonist. These blood pressure lowering medication schedules 
remained unchanged for all 6 of the above described patients for the duration of the 
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entire study. One additional patient, patient 14, was started on antihypertensive treat-
ment with a calcium antagonist during bevacizumab treatment.
Blood pressure, vascular function and vascular structure assessments 
With a general linear model repeated measures test there were no significant changes 
in blood pressure or vascular function and vascular structure parameters, besides FMD 
(Table 2). Comparing results of visit 3 with visit 2, FMD remained unchanged after dis-
continuation of bevacizumab treatment. 
Table 1. Baseline demographics and patient characteristics
Patient characteristics
Pts with data at 
3 visits, including 
after bevacizumab 
discontinuation
Pts with data before and 
during bevacizumab, 
without data after 
discontinuation
N 8 14
  Male gender 4 (50) 6 (43)
  Age (years, range) 59 (49-71) 61 (45-74)
Center
  Leiden University Medical Center 6 (75) 8 (57)
  Rijnland Hospital Leiderdorp 1 (13) 4 (29)
  Deaconess Hospital Leiden 1 (13) 2 (14)
Additional cardiovascular risk factors
  BMI (kg/m2, range) 27.3 (22.8-33.7) 26.2 (20.7-33.7)
  Nicotine abuse; in past or present 5 (63) 6 (43)
  History of CVD 1 (13) 2 (14)
  History of hypertension 2 (25) 4 (29)
  Renal impairment (creatinine > ULN) 0 (0) 0 (0)
WHO performance scale
  0 5 (63) 7 (50)
  1 3 (38) 6 (43)
  unknown 0 (0) 1 (7)
Prior treatment
  Surgery 5 (63) 7 (50)
  Chemotherapy 1 (13) 5 (36)
  Radiotherapy 4 (50) 5 (36)
  Blood pressure lowering drugs at entry 3 (38) 6 (43)
Tumor type
  Colorectal cancer 7 (88) 12 (86)
  Breast cancer 1 (13) 2 (14)
BMI: body mass index; CVD: cardiovascular disease; ULN: upper limit of normal; WHO: world health 
organization
Data are presented as n (%) unless otherwise specified
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Vascular changes during bevacizumab treatment
In a total of 14 patients measurements were performed before and during treatment 
with bevacizumab. 
 In 6 patients additional measurements after discontinuation of bevacizumab treat-
ment could not be performed due to various reasons; 2 patients died, 2 patients were in 
poor clinical condition due to tumor progression, 1 moved out of the region and 1 was 
still receiving bevacizumab treatment.
Capillary density measurements with SDF imaging 
In all 14 patients, the number of capillary loops markedly decreased from 18.2 at base-
line to 13.3 (p=0.00002) after 6 weeks treatment with bevacizumab (Table 2). 
Figure 1: Capillary density of patients with 3 evaluable SDF measurements.  
Visit 1: baseline; visit 2: after 6 weeks of bevacizumab treatment; visit 3: >3 months after 
discontinuation of bevacizumab treatment.  































  mean cap density (n)    18.4                                               13.7                                              20.7                    p=0.00001
 
Fig. 1.  Capillary density of the 7 patients with 3 evaluable SDF measurements. Visit 1: baseline; 
visit 2: after 6 weeks of bevacizumab treatment; visit 3: >3 months after discontinuation of 
bevacizumab treatment.P-value generated by general linear model repeated measures test
Fig. 2.  SDF images demonstrating visible capillary loops of a representative patient. A: at baseline; 
B: after 6 weeks of bevacizumab treatment; C: >3 months after bevacizumab discontinua-
tion.
A B C
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Table 2.  Hemodynamic and vascular function/structure variables; mean values of all pa-
tients. 
Table 2.  2A: 8 patients with measurements available at all 3 predefined timepoints; 
baseline, after 6 weeks of bevacizumab treatment and >3 months after discon-
tinuation. 2B: 14 patients with data available at baseline and after 6 weeks of 






after 6 weeks 
treatment
Visit 3











Capillary density (n) ** 18.4 13.7 20.7 0.00001 *   0.002 * 0.001 *
Capillary diameter (mm) 6.9 5.6 5.7 0.094 0.051 0.816
pSBP (mm Hg) 128.4 134.1 132.6 0.536 0.286 0.768
pDBP (mm Hg) 83.9 90.0 85.3 0.203   0.042 * 0.166
cSBP (mm Hg) 134.4 135.5 132.3 0.877 0.891 0.570
cDBP (mm Hg) 83.8 86.4 86.3 0.634 0.484 0.963
FMD (%) 7.0 3.5 3.8   0.031 *   0.039 * 0.699
NMD (%) 15.5 16.1 9.7 0.186 0.302 0.060
PWV (m/s) 8.9 9.7 9.4 0.169 0.064 0.558
* p < 0.05
** patient 6 no SDF data available at visit 3  
‡ general linear model repeated measures test
† paired Student’s t-test
n: number; pSBP: peripheral systolic blood pressure; pDBP: peripheral diastolic blood pressure; cSBP: central systolic blood 
pressure; cDBP: central diastolic blood pressure; FMD: flow mediated dilatation; NMD: nitroglycerin mediated dilatation; 





after 6 weeks 
treatment
Visit 1 vs. 2
p-value †
Capillary density (n) ** 18.2 13.3 0.00002* 
Capillary diameter (mm) 6.9 5.6    0.002 * 
pSBP (mm Hg) 129.3 133.1 0.368
pDBP (mm Hg) 82.2 87.7 0.033 *
cSBP (mm Hg) 134.8 139.6 0.322
cDBP (mm Hg) 83.4 87.9 0.081 
FMD (%) 6.3 3.2 0.006 *
NMD (%) 12.5 13.7 0.521
PWV (m/s) 8.9 9.6 0.027 *
* p < 0.05
† paired Student’s t-test
n: number; pSBP: peripheral systolic blood pressure; pDBP: peripheral diastolic blood pressure; cSBP: central 
systolic blood pressure; cDBP: central diastolic blood pressure; FMD: flow mediated dilatation; NMD: 
nitroglycerin mediated dilatation; PWV: aortic pulse wave velocity.
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Blood pressure, vascular function and vascular structure assessments
There was no significant change in most of the blood pressure parameters after 6 weeks 
treatment with bevacizumab (Table 2). There was a significant increase in peripheral dia-
stolic blood pressure. The decrease in FMD from 6.3% to 3.2% after 6 weeks treatment 
was statistically significant (p=0.006) when compared with baseline (Table 2). There was 
no change in NMD. Mean PWV significantly increased from 8.9 m/s at baseline to 9.6 m/s 
after 6 weeks treatment (p= 0.027; Table 2).
Association of capillary density with bevacizumab efficacy
Figure 3 shows the relationship between capillary density changes and bevacizumab ef-
ficacy. Amongst the 6 patients that were alive and showed no tumor progression within 
6 months of start of bevacizumab treatment were the 3 patients showing the clearest 
decrease in capillary density after 6 weeks of bevacizumab treatment. 
Discussion
We conducted this study to investigate whether bevacizumab-associated vascular and 
blood pressure effects are reversible after discontinuation of bevacizumab treatment. 
We additionally aimed at providing more information on the mechanisms in the devel-
opment of bevacizumab-associated side effects. 
 To our knowledge, this is the first study describing effects on blood pressure and 
the vascular system after discontinuation of VEGF inhibitory treatment. Until now, the 
reversibility of vascular changes was never documented in humans. We now report that 
the bevacizumab induced decrease in capillary density is reversible. Although this study 
was performed in a limited number of patients, our results are consistent and in line 
with previous preclinical data. Preclinical data show rapid reversibility of capillary regres-
sion after cessation of VEGF inhibition in normal organs and tumors in mice.16-18 Strik-
ingly, most capillaries grew back within 2 weeks after cessation of treatment. 
 In this journal, Mourad et al reported endothelial dysfunction and capillary rarefac-
tion in 18 bevacizumab treated patients.8 We previously reported a reduction in capil-
lary density (rarefaction) and microvascular flow, associated with a reduced vasodilatory 
capacity induced by telatinib, an orally active, small molecule inhibitor of VEGFR-2, VEG-
FR-3, platelet-derived growth factor receptor-a, and c-Kit.7 With the current study, we 
confirm that treatment with bevacizumab results in a clear decrease in capillary density. 
And, after studying both a small molecule tyrosine kinase inhibitor of the VEGF recep-
tor and a monoclonal antibody against VEGF, we conclude that the induced decrease in 
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capillary density probably represents a class effect of all VEGF inhibitors.
 In this study there was a significant decrease in capillary density after 6 weeks of be-
vacizumab treatment, however, there was no significant increase in blood pressure. This 
might be explained by the timing of the measurements, i.e. after six weeks or 2 half-lives 
of bevacizumab. The decrease in capillary density may be induced before an increase in 
blood pressure develops. Other explanations may be the limited number of patients, or 
the use of blood pressure lowering agents in almost half of the patients. 
 We designed our study, such that our data can be extrapolated to the general patient 
population treated with bevacizumab containing anti cancer treatment. To maximally 
imitate daily life, we decided not to exclude patients using blood pressure lowering 
agents at baseline. While multiple measurements were performed in the same patients 
and patients therefore were their own internal control, this resulted in accurate statisti-
Fig. 3.  Change in capillary density after 6 weeks of bevacizumab treatment, compared to baseline. 
Individuals clinical and efficacy parameters are added. In bold patients that were alive and 
showed no tumor progression within 6 months of start of bevacizumab treatment.
Fig. 3. BP-Tx: blood pressure lowering treatment before start of bevacizumab treatment; CRC: 
colorectal cancer; BC: breast cancer; A: adjuvant chemotherapy; C: capecitabine; O: oxalipla-
tin; P: paclitaxel; I: irinotecan; mo: months; surg: surgery; CR: complete response; Tx: therapy; 
Pt: patient
 Ref 9: spatie toevoegen in ‘J Clin Oncol’ 
 Ref 11: spatie toevoegen in ‘J Clin Oncol’ 
 Ref 13: laatste deel vervangen door: Ann Oncol 2008;19:927-34 
Ref 16: spaties toevoegen in ‘Eur J Cancer 
Ref 17: spatie toevoegen in ‘J Hypertens’ 
Ref 31: spatie toevoegen in ‘Res 1996’ 
Ref 32: spatie toevoegen in ‘Hypertension 1983’ 
Ref 35: spaties toevoegen in ‘positive ALL’ en  ’N Eng J Med 2006’ 
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cal data. We also decided to include patients receiving bevacizumab in combination with 
various cytotoxic agents. Since vascular changes were seen in all patients, we can con-
clude that the changes in vascular parameters are linked to the bevacizumab treatment, 
and are irrespective of the cytotoxic agents used in the bevacizumab combination. 
 The sidestream dark field (SDF) method is a very elegant method for measuring capil-
lary density. It is a non-invasive, not painful method, with no side effects for the test sub-
ject. Measurements can be performed in almost all subjects while the mucosal surface 
of the inner lip is intact and easy to reach in most patients. Moreover, the measurement 
time for the patient is limited, while large parts of the data analysis can be performed 
off line. The technique is fairly easy to learn, and reproducibility of data is generally 
high.7,13,14
 Our results may have several implications in the treatment of cancer patients with 
VEGF inhibitors. Recently, increased blood pressure during treatment with VEGF inhibi-
tors has been associated with a longer time to tumor progression.19-22 Possibly, capillary 
density measured by the noninvasive SDF method can be used as an even earlier marker 
for response. In our study we could show that decreased capillary density during beva-
cizumab treatment may be associated with a better prognosis. However, this is explor-
atory and confirmation with adequate sample size is needed. Also, theoretically, combin-
ing capillary density measurements with blood pressure changes can results in a better 
predictive marker than blood pressure alone. Moreover, we would like to stimulate the 
sense of urgency to monitor patients, since the reversibility of vascular changes after 
discontinuation of VEGF-inhibiting therapy might suggest that timely intervention may 
reduce or prevent certain side effects with sometimes high morbidity and even mortality.
This is the first study reporting that the bevacizumab-induced capillary density decrease 
is reversible after discontinuation of bevacizumab treatment. In combination with earlier 
results in VEGF tyrosine kinase inhibitor treatment, we also report that VEGF-associated 
rarefaction is a class-effect generated by all VEGF-inhibitors. 
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Sunitinib is an orally available inhibitor of the vascular endothelial growth factor (VEGF), 
platelet-derived growth factor, kit oncogene, and fms-related tyrosine kinase 3 recep-
tors. As combinations of VEGF-inhibitors with cytotoxic therapy are promising, this 
phase I study aimed to determine the recommended phase II dose (RP2D) of sunitinib in 
combination with 2 different ifosfamide schedules.
Methods 
Patients with progressive solid tumors, good performance score, organ function, and no 
standard therapy available, were eligible. Continuous once daily sunitinib, in escalating 
doses per cohort, was combined with one of two ifosfamide schedules, 3g/m2/days1-3 
and 1.2g/m2/days1-5, both given intravenously every 3 weeks. At RP2D, additional pa-
tients were enrolled to assess pharmacokinetics. Circulating endothelial cells (CECs) were 
measured prior to the 1st, 3rd and 6th cycle.
Results 
The results of the first 26 patients accrued in this phase I study are reported. Combining 
12.5 mg sunitinib with ifosfamide 3g/m2/days1-3 was not feasible due to neutropenia 
>7 days in 2 out of 6 patients. However, when using G-CSF, the RP2D was ifosfamide 
3g/m2/days1-3 plus 12.5 mg sunitinib. Ifosfamide 3g/m2/days1-3 combined with 25 mg 
sunitinib and G-CSF (n=5) was not feasible due to febrile neutropenia in 2 patients and 
hypertension with cardiac chest pain in 1 patient. Sunitinib at 12.5 mg in combination 
with ifosfamide 1.2g/m2/days1-5 was also feasible with 1 out of 6 patients developing 
encephalopathy as dose limiting toxicity.
 Sunitinib co-administration did not affect the pharmacokinetics of ifosfamide or one 
of its metabolites. No consistent change in the number of CECs during treatment was 
observed. Of 25 evaluable patients, 4 showed a partial response (16%) and 12 patients 
had stable disease (48%) as best tumor response. 
Conclusions 
Sunitinib at 12.5 mg/day with ifosfamide 3g/m2/days1-3, and sunitinib at 12.5 mg/day 
with ifosfamide 1.2g/m2/days1-5 every 3 weeks is tolerable if supported by G-CSF.
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Introduction
The use of the so-called targeted drugs including monoclonal antibodies and tyrosine 
kinase inhibitors (TKIs) is rapidly increasing in oncology.1 The anti-tumor effects of these 
targeted drugs applied as single agent, however, is modest in most tumors. Therefore, 
combined therapy of targeted drugs and standard cytotoxic agents has become a treat-
ment and research strategy of interest. Early reports on combining sunitinib with various 
standard chemotherapeutical agents show promising results.2-12
 Sunitinib is an orally available inhibitor of the vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), kit oncogene (C-KIT), and fms-related 
tyrosine kinase 3 (FLT3) receptors. Sunitinib is effective as single agent in several solid 
tumor types and is registered for use in advanced renal cell cancer, and imatinib-resistant 
or -intolerant gastrointestinal stromal tumors (GISTs).13-17 The most common adverse 
events reported in single agent trials are fatigue, diarrhea, nausea, sore mouth, skin dis-
coloration, and hypertension. Hematological adverse events are manageable with grade 
3/4 neutropenia in 13% of patients, anemia in 7% and thrombocytopenia in 3%. Infec-
tious complications of neutropenia are very rare.
 Ifosfamide is one of the oldest chemotherapeutic agents and induces anti-tumor 
activity through DNA alkylation. It is used in the treatment of several tumor types includ-
ing advanced breast cancer, testicular cancer, small cell lung cancer, non-small cell lung 
cancer, soft tissue sarcomas, bone sarcomas, and central nerve system (CNS) tumors 
such as medulloblastomas.18-24 Grade 3/4 toxicities occurring in more than 5% of the 
patients during treatment with ifosfamide comprise neutropenia (56%), neurotoxicity 
(11%), nausea/vomiting (10%), and infection (10%).23
 Combining VEGF-pathway inhibitors with cytotoxic agents has several potential ad-
vantages. VEGF produced by tumor cells results in the formation of new vasculature 
which is abnormal in structure and function. These new vessels are leaky and, therefore, 
result in a higher interstitial pressure within the tumor. Inhibition of VEGF-mediated 
activities by sunitinib results in a decrease of this interstitial pressure and enhanced 
delivery of the concomitantly administered cytotoxic drug.25,26 Therefore, the possibility 
of decreasing ifosfamide dose in order to decrease side effects, without decreasing ifos-
famide exposure to the tumor, may be advocated. Other mechanisms that may account 
for synergistic interaction between VEGF-pathway inhibitors and conventional cytotoxic 
drugs include prevention of endothelial progenitor cell mobilization from the bone mar-
row induced by chemotherapy and decreased expression of tumor factors conferring 
resistance against chemotherapy.27-31  
 In addition to potential synergistic interaction, several issues are important when 
selecting a combination of a targeted drug and a standard chemotherapeutical agent, 
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including single agent activity of both agents, different mechanisms of action, and a 
non-overlapping toxicity profile. In theory, all of these are met by the combination of 
sunitinib and ifosfamide. In this study, two different ifosfamide regimens, which are 
both widely used, are explored for their feasibility to be combined with sunitinib. 
Patients and Methods
Eligibility criteria
Patients with histologically or cytologically confirmed advanced or metastatic solid tu-
mors for whom no standard therapy was available, with an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ≤2 were eligible. Other inclusion criteria were: 
evaluable or measurable disease by RECIST version 1; age ≥18 years; life expectancy ≥12 
weeks; adequate bone marrow, liver, and renal function (hemoglobin ≥6.0 mmol/l; abso-
lute neutrophil count ≥1.5 x 109/L; platelet count ≥100 x 109/L; total bilirubin ≤1.5x the 
upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) ≤2.5x ULN, (liver metastases AST/ALT <5x ULN); serum creatinine ≤1.5x ULN, 
creatinine clearance ≥ 60 ml/min and 2 functioning kidneys); systolic blood pressure 
<150 mmHg and diastolic blood pressure <90 mmHg (treatment with 2 antihyperten-
sive drugs is allowed). Exclusion criteria were: history of cardiovascular disease; known 
HIV seropositivity; signs or symptoms of central nervous system metastases; pregnancy 
or breast-feeding; history of any condition that could endanger the safety of the patient; 
anticancer treatment <4 weeks before the first dose. 
 The study was designed and conducted under the appropriate institutional review 
boards’ approvals and in accordance with the principles embodied in the Declaration of 
Helsinki. Written informed consent was obtained from each participant.
Dose-levels and Dose Escalation Procedure
Daily oral sunitinib was planned to be evaluated in three escalating dose cohorts, 12.5 mg, 
25 mg, and 37.5 mg, in combination with a fixed dose of ifosfamide 3 g/m2/day for three 
days intravenously administered at 3-weekly intervals. After establishing the recom-
mended phase II dose (RP2D) of sunitinib with ifosfamide at 3 g/m2/day for three days, 
this sunitinib dose was also evaluated with ifosfamide iv at 1.2 g/m2/day for 5 days. This 
second ifosfamide schedule was additionally assessed for its feasibility to be combined 
with sunitinib as both ifosfamide schedules are frequently used. 
 Using the National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 3.0, 
dose-limiting toxicity (DLT) was defined as the following toxicity during the first treat-
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ment cycle: grade 4 neutropenia ≥7 days, febrile neutropenia, grade 4 thrombocytope-
nia, creatinine ≥2x ULN and any drug-related grade 3 or 4 non-hematological toxicity 
excluding, nausea and vomiting not refractory to anti-emetics, grade 3 fatigue <7 days, 
and hypertension not refractory to anti-hypertensive medication. If a DLT was observed 
in one patient, three additional patients were recruited at that dose level, with dose 
escalation proceeding if in <2 of 6 patients a DLT occurred. If a DLT was observed in ≥2 
patients in a cohort, RP2D had been exceeded. The RP2D of sunitinib was defined as the 
highest dose level which resulted in pre-defined dose limiting toxicity encountered dur-
ing the first cycle in less than 33% of the patients. 
 At the beginning of each cycle with ifosfamide, patients had to have neutrophils ≥1.5 
x 109/L and platelets ≥100 x 109/L. Treatment could be delayed for a maximum period 
of 2 weeks for hematological recovery. Dose reduction of more than 50% of the initial 
ifosfamide dose was not allowed. If patients developed a systolic blood pressure >160 
mmHg, a diastolic blood pressure >100 mmHg or an increase of diastolic blood pressure 
>20 mmHg, which despite antihypertensive medication with an ACE-inhibitor and a 
calcium-channel blocker was not adequately controlled within 2 weeks, treatment with 
sunitinib was stopped. In case of grade 4 hypertension sunitinib was also stopped.
 If a patient experienced an ifosfamide related DLT the dose of ifosfamide was re-
duced with 25% at every occurrence. Dose reduction of more than 50% of the initial 
ifosfamide dose was not allowed. Patients who experienced a DLT that had not resolved 
to ≤grade 1 within 5 weeks after day 1 of the previous ifosfamide administration (a 
maximum of two weeks delay for the next cycle was allowed) were withdrawn from the 
study. In those patients experiencing a DLT related to sunitinib, sunitinib was withheld 
for a maximum of 2 weeks. If toxicity resolved to ≤grade 1 continuation at the next lower 
dose cohort level was allowed for the subsequent courses. 
 Patients were treated for a maximum of 6 ifosfamide cycles. Those patients who 
experienced a benefit from the combination of sunitinib and ifosfamide were allowed to 
continue treatment with sunitinib alone. Treatment was continued until disease progres-
sion or unacceptable toxicity.
Pre-treatment Evaluation and Safety Assessment
Pre-treatment evaluation consisted of a complete medical history, physical examination, 
WHO performance status assessment, vital signs, 12 lead ECG, blood sample for com-
plete blood count (CBC), biochemistry analysis, serum pregnancy test for women with 
child-bearing potential, and baseline tumor measurements.
 Weekly evaluation consisted of a brief history and physical examination, concomitant 
medication, vital signs, blood samples for CBC (twice weekly in the first cycle), and bio-
Chapter 8
112
chemistry. Response evaluation was performed every 2 cycles and was assessed accord-
ing to RECIST, version 1.32 Patients were evaluated weekly for adverse events and toxicity 
according to the NCI-CTC, version 3.0. 
Pharmacokinetic Evaluation
In order to determine whether co-administration of sunitinib affects ifosfamide pharma-
cokinetics (PKs), plasma concentrations of ifosfamide and its most important metabolites, 
2-dechloroethyl-ifosfamide, 3-dechloroethyl-ifosfamide, and 4-hydroxy-ifosfamide, were 
monitored during the first two cycles. This was performed in the additional patients who 
were treated at the RP2D of sunitinib in combination with the ifosfamide 3g/m2/days 1-3 
schedule. In these patients sunitinib treatment started on day 8.
Blood sample collection
Blood samples for PK evaluation were collected during cycles 1 and 2 via an indwelling 
intravenous catheter. A 7 mL blood sample was collected in the presence of lithium hep-
arin as anticoagulant pre-dose, 3, 6, 10, 24 hours after the start of the ifosfamide infu-
sion, and thereafter every 12 hours until the end of infusion, prior to the end of infusion 
and 1, 3, 6, 12, and 24 hours after the end of infusion. Blood samples were centrifuged 
within 15 minutes after collection for 10 minutes at 3000 x g at 4°C. Subsequently, an 
aliquot of exactly 1 mL of the plasma supernatant was transferred into a vial contain-
ing 100 mL of a 2M semicarbazide solution and was stored at <-70°C until analysis of 
4-hyroxy-ifosfamide. The remaining plasma was stored at <-70°C, without any additive, 
until the simultaneous analysis of ifosfamide its 2- and 3-dechloroethyl metabolites.
Analysis of ifosfamide and its metabolites
Ifosfamide and the 2- and 3-dechloroethyl metabolites were simultaneously quantitated 
by a validated liquid-chromatography-tandem triple quadrupole mass spectrometry (LC-
MS/MS) assay. The analytes were extracted from 10 mL aliquots of plasma with 1.5 mL 
of ethyl acetate after the addition of 10 mL of a 1 mg/mL cyclofosfamide solution in 
methanol (internal standard). Following vigorous vortex mixing for 5 min and centrifu-
gation for 10 min at 18,000 x g, an aliquot of the clear supernatant was evaporated 
to dryness under a gently stream of nitrogen at 70°C. Subsequently the residue was 
dissolved in an aliquot of 100 mL of a 20% methanol solution in water, from which an 
aliquot of 5 mL was injected onto the LC-MS/MS system. The analytes were separated 
by high-performance liquid chromatography (Model 2795 XC, Waters, Mildford, MA) 
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on a Nucleosil C18-AB (150x4.6mm, 5mm) analytical column (Macherey-Nagel, Duren, 
Germany). The mobile phase was composed of methanol and water containing ammo-
nium formate (2mM) at a flow rate of 0.5 mL/min. The first 9 minutes the mobile phase 
consisted of 20% methanol which was linearly increased in 0.5 min to 45% methanol. 
Subsequently the percentage methanol was held at 45% until 20 min after which it was 
linearly decreased to 20% in 0.5 min. The retention times of 2-dechloroethyl-ifosfamide, 
3-dechloroethyl-ifosfamide, ifosfamide and the internal standard cyclofosfamide were 
4.7, 5.9, 13.8 and 14.7 min, respectively, with an overall run time of 25 min. Detection 
was performed with a MicroMass Quatro Micro triple-quadropole mass spectrometer 
(Cary, NC) in the positive ion mode. The electrospray ionization operated at 3.0 kV and 
at a cone voltage of 35 V. The detector was programmed to allow the [MH]+ ions of 
2-dechloroethyl-ifosfamide (m/z 199), 3-dechloroethyl-ifosfamide (m/z 199), ifosfamide 
(m/z 261) and cyclofosfamide (m/z 261) to pass through the first quadropole and into 
the collision cell. The collision energy for collision-induced dissociation of 2-dechloro-
ethyl-ifosfamide, 3-dechloroethyl-ifosfamide, ifosfamide and cyclofosfamide was set at 
22 eV, 20 eV, 22 eV and 20 eV, respectively, with argon used as collision gas at a pres-
sure of 0.005 mbar. The daughter ions of 2-dechloroethyl-ifosfamide (m/z 92), 3-de-
chloroethyl-ifosfamide (m/z 78), ifosfamide (m/z 92) and cyclofosfamide (m/z 140) were 
monitored through the third quadropole. The dwell time per channel for data collection 
was 0.100 seconds. Weighted (1/concentration2) linear regression analysis of peak area 
ratios of analytes and internal standard, versus concentration of analytes were used for 
the quantitation. Peak area ratios were a function of the concentration from 50.0 to 
5,000 ng/mL for ifosfamide and its 2- and 3-dechloroethyl metabolites. The method was 
validated in accordance with the Guidance for Industry, Bioanalytical Method Valida-
tion, as specified by the Food and Drug Administration.33 For ifosfamide, the within and 
between-run precisions at five tested concentrations, including the lower limit of quanti-
tation (LLQ), were ≤3.7 and ≤3.6%, respectively, while the average accuracy ranged from 
92.3 to 104.7%. For 2-dechloroethyl-ifosfamide, the within and between-run precisions 
were ≤4.8 and ≤3.1%, respectively, with the accuracy ranging from 90.0 to 103.1%. And 
for 3-dechloroethyl-ifosfamide, the within and between-run precisions were ≤4.9 and 
≤4.1%, respectively, while the average accuracy ranged from 97.8 to 105.4%.
 4-Hydroxy-ifosfamide was analyzed by a separate validated LC-MS/MS method, based 
on the method describe above. 4-Hydroxy-ifosfamide was extracted from 50 mL aliquots 
of plasma with 1.5 mL of ethyl acetate after the addition of 10 mL of a 1 mg/mL cyclofos-
famide solution in methanol (internal standard). Samples were further processed as de-
scribed above and injected onto the same system and analytical column. The first 2 min-
utes the mobile phase, delivered at a flow rate of 0.5 ml/min, consisted of 20% methanol 
in water which was linearly increased in 0.5 min to 45% methanol. Subsequently the 
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percentage methanol was hold at 45% until 10 min after which it was linearly decreased 
to 20% in 5 min. The retention times of 4-hydroxy-ifosfamide and cyclofosfamide were 
5.8 and 8.5 min, respectively, with an overall run time of 20 min. The electrospray ion-
ization operated at 3.0 kV and at a cone voltage of 20 V for 4-hydroxy-ifosfamide and 
of 35 V for cyclofosfamide. The daughter ions of 4-hydroxy-ifosfamide (m/z 334>80; 
collision energy 27 V) and cyclofosfamide (m/z 261>140; collision energy 20 V) were 
monitored, with argon at a pressure of 0.005 mbar. The dwell time per channel for data 
collection was 0.150 seconds. Weighted (1/concentration2) linear regression analyses of 
peak area ratios of 4-hydroxy-ifosfamide and internal standard, versus concentration of 
4-hydroxy-ifosfamde was used for the quantitation. Calibration curves for were linear 
from 50.0 to 5,000 ng/mL. The accuracy ranged from 94.0% to 105.4%, the within-run 
precisions were ≤4.7% and the between-run precisions were ≤5.2% at five tested con-
centrations, including the lower limit of quantitation of 50.0 ng/mL.
Pharmacokinetic Data Analysis
Individual pharmacokinetic parameters for ifosfamide, 2- and 3-dechloroethyl-ifos-
famide and 4-hydroy-ifosfamide were estimated using noncompartmental analysis (1/y 
weighting factor) using the software program WinNonLin 5.0 (Pharsight, CA, USA). 
Circulating Endothelial Cells 
Two 10 ml blood samples for analysis of circulating endothelial cells (CECs) were col-
lected at baseline, on day 0 of cycles 3 and 6, and 6 weeks after discontinuation of ifos-
famide administrations. Enumeration of CECs was performed using cellsearch analysis 
as previously described.34
Results
This report describes the results of the first 26 of the total number of 32 patients en-
rolled in the recently closed study. Patient characteristics are summarized in Table 1.
Safety and Tolerability
All treatment-related adverse events during combined treatment with sunitinib and 
ifosfamide are summarized in Table 2. Using the combination of sunitinib at 12.5 mg 
with ifosfamide 3g/m2/days1-3 all patients developed hematological toxicity. Two out 
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of 6 patients had grade 4 neutropenia >7 days (DLT) and therefore this combination 
exceeded the recommended phase II dose (RP2D) and was considered not feasible. As 
neutropenia was the sole DLT, an amendment was made to continue the study with the 
addition of granulocyte-colony stimulating factor (G-CSF; pegfilgrastim 6 mg once per 
cycle) in all subsequent patients. 
 In none of the initial three patients at the dose level of sunitinib at 12.5 mg in com-
bination with ifosfamide 3g/m2/days1-3 a DLT occurred. In the subsequent cohort eval-
uating sunitinib 25 mg plus ifosfamide 3g/m2/days1-3 and G-CSF group, three out of 
Table 1. Baseline demographics and patient characteristics.
Baseline characteristics Patients (n (%))
Gender
   Male 15 (58)
   Female 11 (42)
Age, years
   Median (range) 51 (36-69)
WHO performance status
   0 7 (27)
   1 19 (73)
Prior anticancer therapies
   Surgery 20 (77)
   Systemic anticancer therapy
   Number of previous treatments (range)
   0
   1






   Radiation therapy 12 (46)
Tumor type
  Sarcoma 12 (46)
     Chondrosarcoma 2 (8)
     Ewing sarcoma 2 (8)
     Leiomyosarcoma 3 (12)
     Liposarcoma 2 (8)
     Osteosarcoma 1 (4)
     Sarcoma NOS 1 (4)
     Soft tissue sarcoma 1 (4)
  Carcinoma of unknown primary 3 (12)
  Neuroendocrine carcinoma 2 (8)
  Miscellaneous 9 (35)
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5 patients developed a DLT and thus the RP2D was exceeded. DLTs consisted of 2 cases 
of febrile neutropenia and 1 case of hypertension and cardiac chest pain. One out of 9 pa-
tients treated with sunitinib 12.5 mg in combination with ifosfamide 3g/m2/days1-3 and 
G-CSF developed febrile neutropenia. Therefore, the RP2D was established at once daily, 
continuously dosed sunitinib 12.5 mg in combination with ifosfamide 3g/m2/days1-3 and 
G-CSF. The median number of ifosfamide cycles at the RP2D was 3.7, with a median dose 
of 2.9 g/m2 ifosfamide per cycle over all cycles. The median dose of sunitinib at the RP2D 
was 246 mg per course, i.e.11.7 mg of sunitinib per day during the cycles administered 
in combination with ifosfamide. The total given number of sunitinib cycles ranged from 
1 to >21 (patient still on treatment).Across the dose levels of sunitinib, for all patients 
treated with ifosfamide 3g/m2/days1-3 combination, grade 3-4 hematological toxicity 
developing during ifosfamide and sunitinib combination treatment cycles, consisted of 
anemia in 10%, leucopenia in 80%, neutropenia in 80% and thrombocytopenia in 35% 
of patients. Febrile neutropenia was only seen in 3 patients, once in the combination 
with sunitinib 12.5 mg plus G-CSF and twice in the combination with sunitinib 25 mg 
plus G-CSF. Grade 3-4 non-hematological toxicity consisted of fatigue (15%), anorexia 
(5%), and hypertension (5%). 
 When ifosfamide 1.2g/m2/days1-5 was combined with sunitinib 12.mg and G-CSF 
1 out of 6 patients developed a DLT, ifosfamide induced encephalopathy. Therefore, this 
combination was considered feasible as well and was expanded with 6 patients for PK 
analysis. Results of the patients in this additional cohort are not yet available. The most 
frequently reported treatment-related grade 3-4 adverse events in the first 6 patients 
treated with ifosfamide 1.2g/m2/days1-5 were thrombocytopenia (17%), and fatigue 
(17%). 
Pharmacokinetics
Ifosfamide pharmacokinetic parameters derived from patients at the RP2D level (sunitinib 
12.5 mg in combination with ifosfamide 3g/m2/days1-3 and G-CSF) are summarized in 
Table 3. Ifosfamide pharmacokinetics were similar to those reported in the literature.35,36 
Sunitinib co-administration did not affect the pharmacokinetics of ifosfamide or one of its 
metabolites. Figure 1 shows the mean concentrations of ifosfamide and its metabolites of 
the patients treated in the sunitinib 12.5 mg and ifosfamide 3g/m2/days1-3 combination.
 As treatment in the sunitinib and ifosfamide 1.2g/m2/days1-5 combination was still 
ongoing, no pharmacokinetic data for these patients can be reported. Also, data on 
sunitinib pharmacokinetics are not available, yet.
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Table 3.  Plasma pharmacokinetic parameters of ifosfamide and ifosfamide-metabo-
lites during cycle 1 (without sunitinib) and cycle 2 (with sunitinib) in RP2D 
level patients treated with sunitinib 12.5 mg in combination with ifosfamide 
3g/m2/days1-3 and G-CSF.











008 1 6200 358 3.79 2210 2.81
2 6200 354 3.71 1954 3.17
009 1 4400 434 3.32 2415 1.82
2 4400 401 3.49 2270 1.94
010 1 4900 429 2.06 1707 2.87
2 4900 344 2.26 1622 3.02
108 1 7200 395 3.79 2104 3.42
2 7200 416 3.82 2287 3.15
110 1 6600 322 3.71 1834 3.60
2 6600 425 3.38 2039 3.24
111 1 6900 452 3.42 2403 2.87
2 5100 315 4.01 1750 2.91
AUC Ratio C1/C21
Ifosfamide N2-DCE-Ifosfamide N3-DCE-Ifosfamide 4OH-Ifosfamide
008 1.13 1.17 1.21 0.93
009 1.06 0.89 0.92 0.72
010 1.05 1.00 0.93 0.72
108 0.92 1.35 1.36 n.a.
110 0.90 1.04 0.94 n.a.
111 1.02 1.06 1.15 0.89
Cmax: maximal concentration; t1/2,z: terminal half-life; AUC0-¥: areas under the curve up to infinite time, CL: 
systemic clearance, N2-DCE-Ifosfamide: 2-Dechloroethyl-ifosfamide, N3-DCE-Ifosfamide: 3-Dechloroethyl-ifos-
famide, 4OH-Ifosfamide: 4-hydroxy-ifosfamide, n.a.: not available, 1corrected for dose.
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Circulating Endothelial Cells 
In 13 patients data for CECs were available at baseline and after 6 weeks of sunitinib 
and ifosfamide treatment (Figure 2). No consistent change in the number of CECs during 
treatment was observed.
Anti tumor activity
Twenty-five patients were evaluable for anti tumor activity. Best tumor response was a 
partial response seen in 4 patients (16%) and stable disease in12 patients (48%; Table 4). 
Two patients receiving sunitinib and ifosfamide 3g/m2/days1-3 combination treatment 
have long-lasting responses with stable disease for 42 and 63 weeks, respectively. In 
these patients, with mesenchymal chondrosarcoma and chordoma, respectively, treat-
ment with sunitinib is still ongoing. 
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Figure 1: Mean concentrations of ifosfamide and its metabolites of patients treated with the 
sunitinib 12.5 mg and ifosfamide 3g/m2/days1-3 combination.  
 
 


























































































Fig. 1.  Mean concentrations of ifosfamide and its metabolites of patients treated with the sunitinib 




This study shows that combining sunitinib administered at 12.5 mg daily with either 
ifosfamide 3g/m2/days1-3, or with ifosfamide 1.2g/m2/days1-5 is feasible, when sup-
ported with G-CSF.
 Ifosfamide monotherapy is known for substantial grade 3-4 side effects, including 
clinically relevant hematological toxicity.23 In our study, the rate of febrile neutropenia in-
Table 4.  Best tumor response of evaluable patients receiving sunitinib in combination 
with ifosfamide 3g/m2/days1-3 (cohorts 1-4) and sunitinib in combination with 
ifosfamide ifosfamide 1.2g/m2/days1-5 (cohort 5).







1 6 3g/m2/d1-3 12.5 mg/day no 1 3 2
2 3 3g/m2/d1-3 12.5 mg/day yes 0 1 2
3 5 3g/m2/d1-3 25 mg/day yes 2 2 1
4 6 3g/m2/d1-3 12.5 mg/day yes 1 4 1
5 5* 1.2g/m2/d1-5 12.5 mg/day yes 0 2 3
* 1 patient ongoing, no evaluation performed yet.
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Fig. 2.  Circulating endothelial cells during treatment with sunitinib in combination with ifosfamide 
3g/m2/days1-3.
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creased when the dose of sunitinib was increased to 25 mg, suggesting that the addition 
of sunitinib to ifosfamide increases hematological toxicity. Whether this is mainly the result 
of addition or synergism of the two agents on the bone marrow is unclear. Preliminary re-
sults show no influence of sunitinib on ifosfamide PK parameters. The effects of ifosfamide 
on sunitinib PK are unknown and results will follow. Concerning the relatively high fre-
quency of neutropenia, one should also bear in mind that this study enrolled a pretreated 
group of patients (27% ≥2 previous systemic treatment lines) unlike most patients treated 
with ifosfamide. Previously, grade 3-4 neutropenia was reported in 20% of all ifosfamide 
courses in the first-line and in 31% in the second-line with a 5 g/m2/1 day schedule, while 
for the 3 g/m2/3 days schedule the rates were 56 and 77%, respectively.23 In this latter 
study patients with ≥2 previous systemic anticancer treatment lines were excluded.
 Recently, various combinations of sunitinib with chemotherapeutical agents have 
been studied, including combinations with capecitabine, carboplatin plus paclitaxel, 
gemcitabine, irinotecan, gemcitabine plus cisplatin, and 5-fluorouracil plus irinote-
can.2-12 In these phase I and II studies most combinations appeared to be feasible, how-
ever at the expense of increased hematological toxicity. The rate of neutropenia might 
be related to the dose and schedule of sunitinib and on the cytotoxic agent or agents 
in the combination. For example, when sunitinib is combined with capecitabine, grade 
4 neutropenia was reported in <10% of patients.5,10 Sunitinib in combination with iri-
notecan or carboplatin/paclitaxel resulted in grade 3/4 neutropenia in 30-60% of pa-
tients.6,11,12 At this moment, these combination studies are only reported in abstract 
form, and therefore data, and interpretation of data, is limited. 
 Sunitinib RP2D was established at 12.5 mg, continuously dosed, when combined 
with ifosfamide. Given as monotherapy, the recommended sunitinib dose is 50 mg given 
daily for 28 days every 6 weeks.15 Another widely used schedule is 37.5 mg sunitinib, 
once daily, administered continuously. Though data from randomized studies are lack-
ing, theoretically, continuous dosing of sunitinib is likely to be more effective, as contin-
uous inhibition of angiogenesis pathways probably resorts in higher anti-tumor effects 
than intermittent inhibition. Recently, George et al reported that continuous daily suni-
tinib dosing of 37.5 mg achieved and sustained effective drug concentrations without 
additional accumulation across cycles.37 
 The recommended sunitinib dose of 12.5 mg, when combined with ifosfamide, is 
considerably lower that the recommended doses of single agent sunitinib. However, the-
oretically low doses of VEGF-pathway inhibitors may even be more beneficial in combina-
tion therapy. As previously mentioned, VEGF inhibition, in general, results in a decrease 
in interstitial fluid pressure, normalization of tumor vasculature, and increased delivery 
of the chemotherapeutical agent to the tumor site. The optimal dosing and scheduling 
of VEGF inhibitors may be critical. Excessive suppression of the tumor vasculature with 
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complete vasoconstriction or vessel disappearance may result in decreased delivery of 
the chemotherapeutical agent and decreased anti-tumor activity. Therefore, lower doses 
of sunitinib might even result in better anti-tumor efficacy then higher doses. Indeed, 
this was previously reported for sunitinib in a study where interstitial fluid concentra-
tions of the cancer chemotherapeutic drug temozolomide were increased when tumors 
were pretreated with sunitinib at 10 mg/kg but not at 40 mg/kg.4 In addition, a phase 
I study of sunitinib monotherapy showed therapeutic sunitinib plasma concentrations 
and tumor responders even in the lower dose sunitinib group.38 To optimize and study 
these effects of sunitinib on ifosfamide delivery it might be beneficial to evaluate tumor 
blood flow using noninvasive imaging techniques. 
 In our study, we investigated the effects on circulating endothelial cells in order to 
establish whether this is a prognostic factor and reflects treatment-induced antitumor 
activity in patients treated with the combination of sunitnib and ifosfamide. We did not 
observe consistent changes in the number of CECs, suggesting no relevance of CEC level 
as biomarker in the sunitinib and ifosfamide combination. However, patient numbers 
are limited.
 One of the tumor types for which the combination of sunitinib and ifosfamide is in-
teresting is soft tissue sarcoma. In patients with advanced soft tissue sarcoma, it was re-
cently revealed that the combination of a VEGF-inhibitor with doxorubicin, a frequently 
applied drug in soft tissue sarcomas, is not feasible because of an unacceptable high 
incidence of doxorubicin-mediated cardiotoxicity.39 Ifosfamide is the only drug, besides 
doxorubicin, with consistent efficacy against soft tissue sarcomas and is therefore fre-
quently used as first-line treatment against this tumor entity.40 As ifosfamide is not fea-
tured by the occurrence of cardiotoxicity, the combination of sunitinib and ifosfamide 
is attractive to explore in soft tissue sarcomas. In addition, this combination can be 
explored in other tumor types, including relapsed testicular cancer, advanced breast can-
cer, lung cancer, small blue round cell tumors and certain central nervous system tumors. 
Today, to our knowledge, no reports on the use of ifosfamide in combination with other 
VEGF inhibitors are published.
 In conclusion, sunitinib at 12.5 mg/day with ifosfamide 3g/m2/days1-3, and sunitinib 
at 12.5 mg/day with ifosfamide 1.2g/m2/days1-5 every 3 weeks supported by G-CSF is 
tolerable in patients with advanced solid tumors. Future studies should aim at evaluating 
efficacy in specific tumor types.
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Danusertib (PHA-739358) is a small-molecule pan-aurora kinase inhibitor. This phase I 
dose escalation study was conducted to evaluate safety and tolerability of danusertib 
with additional pharmacokinetics, biomarker and efficacy assessments.
Patients and methods
Patients with solid tumors refractory to standard therapies or with no standard therapy 
available were enrolled. Danusertib was administered intravenously on days 1,8,15 every 
28 days in 6-hour or 3-hour infusion schedules (6h-ivS, 3h-ivS). Dose levels from 45 mg/m2 
in the 6h-ivS, and from 250 mg/m2 in the 3h-ivS were studied.
Results 
Fifty patients were treated. For the 6h-ivS, the most frequently reported side effects were 
neutropenia (55%), nausea (25%), anorexia (23%), fatigue (20%), and diarrhea (18%). 
In the 3h-ivS, fatigue (70%), neutropenia (60%), diarrhea (50%), and nausea (30%) were 
seen. Non-hematological toxicity was mild to moderate. Neutropenia was dose limiting. 
The maximum tolerated dose was 330 mg/m2 for the 6h-ivS and not identified for the 
3h-ivS. The systemic exposure to danusertib increased linear with dose. The infusion rate 
did not appear to influence remarkably the pharmacokinetics of danusertib. Biomarker 
analysis showed inhibition of histone H3 phosphorylation, indicative of Aurora B inhibi-
tion, at doses ≥190 mg/m2. Stable disease was observed in 23.7% of evaluable patients 
with disease stabilization ≥6 months in 5 patients. 
Conclusions
Dose limiting toxicity of danusertib is neutropenia which was short lasting and gener-
ally uncomplicated, with limited non-hematological toxicity. The recommended dose of 
danusertib for phase II studies is 330 mg/m2 infused over 6 hours on days 1, 8, 15 every 
28 days.
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Introduction
Aurora kinases are serine/threonine kinases with a key role in mitosis. The aurora kinase 
family consists of 3 members, aurora-A, B, and C. Aurora-A is localized to the centro-
somes of interphase cells and to the mitotic spindle of cells from prophase throughout 
telophase, and is required for proper spindle maturation and assembly.1-3 Aurora-B is 
critical for chromosomal condensation, the attachment of the microtubules to the ki-
netochore of chromosomes and for proper execution of cytokinesis.4,5 Aurora-C is found 
in the testes where it has a role in spermatogenesis. In addition aurora-C might act as 
a chromosomal passenger protein that can complement aurora-B kinase function in 
mitotic cells.6,7
 Since aurora kinases are largely involved in cell cycle progression and mitosis, which 
is disturbed in cancer cells, their inhibition is considered to have potential as anti cancer 
treatment. In vitro, inhibition of aurora-A or aurora-B activity in tumor cells results in 
impaired chromosome alignment, weakening of the mitotic checkpoint, polyploidy, and 
subsequent cell death.8,9
 Danusertib is a potent small-molecule inhibitor of the ATP site of the aurora-A 
(IC50: 13 nM), aurora-B (IC50: 79 nM) and aurora-C (IC50: 61 nM) serine/threonine ki-
nases.10,11 The chemical structure of 
danusertib is demonstrated in Fig-
ure 1. Danusertib is active in a wide 
range of cancer cell lines and xeno-
grafts models.10 In mice, danusertib 
inhibits phosphorylation of histone 
H3, a protein implicated in chromo-
some condensation that is phos-
phorylated by aurora-B. This effect 
is observed in skin, bone marrow 
and xenograft tumors.12 Therefore, 
inhibition of histone H3 phosphory-
lation has been identified as mark-
er of danusertib biological activ-
ity. Preclinical pharmacokinetics of 
danusertib were dose-proportional 
and time-independent. The major 
route of metabolism involved the 
formation of the N-oxide derivative. 
The N-oxide metabolite was deter-
 22
Figure 1, online only: Chemical structure of PHA-739358. 
 
 
Fig. 1. Chemical structure of PHA-739358
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mined to have less than 1% of the activity of the parent compound. Danusertib did not 
inhibit any cytochrome P450 isoenzymes and was not a potent inhibitor of P-glycopro-
tein.11 We performed a phase I pharmacological and biomarker study of danusertib in 
patients with solid tumors. Objectives of this study were to (1) determine the maximum 
tolerated dose (MTD) and define dose-limiting toxicities (DLT), (2) characterize safety, 
(3) characterize pharmacokinetics, (4) analyze biomarkers of biological activity, includ-




Patients with histologically or cytologically confirmed advanced or metastatic solid 
tumors for whom no standard therapy was available, with an Eastern Cooperative 
Oncology Group (ECOG) performance status ≤1 were eligible. Other inclusion criteria 
were: evaluable or measurable disease by RECIST13; age ≥18 years; life expectancy ≥12 
weeks; tumor progression prior to study entry, adequate bone marrow, liver, and re-
nal function (hemoglobin ≥10.0 g/dl; absolute neutrophil count ≥1,500/mm3; platelet 
count ≥100,000/mm3; total bilirubin ≤1.5x the upper limit of normal (ULN); ALT and 
AST ≤2.5x ULN, (<5x ULN in case of liver metastases); serum albumin ≥3.0 g/dL; serum 
creatinine ≤1.5 mg/dL); blood pressure ≤140/90 mm Hg. Exclusion criteria were: previ-
ous high-dose chemotherapy requiring bone marrow rescue; known brain or lepto-
meningeal disease; pregnancy or breast-feeding; active inflammatory bowel disease, 
bowel obstruction or chronic diarrhea; abnormal left ventricular ejection fraction, 
thromboembolic events in the year prior to enrollment; ongoing cardiac dysrhythmias 
grade ≥2; known active infections; any condition that could endanger the safety of 
the patient. 
 Written informed consent was obtained from all patients before any study related 
procedure was performed, and approval from the institutional medical ethical review 
boards was obtained.
Drug Administration and Dose Escalation Procedure
Danusertib was administered intravenously for 3 consecutive weeks in 4-week cycles. 
Patients were divided into cohorts with escalating doses, starting with 6h-ivS. After 
MTD definition with the 6h-ivS, in the attempt of shortening the in hospital-time, two 
additional cohorts of patients were included to study the 3h-ivS. Based on animal 
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toxicology and pharmacokinetic data, the starting dose for the 6h-ivS of danusertib 
was 45 mg/m2 (target exposure 1/10th of the AUC at MTD in dogs, most sensitive spe-
cies in toxicology studies). The starting dose for the 3h-ivS was 250 mg/m2 based on 
toxicity and pharmacokinetic results of the 6h-ivS. Dosing schedules were based on 
preclinical animal toxicity studies, with higher doses and/or shorter infusion times re-
sulting in increased bone marrow, gastrointestinal, cardiovascular and renal toxicity.
 A two-stage accelerated titration design was adopted. During the initial phase a 
rapid dose escalation scheme was used with 100% dose increments until occurrence 
of drug-related first cycle DLT in 1 patient or grade ≥2 drug-related toxicity in ≥2 pa-
tients during any treatment cycle. For subsequent dose escalation steps a modified 
Fibonacci scheme was foreseen with 50, 40 and 33% dose increments in subsequent 
dose levels.
 DLT was defined as grade 4 neutropenia ≥7 days, febrile neutropenia, neutropenic 
infection, grade 4 thrombocytopenia, grade 3 thrombocytopenic bleeding, and any 
drug-related grade 3 or 4 non-hematological toxicity (excluding nausea, vomiting 
or diarrhea not refractory to adequate treatment), decrease in LVEF to ≤40% or a 
decrease of ≥20% compared to baseline, interruption of infusion due to a diastolic 
blood pressure increase of >20 mm Hg or to >150/100 mm Hg during drug adminis-
tration, next cycle delayed by ≥2 weeks, and omission of day 8 and/or 15 dose due to 
danusertib-related toxicity (after the 250 mg/m2 6-hour cohort protocol amendment 
allowed dosing on day 8 and/or 15 in the event of grade 3 uncomplicated neutro-
penia). If DLT was observed in one patient, three additional patients were recruited 
at that dose level, with dose escalation proceeding if <2 of 6 patients exhibited DLT. 
If DLT was observed in ≥2 of 3 or ≥2 of 6 patients, the MTD had been exceeded, and 
additional patients were recruited at the previous lower dose level. 
 The MTD was defined as the highest dose level that could be given to 6 patients 
with no more than 1 patient experiencing DLT. If a patient experienced a drug related 
DLT, further danusertib administration was withheld in that cycle. If the toxicity re-
solved to ≤grade 1, the dose was reduced to the previous lower dose level. Otherwise, 
the patient was withdrawn from the study. 
 Therapy continued until disease progression or unacceptable toxicity 
Pre-treatment Evaluation and Safety Assessment
Pretreatment evaluation consisted of a complete medical history, physical examination, 
ECOG performance status assessment, vital signs, ECG, blood sample for complete blood 
count (CBC; hemoglobin, white blood cell count with differential, platelet count) and 
biochemistry analysis (BUN or blood urea, creatinine, albumin, aspartate aminotransfer-
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ase, alanine amintotransferase, bilirubin, alkaline phosphatase, lactate dehydrogenase, 
sodium, potassium), sample for urinalysis, serum pregnancy test, multigated acquisition 
(MUGA) scan, chest X-ray and baseline tumor measurements.
 On days 1, 8, 15 and 22 of each cycle evaluation consisted of a brief history and 
physical examination, vital signs, blood samples for CBC and biochemistry, urinalysis, 
ECG. MUGA scans were repeated after cycle 1, and every even cycle. Response evaluation 
was performed every 2 cycles according to RECIST13. Patients were evaluated weekly for 
adverse events and toxicity according to the National Cancer Institute Common Toxicity 
Criteria (NCI-CTC), version 3.0. 
Pharmacokinetic Evaluation
Pharmacokinetic (PK) evaluation was performed by collecting blood samples via an in-
dwelling intravenous catheter in the opposite arm of the infusion. In cycle 1, on days 1 
and 15 a 5 mL sample was collected pre-dose and at 0.5, 1, 3 and 6 (5 min before end 
infusion) h after start of the infusion, and 5, 15 and 30 min, 1, 2, 4 and 6 h after the end 
of the infusion. On days 2-4 and 15-18 blood samples were taken corresponding to 24, 
48 and 72 h after the start of infusion. On day 8, blood samples were taken predose and 
5 min before the end of infusion. On day 22, one blood sample was taken. In subsequent 
cycles an abbreviated sampling schedule was used. Urine samples were collected pre-
dose and up to 72 h after the first dose of cycle 1. 
 Pharmacokinetic evaluation was carried out using a non-compartmental approach 
with the aid of WinNonlin software (version 3.1, Pharsight Inc., Mountain View, CA, 
USA). Plasma and urine concentrations of danusertib and of its N-oxide metabolite were 
measured by validated liquid chromatography-tandem mass spectrometry techniques. 
Detailed methods are described in the online only appendix.
Biomarker Analysis
Skin biopsies for biomarker analysis were performed on day 1 of the first cycle, before 
start and 10 minutes before end of the infusion. Biopsies were processed for immu-
nohistochemistry (IHC), using an anti-phospho histone H3 antibody, as a measure of 
aurora-B inhibition.10,14,15 Detailed methods are described in the online only appendix.
Blood samples for blood pressure biomarker analysis (norepinephrine, epinephrine, en-
dothelin A and B, vascular endothelial growth factor, and angiotensin II) were scheduled 
to be taken pre-dose and every hour during infusion in cycle 1 and in case of a hyper-
tensive event. 
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Results
Between June 2004 and September 2007, 52 patients were enrolled. Two patients never 
started treatment because of clinical deterioration due to rapid tumor progression. Pa-
tient characteristics are summarized in Table 1.
Table 1. Baseline demographics and patient characteristics.







     Male 29 (73)  8 (80)
     Female 11 (28)  2 (20)
Age, years
     Median (range) 54 (22-75) 61 (46-74)
ECOG performance scale, n (%)
     0  6 (15)  3 (30)
     1 34 (85)  7 (70)
Previous lines of systemic therapies
      Median (range)  4 (0*-12)  3 (1-6)
Tumor type, n (%)
     Colorectal cancer 13  6
     Sarcoma  6  1
     Esophageal cancer  4  –
     Pancreatic cancer  3  –
     Cholangiocarcinoma  2  –
     Ovarian cancer  2  –
     Prostate cancer  2  –
     Renal cancer  2  –
     Other
ACUP  1  1
Adrenal cancer  1  –
Bladder cancer  1  1
Breast cancer  1  –
Mesothelioma  –  1
NSCLC  1  –
Thyroid cancer  1  –
ECOG: Eastern Cooperative Oncology Group, 
ACUP: Adenocarcinoma of unknown primary, NSCLC: non small cell lung cancer
* 3 pancreatic cancer, 1 cholangiocarcinoma had only previous surgery
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 The percentage of evaluable patients was 94% for PK analyses, 60% for Histone H3 anal-
yses, 100% for toxicity, and 78% for efficacy. A total of 148 cycles were administered. The 
median number of cycles per patient was 2 (range 1-28). Dose reductions were required 
in 12% of patients. Reasons for study discontinuation were lack of efficacy (69%) and ad-
verse events (20%). Two patients withdrew consent, and one patient is still on treatment. 
Safety and Tolerability
Dose levels for the 6h-ivS were 45 mg/m2 (n=3), 90 mg/m2 (n=7), 135 mg/m2 (n=4), 
190 mg/m2 (n=4), 250 mg/m2 (n=10), 330 mg/m2 (n=8), and 400 mg/m2 (n=4), and 
250 mg/m2 (n=3), and 330 mg/m2 (n=7) for the 3h-ivS.
 In the 6h-ivS, DLT consisted of grade 2 hypertension leading to interruption of infu-
sion in one patient (90 mg/m2); febrile neutropenia and grade 3 fatigue in one patient 
(330 mg/m2); dose omission due to grade 4 neutropenia in 2 patients (400 mg/m2). Us-
ing the 3h-ivS DLT consisted of dose omissions due to grade 4 neutropenia and grade 3 
fatigue (330 mg/m2).
 All treatment-related hematological and non-hematological adverse events are sum-
marized in Table 2.
 For the 6h-ivS (total of 120 cycles), most frequently observed drug-related side 
effects were neutropenia, nausea, anorexia, and fatigue. For the 3h-ivS (total of 28 cy-
cles), most frequently observed drug-related side effects were fatigue, neutropenia, 
diarrhea, and nausea. Grade 3-4 drug-related events were neutropenia, febrile neu-
tropenia, leucopenia, and fatigue reported at doses of 250 mg/m2 and higher for the 
6h-ivS and fatigue, diarrhea, neutropenia, leucopenia, and dehydration at 330 mg/m2 
of the 3h-ivS. Injection site reactions were reported in 3 patients each with both infu-
sion schedules.
 For the 6h-ivS drug-related adverse events requiring dose reduction or omission were 
mainly due to hematological toxicity and started at 250 mg/m2 (5 cases). In the 3h-ivS 
dose reduction was pursued in 1 patient for hematological toxicity (330 mg/m2). Perma-
nent treatment discontinuation for drug-related toxicity was required in 3 patients, for 
grade 2 anemia associated with fatigue, pain and nausea (190 mg/m2, 6h-ivS), grade 1 
hypertension (330 mg/m2, 6h-ivS), and grade 3 fatigue (330 mg/m2, 3h-ivS).
 Neutropenia was uncomplicated except for one case of febrile neutropenia 
(330 mg/m2, 6h-ivS). Median time to neutropenia nadir was 15 days and median time 
to recovery 7 days.
 The MTD was 330 mg/m2 for the 6h-ivS, and not defined for the 3h-ivS. The 250 mg/m2 
dose level was not further expanded to confirm it as the MTD for the 3h-ivS, as available 
data supported the feasibility of a safe administration of 330 mg/m2 using the 6h-ivS.

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Any grade 
n (%)
Treatment-Emergent Hematological Adverse Events
Anemia 2 – 4 – 6 (60.0)
Leukopenia 2 – 2 2 6 (60.0)
Neutropenia 1 – 1 4* 6 (60.0)
Febrile neutropenia – – – – 0 (0.0)
Thrombopenia – – 1 – 1 (10.0)
Treatment–Related Non–Hematological Adverse Events
Any event 3 – 2 4 9 (90.0)
GI toxicity
   Anorexia – – 2 – 2 (20.0)
   Constipation – – 2 – 2 (20.0)
   Dehydration – – – 1 1 (10.0)
   Diarrhea 2 – 1 2 5 (50.0)
   Dyspepsia 1 – 1 – 2 (20.0)
   Nausea 1 – 2 – 3 (30.0)
   Vomiting 1 – 1 – 2 (20.0)
Constitutional toxicity
   Fatigue 2 – 3 2* 7 (70.0)
Miscelaneous
   Abdominal pain – – 2 – 2 (20.0)
   Alopecia – – 1 – 1 (10.0)
   Dizziness – – – – 0 (0.0)
   Headache – – 1 – 1 (10.0)
   Hypertension – – – – 0 (0.0)
   Influenza like – – – – 0 (0.0)
   Myalgia – – 2 – 2 (20.0)
   Phlebitis – – 2 – 2 (20.0)
   Somnolence – – 2 – 2 (20.0)
Pharmacokinetics
Danusertib pharmacokinetic parameters are summarized in Table 3. Day 1 danusertib 
plasma concentrations after 6-hour infusion dose of danusertib of a representative pa-
tient at each dose level are plot in Figure 2. The pharmacokinetics of danusertib were 
characterized by high volume of distribution and low to moderate plasma clearance 









































































































































































































































































































































































































































































































































































































































































































































































































































(range 10-59 L/hour). The half-life was about 30 hours. Accumulation was negligible. 
Renal clearance accounted for a small proportion of plasma clearance. The metabolite 
to parent AUC ratio was similar across doses and approximately equal to 1. Metabolite 
concentrations declined in parallel with those of the parent compound. The system-
ic exposure to danusertib increased linear with dose (Figure 3A). Pharmacokinetics of 
danusertib were not influenced by infusion rates (p-values >0.1; independent samples 
Student’s t-test). However, patient numbers were limited. PK data on days 1 and 15 were 
comparable (p-values >0.1; paired samples t-test; Figure 3B).
Correlation between Toxicity and Exposure
Figure 4 shows a positive correlation between the percentage decrease in neutrophil 
counts in cycle 1 in function of the AUC, thus demonstrating that a higher AUC is related 
to a greater decrease in neutrophil counts during danusertib treatment.16
Biomarker Analysis
Histone H3 phosphorylation in skin
Pre-and on-treatment skin biopsies were obtained from 35 patients in the danusertib 
6-hour infusion schedule and in 8 patients in the 3-hour schedule. Samples from pa-
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Figure 2. Representative day 1 individual plasma concentrations (μM) of PHA-739358 




























Fig. 2  Representative day 1 individual plasma concentrations (mM) of PHA-739358 after 6 hour infu-
sion of PHA-739358 at each dose level
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tients at the 90 and 135 mg/m2 dose levels (6h-ivS) were not evaluated because no 
phosphorylated histone H3 (pH3) was appreciated by Western blot (WB). In total, 30 pa-
tients had both pre and post treatment evaluable samples by IHC. By both WB (data not 
shown) and IHC (Figure 5) more than 80% pH3 inhibition was observed starting from 
the 190 mg/m2 dose level (6h-ivS). These results are in agreement with the literature. Ex-
 23
Figure 3A, online only: Day 1 individual AUC0-∞ of PHA-739358 vs. dose after 6-hour infusion of PHA-
739358. 
Slope t-test: 

























Fig. 3 A  Day 1 individual AUC0-  of PHA-739358 vs. dose after 6-hour infusion of PHA-739358. 
Slope t-test: Day 1: t = 1.277, NS (df = 37)
Fig. 3 B  Day 1 and day 15 individual AUC0-  of PHA-739358 vs. dose after 6-hour infusion of PHA-
739358. Slope t-test: Day 1: t = 1.277, NS (df = 37)
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Figure 3B, online only: Day 1 and day 15 individual AUC0-∞ of PHA-739358 vs. dose after 6-hour 
infusion of PHA-739358. 
Slope t-test: 
Day 1: t = 1.277, NS (df = 37) 
Day 15: t = 0.793, NS (df = 28) 
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Figure 5: Mean % change in number of Histone H3 positive cells by immunohisto-
chemistry in skin biopsies; PHA-739358 on-treatment compared to pre-treatment. 
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Figure 4: Correlation between the percentage of decrease in neutrophil count, nadir 
vs baseline, during cycle 1 and the plasma AUC of PHA-739358.  
The green dot represents the patient with febrile neutropenia (FN) 
AUC0-inf
























Fig. 4  Correlation between the percentage of decrease in neutrophil count, nadir vs baseline, dur-
ing cycle 1 and the plasma AUC of PHA-739358. 
Fig. 5  Mean % change in number of Histone H3 positive cells by immunohisto-chemistry in skin 
biopsies; PHA-739358 on-treatment compared to pre-treatment.
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ploratory analysis of correlation between pH3 and clinical outcome was not conducted 
due to limited patient numbers.
Blood Pressure Mediators in Plasma
In the absence of a clear modulation of blood pressure mediator levels and blood pres-
sure increase in two patients (one with hypertension during infusion and one without) 
(data not shown), these markers were not further explored and the blood sampling for 
this purpose was stopped.
Anti tumor activity
There were no complete or partial responses. An overall disease control rate (DCR) of 
20.0% (6/30 patients) was observed in the 6h-ivS. DCR was 37.5% in the 3h-ivS (3/8 
patients). Disease stabilization lasting >6 months was seen in 4 patients in the 6h-ivS, 
and in 1 patient in the 3h-ivS. One patient with progressive non small cell lung cancer 
prior to study entry, showed disease stabilization for over 2 years on the 6h schedule 
(Figure 6). 
Discussion
In this study we demonstrate that treatment with the pan-aurora (A, B, and C) kinase 
inhibitor danusertib is well tolerated.
 As aurora kinases are key regulators of mitosis, inhibition of their activity is likely to 









Fig. 6  Characteristics of patients with stable disease.
Chapter 9
140
limiting in this and other studies with aurora kinase inhibitors.17-27 Neutropenia is gen-
erally uncomplicated and of short duration. Limited non-hematological toxicity, such as 
mucositis, nausea, vomiting, diarrhea or alopecia is seen.
 Recently aurora-A knockout mice were generated.28,29 The aurora-A null mice died 
early during embryonic development, supporting the fact that aurora-A has a critical 
role in normal mitosis. Disturbingly, aurora-A heterozygote mice showed an increased 
incidence of malignancy.28 The long-term effects of aurora kinase inhibition in man re-
main unknown. 
 Inhibition of pH3 more than 80%, indicating adequate aurora-B inhibition, was ob-
served at dose levels ≥190 mg/m2. This is in line with other publications.10,12,14,21,25 How-
ever, since pH3 was inhibited in almost all patients, even in patients with clear tumor 
progression, the usefulness of this biomarker should be subject to exploration in future 
phase II and III studies. Other biomarkers like the number of mitotic cells in basal epi-
thelium, FDG-PET, and dynamic-contrast enhanced magnetic resonance imaging are also 
being evaluated.17,22,26,27,30
 Determining antitumor activity of danusertib was a secondary endpoint. Complete or 
partial responses were not observed. However, the overall disease control rate of 23.7% 
and long lasting disease stabilization (≥6 months) in some patients are indicative of anti-
tumor activity and merit confirmation in a phase II study program. 
 Due to the limited patient numbers superiority or equivalence of the 3h or 6h schedule 
could not be concluded based on the PK results. The decision to recommend 330 mg/m2 
danusertib infused over 6 hours using the days 1, 8, 15 in a 28-day cycle schedule as 
the dose regimen for phase II investigations in solid tumors of  is based on two observa-
tions. First, by shortening the infusion time to 3 hours, the dose intensity would have 
been lower that with the 6h-ivS (250 vs. 330 mg/m2). Second, incidence and severity of 
toxicities was higher at the 330 mg/m2 dose level when infusion time was shortened. 
Phase I studies investigating 24-hour infusion of danusertib are ongoing. danusertib also 
inhibits wild-type and mutated form of Abl, including the T315I mutant. A pilot phase II 
clinical study with the 6-h-IV schedule every 28 days is ongoing in patients with chronic 
myeloid leukemia (CML) relapsing on imatinib or other c-ABL therapy.31,32 Preliminary 
results showed objective responses in 2 out of 7 CML patients with T315I mutations with 
an acceptable tolerability and safety profile.33 Other cross-reactivities, including FGFRs, 
Ret and TrkA have been identified and could open additional venues for clinical develop-
ment of danusertib.10,11 
 Currently many aurora-selective small-molecule inhibitors are undergoing preclinical 
and clinical studies. All have their individual advantages and disadvantages. MLN8054 
was the first aurora kinase inhibitor with the advantage of oral administration. However, 
in phase I studies grade 3 somnolence was the main dose limiting toxicity, resulting from 
A phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib (PHA-739358) 
141
binding of MLN8054 to the g-aminobutyric acid a 1 benzodiazepine receptor.17,26 MK-
0457 is an intravenously administered aurora kinase inhibitor with positive off-target 
effects blocking the T315I-mutant BCR-ABL leading to clinical responses in 3 BCR-ABL 
dependent leukemia patients.34 Danusertib, that inhibits all three aurora kinases, is also 
able to inhibit wild-type Abl as well as the most clinically frequent imatinib-resistant Abl 
mutants.31 
 The aurora kinase inhibitors have the advantage of not inducing alopecia and neuro-
toxicity related to other microtubular inhibitory agents. This can be taken into account 
when combining aurora kinase inhibitors with standard chemotherapy or targeted 
agents which will likely be part of future investigations.
 In conclusion, danusertib administered in a 6h-ivS and 3h-ivS on days 1, 8, 15 of a 28 
day cycle is safe and well tolerated. Based upon clinical endpoints, 330 mg/m2 as 6h-ivS 
is the recommended dose for phase II studies.
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Appendix:
Pharmaceutical preparation of danusertib
Danusertib was supplied as a 10 mg/mL concentrate for solution for infusion, dosed at 
15 mL/vial. One vial contained 150 mg of Danusertib in 5% dextrose solution adjusted to 
pH 5 with hydrochloric acid or sodium hydroxide (the hydrochloride salt of Danusertib is 
formed in situ during sterile aqueous solution manufacture).. 
Pharmacokinetic Evaluation
Concentrations of danusertib were determined in human plasma by liquid chromatog-
raphy-tandem mass spectrometry techniques (LC-MS-MS) following plasma protein pre-
cipitation in the 96-well plate format.. 
 Briefly, plasma samples were extracted with acetonitrile containing a stable labeled 
internal standard. After centrifugation, the organic phase was transferred into a fresh 
96-well and dried under nitrogen gas at 37°C. The residue was re-constituted with 15 
mM ammonium formate buffer solution pH 3.0 and then aliquots injected into the LC-
MS-MS system. Detection was by positive ion electrospray tandem mass spectrometry 
using Multiple Reaction Monitoring (MRM) following reversed phase chromatography 
on a Bonus RP column. The method was fully validated within the calibration range of 
0.5-500 ng/ml.
Phospho histone H3 analysis in skin
Skin biopsies for biomarker analysis were performed on day 1 of the first cycle, before 
start and 10 minutes before end of the infusion. Skin samples were fixed in formalin, 
paraffin embedded and then analyzed for the phospho histone H3 staining by immu-
nohistochemistry (IHC). The sections were stained with an anti-phosphorylated histone 
H3 (pH3) Ser10 polyclonal antibody (Upstate Biotechnology, NY, USA) and then coun-
terstained with hematoxylin. A median number of linear dermis evaluated was 16 mm/
sample. For every patient, the number of pH3 positive cells every 2 mm of dermis at 
pretreatment and at the end of treatment was defined as well as the % of change versus 
pretreatment. Biopsies were processed for immunohistochemistry (IHC), using an anti-
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Danusertib is a serine/threonine kinase inhibitor of multiple kinases, including aurora-A, 
B, and C. This explorative study aims to identify possible relationships between single nu-
cleotide polymorphisms in genes coding for drug metabolizing enzymes and transporter 
proteins and clearance of danusertib, to clarify the interpatient variability in exposure. 
In addition, this study explores the relationship between target receptor polymorphisms 
and toxicity of danusertib. 
Methods
For associations with clearance cancer patients treated in a phase I study were analyzed 
for ABCB1, ABCG2 and FMO3 polymorphisms. Association analyses between neutrope-
nia and drug target receptors, including KDR, RET, FLT3, FLT4, AURKB and AURKA, were 
performed in patients treated at recommended phase II dose-levels in three danusertib 
phase I or phase II trials. 
Results
For the FMO3 18281AA polymorphism, a significantly higher clearance was noticed, 
compared to patients carrying at least 1 wild type allele. For the other enzymes and 
transporters, no relationships between danusertib clearance and drug metabolizing en-
zymes and transporter protein polymorphisms were found. No effect of target receptor 
genotypes or haplotypes on neutropenia was observed.
Conclusions
The relationship between FMO3 polymorphisms and clearance of danusertib warrants 
further research, as we could study only a relatively small and heterogeneous group of 
patients. However, as we did not find any major correlations between pharmacogenetic 
variability in the studied enzymes and transporters and pharmacokinetics nor toxicity, it 
is unlikely that danusertib is highly susceptible for pharmacogenetic variation. Therefore, 
no dosing alterations of danusertib are expected in the future, based on the polymor-
phisms studied here. 
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Introduction
Aurora kinases are serine/threonine kinases with a key role in mitosis.1-9 Danusertib 
(PHA-739358) is a new active moiety in cancer treatment which selectively inhibits the 
ATP site of aurora-A (AURKA, IC50 = 13 nM), aurora-B (AURKB, IC50 = 79 nM) and au-
rora-C (AURKC, IC50 = 61 nM) kinases.
10,11 Inhibition of aurora-A or aurora-B activity in 
tumor cells results in impaired chromosome alignment, weakening of the mitotic check-
point, polyploidy, and subsequent cell death.12,13 Danusertib shows anti-tumor activity 
in a wide range of cancer cell lines and xenograft tumor models.10 Tested in a panel of 
32 kinases, danusertib also showed increased affinity for multiple other kinases (IC50 
<0.50 µM), including ret proto-oncogene (RET), vascular endothelial growth factor re-
ceptor 3 (FLT4, VEGFR3), and fms-related tyrosine kinase 3 (FLT3). Therefore, inhibition of 
these kinases may influence danusertib efficacy or toxicity in cancer patients. 
 The major route of metabolism of danusertib involves the formation of the N-oxide 
metabolite, mainly through the enzyme flavin containing monooxygenase 3 (FMO3), 
forming an inactive metabolite. Furthermore, danusertib was found to be a substrate 
for efflux proteins ATP-binding cassette B1 (ABCB1/MDR1) and G2 (ABCG2/BCRP in in 
vitro studies (unpublished data). In addition, it has been shown that histone H3 is phos-
phorylated by aurora-B and phosphorylation of histone H3 is inhibited in skin, bone 
marrow and xenograft tumors after treatment with danusertib.10 As a consequence, the 
extent of histone H3 phosphorylation is studied as a pharmacodynamic biomarker of 
danusertib effectiveness.
 Recently, this new compound has been introduced in human research. In a phase I 
study, performed at the Leiden University Medical Center, Leiden and the Erasmus Uni-
versity Medical Center, Rotterdam (The Netherlands), the pharmacokinetics of danusertib 
were characterized by relatively low to moderate plasma clearances (range 10-59 L/hour) 
and an elimination half-life of about 30 hours.14 Danusertib showed linear pharmaco-
kinetics over the dose-range studied. At all dose levels, the inter-patient variability of 
the primary pharmacokinetic parameters of danusertib was remarkably high, with a 
coefficient of variation of 40-50%, which is in line with other anti-cancer drugs. Toxicity 
increased with danusertib dose. However, currently it is unclear whether pharmacoge-
netic variability in drug metabolizing or transporting proteins can explain a large part of 
the inter-individual variability in pharmacokinetics and/or toxicity-profile. Therefore, the 
current explorative study aims to identify possible (and clinically relevant) relationships 
between single-nucleotide polymorphisms (SNPs) in genes coding for drug metabolizing 
enzymes and for transporter proteins and pharmacokinetic parameters of danusertib. 
In this study we also explore the possible relationship between polymorphisms in genes 




This study was conducted on three different groups of patients. Group A consisted of 
patients enrolled into a phase I dose-escalating study of danusertib in patients with 
advanced or metastatic solid tumors. Group B and group C consisted both of subsets of 
patients enrolled into phase II studies of danusertib in patients with various tumor types, 
including breast cancer, pancreatic cancer, colorectal cancer, ovarian cancer, or hormone 
refractory prostate cancer. 
 From patients treated in the phase I study (Group A) residual blood samples were 
available for pharmacogenetic analyses to compare with pharmacokinetics (all patients) 
and toxicity (patients at the recommended phase II dose (RP2D)). Groups B and C consist-
ed of patients treated in two ongoing phase II studies. They were all treated at the RP2D 
and had blood samples available for pharmacogenetic analysis to compare with toxicity. 
Patients and samples
Eligibility criteria, drug administration procedures, safety, pharmacokinetic and efficacy 
methods as used in the phase I trial are described in detail elsewhere.14 
 Briefly, Group A patients had histologically or cytologically confirmed advanced or 
metastatic solid tumors for whom no standard therapy was available, with an Eastern 
Cooperative Oncology Group (ECOG) performance status ≤1. Danusertib was administered 
intravenously on days 1, 8, 15 every 28 days. Doses were escalated from 45 mg/m2 to 
400 mg/m2 in the 6-hour infusion schedule, and from 250 mg/m2 to 330 mg/m2 in the 
subsequent 3-hour infusion schedule. The trial had a standard 3+3 phase I dose esca-
lation study design. In the phase II study from which group B patients were entered, 
men with metastatic hormone refractory prostate cancer, progressive after docetaxel 
treatment were eligible. Patients of group B were randomized between treatment with 
330 mg/m2 of danusertib on days 1, 8, 15 every 28 days in a 6-hour infusion schedule 
or with 500 mg/m2 of danusertib on days 1 and 15 every 28 days in 24-hour infusion 
schedule according to the phase II study protocol. The total exposure in both groups 
is expected to be identical, and in line with the RP2D as determined in phase I stud-
ies.8,14 For group C, patients with several tumor types (see table 1), progressive after 1 or 
2 lines of chemotherapy depending on tumor type were eligible. Treatment consisted of 
500 mg/m2 of danusertib on days 1 and 15 every 28 days in 24-hour infusion schedule. 
No pharmacokinetic analyses were performed in the phase II trials.
 For all groups, patients were evaluated for adverse events and toxicity according to the 
National Cancer Institute Common Terminology Criteria (NCI-CTC), version 3.0. Response 
evaluation was performed every 2 cycles and was assessed according to RECIST 1.0.15 
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Table 1.  Patient characteristics, danusertib induced toxicity in the first cycle, and phar-
macokinetic/pharmacodynamic results. 









Gender, male 43 (68) 35 (73) 20 (67)
Race, caucasian 62 (98) 47 (98) 29 (97)
Age, years
   Median (range) 58 (22-75) 58 (22-75) 60 (38-74)
Patient Group
   A (phase I) 48 (76) 48 (100) 15 (50)
   B (phase II, prostate cancer)  7 (11) –  7 (23)
   C (phase II, various tumor types)  8 (13) –  8 (27)
RP2D Group
   330 mg/m2 d1,8,15 every 4 weeks 20 (31) 15 (31) 20 (67)
   500 mg/m2 d 1 and 15 every 4 weeks 10 (16) – 10 (33)
Tumor type
   Colorectal cancer 19 (30) 18 (38) 10 (33)
   Breast cancer  6 (10)  1 (2)  5 (17)
   Esophageal cancer  4 (6)  4 (8)  2 (7)
   Ovarian cancer  3 (5)  2 (4)  1 (3)
   Pancreatic cancer  4 (6)  3 (6)  1 (3)
   Prostate cancer  8 (13)  1 (2)  7 (23)
   Miscellaneous 19 (30) 19 (39)  4 (13)
ECOG performance score
   0 15 (24)  8 (17) 11 (37)
   1 48 (76) 40 (83) 19 (63)
Nr of previous treatment lines
   Median (range)  3 (0-12)  3 (0-12)  3 (1-7)
Toxicity during cycle 1
   Any toxicity grade 1-4 51 (81) 37 (77) 28 (93)
   Any toxicity grade 3 or 4 22 (35) 15 (31) 15 (50)
   Neutropenia grade 1-4 34 (54) 25 (52) 19 (63)
   Neutropenia grade 3 or 4 18 (29) 12 (25) 13 (43)
   Febrile neutropenia  1 (2)  1 (2)  1 (3)
Clearance day 1 cycle 1 (L/hour/m2), n=47
   Median ± SD n.a. 17.8 ± 5.8 n.a.
Histone H3 phosphorylation, n=28, Δ%
   Median ± SD n.a. -92.3 ± 13.1 n.a.
Number of treatment courses
   Median (range)  2 (1-31)  2 (1-31)  2 (1-15)
RP2D: Recommended phase 2 dose; ECOG: Eastern Cooperative Oncology Group; SD: standard deviation; 
Histone H3 phosphorylation:% change in number of positive cells by immunohistochemistry for Histone H3 
phosphorylation, * One patient included in toxicity analyses, but no PK data available, **Fifteen patients of 
the phase I trial were treated at the RP2D level.
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 Residual blood samples taken for routine patient care were stored at -20ºC at the lo-
cal hospital laboratories. Of each patient, one frozen whole blood sample was collected 
from the two participating hospitals. All samples were anonimyzed by a third party, 
according to the instructions stated in the Codes for Proper Use and Proper Conduct 
(www.federa.org). Approval from the institutional medical ethical review boards was 
obtained prior to analysis.
Pharmacokinetic, toxicity and biomarker parameters
Pharmacokinetic (PK) evaluation was performed by collecting blood samples on days 1 
to 4, day 8, days 15 to18 and day 22 of cycle 1, and days 1 and 15 of cycles 2 and 4. 
Pharmacokinetic evaluation was carried out using a non-compartmental approach with 
the aid of WinNonlin software (version 3.1, Pharsight Inc., Mountain View, CA, USA). In 
this study, danusertib clearance (L/hour/m2) was selected as the pharmacokinetic param-
eter to associate with enzyme and transporter genetic polymorphisms. As mentioned 
in the phase I report, clearance was not influenced by duration of infusion and was 
comparable in both 3-hour and 6-hour infusion schedules; 16.2 and 18.0 L/hour/m2 re-
spectively.14 Clearances in our study were also comparable to mean danusertib clearance 
reported in another phase I study using even a 24-hour infusion schedule.8 Therefore, 
patients treated at both 3-hour and 6-hour infusion schedules were included in the 
pharmacokinetic association analyses.
 The most frequent and clinically relevant danusertib induced side effects, known 
from phase I trials, are grade 3 and 4 neutropenia, defined as neutrophil counts 0.5-
1.0*109/L and <0.5*109/L, respectively, and febrile neutropenia. These side-effects were 
therefore considered to be the best candidate toxicity parameters for the association 
analyses with drug target receptor genetic polymorphisms. 
 For the association analysis with neutropenia, we included patients treated at the 
RP2D (thus, 330 mg/m2 days 1, 8, 15 q4w or 500 mg/m2 days 1 and 15 q4w equivalent). 
Since grade 3-4 neutropenia was associated with danusertib dose, association analyses 
were performed with neutropenia developing in the first cycle only, excluding the ef-
fects of cumulative danusertib dose and dose reductions in subsequent cycles.14 The 
probability of grade 3 or 4 neutropenia in the first danusertib cycle was not influenced 
by infusion duration and this toxicity was also comparable in both used schedules.8,14 
Therefore, for the purpose of analyzing associations between drug target receptor poly-
morphisms and neutropenia all patients treated at the RP2D were combined. Only one 
case of febrile neutropenia was observed, and as a result association analyses with fe-
brile neutropenia could not be performed. 
 Skin biopsies for biomarker analysis (Group A) were performed at baseline, and 
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10 minutes before the end of the first infusion in the first cycle. As a biomarker for 
aurora-B inhibition, the inhibition of histone H3 phosphorylation in the skin was mea-
sured by immunohistochemistry.10,16,17 Change in histone H3 phosphorylation was used 
as parameter for association analyses with polymorphisms in the aurora-B receptor. 
Selection of candidate genes 
Candidate genes were selected based on the information of preclinical pharmacology 
studies as reported in the Investigator’s brochure (Nerviano Medical Sciences on file). 
For association with clearance ABCB1, ABCG2, and FMO3 were the genes selected. For 
correlation with danusertib toxicity selected genes were the drug target genes encod-
ing AURKA, AURKB, AURKC, C-ABL, NTRK1, RET, FGFR1, LCK, FLT4, C-KIT, KDR, CDK2A, 
STLK1, and FLT3. 
 The single-nucleotide polymorphisms (SNPs) were selected, taking into consideration 
one or more of the following criteria: a validated SNP assay, SNP should preferably cause 
non-synonymous amino acid changes, an indication for clinical relevance should be avail-
able from previous publications, and the preferred minority genotype allele-frequency 
should be at least ~10% in Caucasians. For ABCB1, ABCG2, FMO3, AURKA, AURKB, RET, 
FLT4, KDR, and FLT3, one or multiple SNPs could be selected according to these criteria. 
DNA extraction, SNP analysis, and haploblock selection
DNA was isolated from EDTA-blood samples with MagNA Pure Compact DNA Isolation kit 
(Roche Diagnostics, Almere, The Netherlands). DNA concentrations were quantified on 
the nanodrop (Isogen, IJsselstein, The Netherlands). From the patients of whom whole 
blood samples were unavailable, DNA was isolated from blood-serum with MagNA Pure 
Compact DNA Isolation kit. Taqman assays were obtained from Applied Biosystems (Ap-
plied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). SNP genotyping was 
performed with the BIOMARK 48.48 dynamic array (Fluidigm Corporation, South San 
Francisco, CA, USA). All assays were performed according to protocols provided by the 
manufacturer. As a quality control, 4 samples were genotyped in duplicate for all assays 
and 2 assays were tested in duplicate on all samples. As negative controls water was 
used. Overall, no inconsistencies in genotypes were observed. To genotype DNA extract-
ed from blood serum on the Biomark, a pre-amplification step was necessary. Briefly, to 
1.25 ml of serum-DNA a dilution of all taqman assays in a total volume of 1.25 ml and 
2.5 ml of pre-amplification mastermix (Applied Biosystems) was added, and amplified on 
a conventional PCR machine. This mixture was 20x diluted and 2.5 ml was used in the 
Biomark conform their protocol.
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 Genotype distributions are presented in Table 2. The success rates for all genotyping 
analyses were 100%, except for RET 135G>A with 22% invalid results, despite repeated 
analyses. Genotype frequencies for 21 of 22 SNPs were in Hardy-Weinberg equilibrium 
(P >0.05). KDR 1719A>T (rs1870377) was not in Hardy-Weinberg equilibrium which 
was most likely due to the limited population size. Our genotype frequencies were in line 
with previously reports and frequencies for Caucasians, as reported in the NCBI database 
(www.ncbi.nlm.nih.gov). 
 If linkage disequilibrium between SNPs was detected, haplotypes were set with gPLINK 
(http://pngu.mgh.harvard.edu/purcell/plink/).18 No phase uncertainty in the defined hap-
loblocks and haplotypes (Rh^2> 0.98) was seen. The haploblock for ABCB1 included 
1236C>T, 2677G>A/T, and 3435C>T; the haploblock for ABCG2 included 15994G>A, 
and 1143C>T; and the haploblock for FMO3 included 15167G>A, 21443A>G, and 
18281G>A (Table 4). 
Statistical analysis
Differences in pharmacokinetic and pharmacodynamic parameters among genotypes 
were analyzed by the Student’s t-test, or analysis of variance (ANOVA) for continuous 
variables or chi-square test for dichotomous variables, where appropriate. For toxicity, dif-
ferences in genotype distribution were tested by 3 × 2 cross-tabulations for each geno-
type, and by 2 × 2 cross-tabulations for carriers versus noncarriers, with analysis by a 
two-sided chi-square test. Polymorphisms within a gene were tested with the chi-square 
test (P-value < 0.05) to detect linkage disequilibrium. Associations between the number 
of copies of a haplotype and clinical parameters were performed using a chi-square test 
for dichotomous variables and Student’s t-test, ANOVA for continuous variables.
 All statistical analyses were performed using SPSS 16.0 software (SPSS, Chicago, IL) 
and were two-sided, with a level of significance of a=0.05. Because of the explorative 
nature of this study, we did not perform a correction for multiple comparisons.
Results
Baseline patient characteristics, observed treatment-related toxicities, pharmacokinetics 
and treatment duration are presented in Table 1. Our population comprised 98% Cau-
casians with 68% males and 32% females. Most frequent tumor types were colorectal 
cancer (30%), prostate cancer (13%) and breast cancer (10%). Danusertib doses used 
ranged from 45 mg/m2 to 500 mg/m2, with infusion times of 3 (14%), 6 (70%) and 
24 hours (16%), according to the designs of the mentioned phase I and phase II trials. 
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 Haplotype frequencies for ABCB1 were GCC 0.443, TTT 0.412, GTC 0.096, and GCT 
0.024, for ABCG2 CC 0.691, TT 0.230, and TC 0.079, and for FMO3 AGA 0.437, GGG 
0.437, and GAG 0.127. Haploblock for KDR included -604 T>C, 1192G>A, and 1719A>T, 
for RET 37412G>A, and 135G>A, and for AURKA 169G>A, and 91A>T. Haplotype fre-
quencies for KDR were TCT 0.410, CCT 0.316, CCA 0.109, TCA 0.087, CTA 0.047, CTT 
0.021, and TTA 0.0114, for RET GG 0.602, and GA 0.938, and for AURKA GA 0.556, AA 
0.222, and GT 0.222. 
 There was no apparent association between cycle 1 day 1 danusertib clearance 
Table 2. Genotype frequency results.
Gene and Variant No. Patients p* q**
ABCB1 1236C>T 63 0.556 0.444
ABCB1 2677G>A/T 63 0.563 0.437
ABCB1 3435C>T 63 0.484 0.516
ABCG2 421C>A 63 0.889 0.111
ABCG2 346G>A 63 0.952 0.048
ABCG2 1143C>T 63 0.770 0.230
ABCG2 15994G>A 63 0.690 0.310
FMO3 15167G>A 63 0.563 0.437
FMO3 21443A>G 63 0.794 0.206
FMO3 18281G>A 63 0.873 0.127
KDR -604T>C 63 0.508 0.492
KDR 1192G>A 63 0.921 0.079
KDR 1719A>T 63 0.254 0.746
KDR 54G>A 63 0.563 0.437
KDR -92G>A 63 0.762 0.238
RET 37412G>A 63 0.810 0.190
RET 135G>A 49 0.776 0.224
FLT3 738C>T 63 0.397 0.603
FLT4 1480A>G 63 0.881 0.119
AURKB 893G>A 63 0.889 0.111
AURKA 169G>A 63 0.778 0.222
AURKA 91A>T 63 0.778 0.222
*p: frequency of wild-type allele; **q: frequency of variant allele
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Table 4.  Association between genetic polymorphisms and grade 3-4 neutropenia in cycle 
1 in all patients at RP2D levels. 
Neutropenia grade 3-4 p-value
Gene Polymorphism Genotype Total No. 
Patients
No Yes wt/wt vs wt/m 
vs m/m
KDR -604T>C TT 6 3 3 0.308
TC 15 7 8
CC 9 7 2
1192G>A GG 27 15 12 1.000
GA 3 2 1
1719A>T AA 1 0 1 0.426
AT 15 8 7
TT 14 9 5
54G>A GG 9 5 4 0.673
GA 16 10 6
AA 5 2 3
-92G>A AA 3 3 0 0.265
AG 7 4 3
GG 20 10 10
RET 37412G>A GG 24 14 10 0.507
GA 5 2 3
AA 1 1 0
135G>A GG 16 9 7 0.489
3 missing GA 8 6 2
AA 3 1 2
FLT3 738C>T CC 5 4 1 0.414
 CT 15 7 8
TT 10 6 4
FLT4 1480A>G AA 23 12 11 0.427
AG 7 5 2
AURKB 893G>A GG 22 11 11 0.407
GA 8 6 2
AURKA 169G>A GG 18 10 8 0.672
GA 11 6 5
AA 1 1 0
91A>T AA 20 11 9 0.110
AT 6 2 4
TT 4 4 0
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(L/hour/m2) and genetic polymorphisms in ABCB1 or ABCG2 (Table 3). However, for 
FMO3, patients carrying at least one G allele had a significantly slower clearance com-
pared to the 18281 AA patients (P = 0.017). 
 No relationship between observed grade 3-4 neutropenia in the first treatment cycle 
and KDR, RET, FLT3, FLT4, AURKB or AURKA genotype was observed (Table 4). Also the 
ABCB1, ABCG2, and FMO3 haplotypes did not show an association with danusertib 
clearance, nor did KDR, RET, AURKA haplotypes relate to danusertib induced grade 3-4 
neutropenia (Table 5).
 Also, no association was observed between the studied AURKB polymorphism and 
change in level of histone H3 phosphorylation induced by danusertib. The decrease in 
histone H3 phosphorylation for AURKB homozygous wild type genotypes (GG) was 91% 
(SD 13.3%), while the heterozygous genotype (GA) had a decrease of 84% (SD 12.2%, 
P=0.223).
Discussion 
Aurora kinase inhibitors are relatively new and promising agents in development for an-
ticancer treatment.1-9 The current knowledge on treatment actions, toxicity, biomarkers 
and efficacy is still very limited. danusertib is the first aurora kinase inhibitor in which a 
pharmacogenetic pathway analysis has been performed to clarify pharmacokinetic and 
pharmacodynamic features of the drug. 
 In the last decade, well known examples of anti-cancer drugs can be given, for which 
initial recommended dose-levels had to be changed based on toxicity in subgroups of 
patients.19-22 These subgroups of patients, with in general decreased enzymatic function 
based on genetic polymorphisms, could have been identified earlier if pharmacogenetic 
knowledge was available at an earlier stage. Therefore, it is recognized more and more 
that pharmacogenetic research in the earliest stages of development of new anti-cancer 
agents is highly relevant. While the basic characteristics of the new agent have to be-
come more clear, also selection of patients with potential increased toxicity, or decreased 
efficacy, should be performed as early as possible. Therefore, the decision was made not 
to delay the pharmacogenetic analyses till after registration of the compound, but to 
explore potentially clinical relevant pharmacogenetic variation at this stage of develop-
ment.
 Our study was conducted in patients of a recent phase I trial and subsets of two 
phase II trials of danusertib, and therefore patient numbers for both pharmacokinetic 
and pharmacodynamic association analyses are relatively limited. However, in the phase 
I trial DNA-data were available for almost the entire patient population, making selec-
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Table 3. Association between genetic polymorphisms and danusertib clearance.




ABCB1 1236C>T CC 16 17.8 6.5
CT 21 18.3 5.9
TT 10 18.6 4.9
P-value 0.930
2677G>A/T GG 17 18.2 6.6
GT 20 18.5 5.8
TT 10 17.7 4.9
P-value 0.948
3435C>T CC 13 19.5 6.1
CT 21 17.7 5.9
TT 13 17.8 5.6
P-value 0.638
ABCG2 421C>A CC 36 18.1 6.1
CA 11 18.8 4.8
P-value 0.621
346G>A GG 45 18.2 5.9
GA 2 18.6 5.2
P-value 0.755
143C>T CC 29 18.9 6.1
CT 15 17.3 5.5
TT 3 16.5 3.6
P-value 0.537
15994G>A GG 23 18.5 5.0
GA 21 18.2 6.2
AA 3 16.5 3.6
P-value 0.859
FMO3 15167G>A GG 15 19.5 6.6
GA 20 18.1 6.0
AA 12 16.9 4.2
P-value 0.537
21443A>G AA 27 19.2 6.3
AG 18 16.9 5.1
GG 2 16.4 1.3
P-value 0.382
18281G>A GG 35 18.1 5.2
GA 11 17.2 6.1
AA 1 34.0 n.a.
P-value 0.017
n.a: not applicable
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tion bias less likely. The two phase II trials are still ongoing and blood for DNA analysis 
was available for all patients included in the trials at the Erasmus University Medical 
Center at the moment of pharmacogenetic analyses. 
 A correlation between danusertib pharmacokinetics and pharmacogenetic variation 
is only seen for the FMO3 18281G>A homozygous variant and clearance. We can not 
exclude that this is the result of chance, but also for the other 2 SNPs (15167 G>A and 
21443G>A) in this gene, a pattern to altered clearance, based on genotype, is sug-
gested. As FMO3 is responsible for the main route of metabolism of danusertib, this 
warrants further research.  
 Currently, the mechanism causing neutropenia after danusertib treatment is unclear 
and could be associated with peak values (Cmax) or threshold values. Based on the new 
pharmacogenetic data from our current analysis no predisposition for the severity of 
hematological toxicity could be identified.
Table 5.  Haplotype analysis: uncorrected P values using Pearson X2 analysis, independent 
samples Student’s t-test or one-way ANOVA where appropriate
Gene SNPS Haplotype Neutropenia grade 3-4 
p-value
KDR -604T>C TCT 0.146
1192G>A CCT 0.460
1719A>T CCA 1.000
RET 37412G>A GG 0.773
135G>A GA 0.773
AURKA 169G>A GA 0.205
91A>T AA 0.672
GT 0.110
Gene SNPS Haplotype clearance L/hour/m2 d1c1
p-value
ABCB1 1236C>T GCC 0.953
2677G>A/T TTT 0.935
3435C>T
ABCG2 15994G>A CC 0.859
1143C>T TT 0.588





 Clearly, this study has its limitations. As described earlier, due to the phase I and II na-
ture of the studies patient numbers were limited and the group is quite heterogeneous. 
The power to find statistical significant differences in genotype of haplotype analyses 
was limited. 
 That correlations between the main enzymes and transporters involved in danusertib 
metabolism, and pharmacokinetics and toxicity are absent, does not mean that these 
results are unimportant. This study outcome makes the chance that danusertib is high-
ly susceptible to pharmacogenetic variation less probable. More discrete differences, 
based on pharmacogenetic variability, should be explored further in additional (popula-
tion based) pharmacogenetic studies for this compound.23-25 The relatively high inter-
individual variation observed could not be explained through pharmacogenetics and, for 
instance, the role of environmental factors might be important.
 The reason for a lack of association between Histone H3 phosphorylation and the 
studied AURKB polymorphism is unclear. Whether the 893G>A mutation results in al-
tered gene function is unknown.
 Since danusertib is currently used in two treatment schedules, 330 mg/m2 on days 
1, 8 and 15 every 4 weeks and 500 mg/m2 on days 1 and 15 every 4 weeks, a popula-
tion based pharmacokinetic-pharmacogenetic model might help in selecting the optimal 
treatment schedule.23-25 A second advantage of a population based pharmacokinetic-
pharmacogenetic model is that the relative impact of all individual SNPs as covariates 
can be explored.
 In conclusion, in this explorative study no highly significant associations between 
polymorphisms in genes coding for drug metabolizing enzyme, for transporter proteins 
and clearance of danusertib, between target receptor polymorphisms and toxicity of 
danusertib and between polymorphisms in the aurora kinase B receptor and the extent 
of histone H3 phosphorylation were seen. Future studies, including analyses of more pa-
tients on danusertib treatment and the use of population based pharmacokinetic-phar-
macogenetic models to select the optimal danusertib treatment schedule are planned. 
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Conventional chemotherapeutical agents act by creating toxic effects on all dividing 
cells, frequently resulting in severe damage of normal tissues leading to side effects like 
myelosuppression, alopecia, or gastrointestinal problems. The optimum goal is to find 
a treatment modality that specifically kills malignant cells and causes little or no side ef-
fects. Targeted therapies were developed to target key elements that play a role in tumor 
development and tumor growth.
There is not one unanimous definition for the term ‘targeted therapies’. In theory all 
therapies are ‘targeted’, so the term ‘targeted therapies’ is artificial when not used by a 
certain definition.1 One common definition, and used in this thesis, is ‘Targeted therapy 
is a type of medication that blocks the growth of cancer cells by interfering with specific 
targeted molecules needed for carcinogenesis and tumor growth, rather than by simply 
interfering with rapidly dividing cells (e.g. with traditional chemotherapy)’. There are 
various ways to categorize targeted agents, including categorizing by mode of inhibi-
tion of a signaling pathway, e.g. small molecule vs. antibody or by type of receptor that 
is blocked, e.g. EGFR, VEGFR, c-KIT etc. Another way of categorizing targeted agents is 
by effects in the tumor development, e.g. angiogenesis inhibitor, apoptosis inducer etc.
Trastuzumab (Herceptin®) is an excellent example of a targeted agent in the category 
of the monoclonal antibodies and is directed against the Her2 (EGFR2) receptor. In the 
category of targeted small molecules, imatinib (Gleevec®/Glivec®) was the first agent 
that was successfully developed. The results of imatinib in GIST, a tumor that is poorly 
affected by chemotherapy and radiotherapy, were astonishing and lead to a boost in re-
search of small molecule tyrosine kinase inhibitors in solid tumors.2,3 Also, the prognosis 
of Her2 positive breast cancer patients has improved significantly since the development 
of trastuzumab.4,5 
 On the contrary, most targeted agents do not meet up to the high expectations. The 
hope was that when crucial receptor and downstream signaling could be inhibited, pro-
liferation of cancer cells was blocked and cancer could subsequently become a chronic 
illness. However, it becomes more and more clear that proliferation of cancer cells, in 
general, cannot be stopped by blocking only one or two signaling pathways. 
Drug-development and patient selection in the treatment with tar-
geted agents
Alterations should be made to the conventional phases of drug-development in oncol-
ogy. In my opinion, maximum tolerated dose (MTD) can no longer be the only end-point 
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in oncological phase I studies, since targeted agents have limited side effects and MTD 
might never be reached. Instead, phase I studies should aim at identifying the maximum 
biological active dose, i.e. the dose that creates the maximum target inhibition. In our 
phase I study with telatinib, a small molecule angiogenesis inhibitor, we performed ad-
ditional measurements with DCE-MRI, and plasma VEGF and s-VEGFR levels. Biomarker 
analyses showed dose-dependent increase in VEGF levels and decrease in sVEGFR-2 lev-
els, with a plateau at 900 mg bid. A decrease in tumor blood flow (Ktrans and IAUC60) was 
observed with DCE-MRI. These results, together with the PK results were the main fac-
tors in determining the recommended phase II dose of a drug with limited side effects.
 In phase II/III studies, instead of response rate, other endpoints should be chosen, 
like time to progression, while with targeted agents it might take some time before sta-
bilization of the disease occurs. When agents like telatinib or danusertib are evaluated in 
phase II trials these changes to, in my opinion, ‘old’ trial designs should be made.
The observation that the efficacy of most targeted agents is limited in unselected pa-
tients warrants studies aiming at selecting subgroups of patients for which these drugs 
are beneficial. Exploration of predictive receptor polymorphisms or specific tumor sub-
types with specific overactivity of certain signaling pathways may help to achieve this 
goal. In phase III studies, selection of the study population should be made based on 
biogenetics of the tumor, and investigations should also include pharmacodynamic anal-
ysis of target inhibition. In previous large phase III trials in unselected patients, targeted 
agents were incorrectly judged to be ineffective, and research of an effective drug has 
incorrectly been stopped.
 In the studies reported in this thesis we aimed at selection of the best patient groups. In 
sarcomas we searched for EGFR and Her2 expression to select those patients who could 
benefit from EGFR/Her2 directed therapies. With pharmacogenetic studies we aimed to 
select those patients treated with the aurora kinase inhibitor danusertib or the small 
molecule VEGF inhibitor telatinib who would benefit most from those targeted agents 
without experiencing unnecessary side effects.
Toxicity of targeted agents
Unexpectedly, the toxicity of these new and specific agents is sometimes severe and may 
be unrecognized by the treating physician due to lack of experience. One example is the 
difference in monitoring of cardiovascular toxicity of trastuzumab and sunitinib, both 
known for their cardiotoxic side-effects. Trastuzumab has been part of the therapeutic 
arsenal far longer then sunitinib. In the five major randomized adjuvant trials, the use 
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of trastuzumab combination therapy resulted in severe congestive heart failure (New 
York Heart Association class III or IV) in 0-3.9% of patients treated in the trastuzumab 
arms versus 0-1.3% in the control arms. Ejection fraction decline of ≥10- 15% was re-
ported in 3-34% of trastuzumab treated patients in these trials.6 For sunitinib, data on 
cardiovascular toxicity are more recent, however in some reports the rate of congestive 
heart failure and reductions in ejection fraction are even higher then with trastuzumab 
treatment.7,8 
As new therapies become available, new side effects emerge. Physicians have to be 
aware of those new side effects and monitoring for newly emerging side effects should 
be optimalized. Ongoing research should include studies on side effects of new and 
older agents, and studies to prevent or limit these toxicities. Clinical studies with trans-
lational research on mechanisms of toxicity and pharmacogenetic investigations have 
expanded the insight of and experience with selected targeted anti-cancer drugs.
This thesis focusses on hypertension, a specific side effect that is frequently seen in the 
treatment with VEGF inhibitors. The relevance of hypertension monitoring and treat-
ment during anti-angiogenic treatment in cancer is often underestimated by clinicians. 
Acute rises in blood pressure caused by VEGF inhibitors may cause posterior leukoence-
falopathy syndrome, with high morbidity and even mortality, which may be prevented 
by in time regulation of blood pressure.9 Even more, multiple trials have shown that 
poorly controlled hypertension can lead to serious cardiovascular problems.10,11 A long-
term rise in diastolic blood pressure of 5-6 mm Hg is associated with 35-40% more 
stroke and 20-25% more coronary heart disease within 5 years.12 We have shown that 
treatment with bevacizumab and telatinib, a monoclonal antibody against VEGF and a 
small molecule VEGF tyrosine kinase inhibitor, both result in decreased capillary density. 
This decreased capillary density is probably the basis for the VEGF-inhibitor induced 
hypertension. We could also show that the changes in capillary density are reversible 
after discontinuation of the VEGF-inhibitor. These studies increase the knowledge on 
the mechanisms of action of angiogenesis inhibitors and on angiogenesis induced side 
effects. 
Future directions
In the coming years the use of targeted agents will probably expand even more rap-
idly. The indications might expand to almost all tumor types, to advanced and adjuvant 
therapy settings, and to combinations of multiple targeted agents or combinations of 
a targeted agent with conventional chemotherapy. Many clinical trials are already initi-
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ated to explore which (combination of) agents in specific patient groups have the most 
potential and should be further investigated. The final position of certain targeted drugs 
in anti-cancer treatment will become more clear in the next decades. Agents will be 
registered for use when a clear survival benefit is observed for a certain indication, first 
in advanced stages of disease and then in the adjuvant setting. Moreover, new targeted 
agents directed at new pathways important in angiogenesis, apoptosis, cell division, and 
many others will hopefully be found. 
This thesis reports a few of many trials that will increase the knowledge on targeted 
agents, on how to use them, whom to give them and hopefully increase the life expec-
tancy and quality of life of future cancer patients.
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In this chapter the reported studies presented in this thesis are summarized.
This thesis focuses on targeted anti cancer agents in solid tumors. Pharmacokinetics, 
safety, pharmacodynamics, and pharmacogenetics of selected targeted therapies, alone 
or in combination with conventional chemotherapy, are studied. Moreover, new target-
ed treatment options for sarcomas are explored. Chapter 1 gives a general introduction 
of this thesis.
In Chapter 2, a review of small molecule tyrosine kinase inhibitors in the treatment of 
solid tumors is presented. It updates the information on the small molecule tyrosine ki-
nase inhibitors (TKIs) that are already registered for use or those who are in an advanced 
stage of development. Furthermore, the future role of tyrosine kinase inhibitors in the 
treatment of solid tumors is discussed.
Targeted agents may have potential in a wide range of tumor types, including sarco-
mas for which only limited treatment options are available. Chapter 3 describes the 
construction and analysis of a tissue micro-array with 18 different types of soft tissue 
tumors. Positive membranous staining for EGFR (Her1) was observed in various sarco-
ma subtypes, including liposarcomas, leiomyosarcomas, synovial sarcomas, malignant 
peripheral nerve sheath tumors, rhabdomyosarcomas, solitary fibrous tumors, and an-
giosarcomas. Immunohistochemical staining for ERBB2 (Her2Neu) was negative in all 
subtypes. However, the immunohistochemical presence of growth factor receptors does 
not necessarily implicate that the subsequent pathway is activated, or is a potential tar-
get for therapy. These results, however, open the possibility to study the effect of EGFR 
blocking therapies, and give insight into previous study results showing that ERBB2 is 
not a potential treatment target in sarcomas.
A phase I dose escalation study of telatinib (BAY 57-9352), an orally available tyrosine 
kinase inhibitor, in patients with advanced or metastatic solid tumors is reported in 
Chapter 4. This phase I dose escalation study was conducted to evaluate the safety 
and tolerability of telatinib, with additional pharmacokinetics, pharmacodynamics and 
efficacy assessments. Telatinib was safe and well tolerated up to 1500 mg bid. Based 
upon pharmacodynamic and pharmacokinetic endpoints, telatinib 900 mg bid is the 
recommended dose for subsequent phase II studies.
Pharmacogenetics of telatinib are described in Chapter 5. This study was an exploratory 
side study conducted on a subset of patients enrolled into the phase I dose-escalating study 
of oral telatinib. Our pharmacogenetic analysis could not reveal an association between 
relevant genetic polymorphisms and clinical and pharmacokinetic observations of telatinib. 
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Chapter 6 focuses on hypertension and rarefaction during treatment with telatinib. 
Hypertension is a side-effect in anti-angiogenic therapy. We performed measurements 
of blood pressure, flow-mediated dilatation (FMD), nitroglycerin-mediated dilatation 
(NMD), aortic pulse wave velocity (PWV), skin blood flux, and capillary density during 
treatment with telatinib. A significant increase in blood pressure and PWV, combined 
with a significant reduction in NMD, FMD, skin blood flux and capillary density are re-
ported. This study shows that the increase in blood pressure observed in the treatment 
with angiogenesis inhibitors may be caused by rarefaction, a functional or structural 
decrease in perfused microvessels.
The underlying mechanisms of bevacizumab (Avastin®) related hypertension are report-
ed in Chapter 7. Hypertension is a common side effect of bevacizumab, a monoclonal 
antibody directed at VEGF, and can lead to severe complications. We demonstrated 
that the decreased capillary density induced by bevacizumab treatment is reversible 
after discontinuation of the bevacizumab treatment. In combination with earlier results 
in VEGF tyrosine kinase inhibitor treatment, we also conclude that VEGF-associated 
rarefaction is a class-effect generated by all VEGF-inhibitors. These results implicate 
rarefaction, a decreased capillary density, as the most probable cause for hypertension 
in VEGF inhibition.
In Chapter 8, a phase I dose escalation study of sunitinib in combination with ifosfamide 
is reported. Patients with progressive solid tumors, good performance score, adequate 
organ function, and no standard therapy available, were eligible. Continuous once daily 
sunitinib, in escalating doses per cohort, was combined with one of two ifosfamide 
schedules, 3g/m2/days1-3 and 1.2g/m2/days1-5, both given intravenously every 3 weeks. 
Sunitinib co-administration did not affect the pharmacokinetics of ifosfamide or one of 
its metabolites. No consistent change in the number of circulating endothelial cells dur-
ing treatment was observed. Sunitinib at 12.5 mg/day with ifosfamide 3g/m2/days1-3, 
and sunitinib at 12.5 mg/day with ifosfamide 1.2g/m2/days1-5 every 3 weeks supported 
by G-CSF are tolerable in patients with advanced solid tumors. Grade 3/4 neutropenia 
was the most reported side effect, seen in 89% of patients (8/9) treated at the recom-
mended phase II dose. Neutropenia was uncomplicated in all but one patient (1/9).
A second phase I study of a new targeted agent is reported in Chapter 9. It involves 
a phase I dose-escalation study of the small-molecule pan-aurora kinase inhibitor 
danusertib. This dose escalation study was conducted to evaluate the safety and toler-
ability of danusertib, with additional pharmacokinetics, biomarker and efficacy assess-
ments. Dose limiting toxicity of danusertib is neutropenia (short lasting and generally 
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uncomplicated), with limited non-hematological toxicity. The recommended dose for 
subsequent phase II studies is 330 mg/m2 infused over 6 hours.
Chapter 10 reports the pharmacogenetics of danusertib. The aim of this exploratory 
side study was to identify possible associations between single-nucleotide polymor-
phisms (SNPs) in candidate genes with pharmacokinetic and pharmacodynamic param-
eters of danusertib. In patients with the FMO3 18281AA polymorphism, a significantly 
higher clearance was noticed, compared to patients carrying at least 1 wild type allele. 
For the variants in the genes encoding the transporters ABCB1, ABCG2, no relationships 
with danusertib clearance were found. Also for variants in the genes encoding the drug 
targets AURKA, AURKB, RET, FLT4, KDR and FLT3, no associations with neutropenia were 
observed. These findings make it unlikely that danusertib’s pharmacokinetics and phar-








In dit hoofdstuk worden de studies die in dit proefschrift worden beschreven samenge-
vat en bediscussieerd. Dit proefschrift richt zich op kankercel specifieke middelen, ofwel 
‘targeted anti cancer agents’, in solide tumoren. Farmacokinetiek, veiligheid, faramcody-
namiek en farmacogenetica van kankercel specifieke middelen, alleen of in combinatie 
met conventionele chemotherapie, wordt onderzocht. Daarnaast worden nieuwe thera-
pie mogelijkheden voor sarcomen bekeken. Hoofdstuk 1 geeft een algemene inleiding 
op het onderzoek beschreven in dit proefschrift.
Hoofdstuk 2 bespreekt de intracellulair werkende tyrosine kinase remmers, ofwel ‘small 
molecule tyrosine kinase inhibitors’, in de behandeling van solide tumoren. De nieuwste 
informatie over de intracellulair werkende tyrosine kinase remmers die al geregistreerd 
zijn voor behandeling of in een ver stadium van ontwikkeling zijn, wordt besproken. 
Daarnaast wordt de toekomstige rol van de intracellulair werkende tyrosine kinase rem-
mers in de behandeling van solide tumoren bediscussieerd.
Kankercel specifieke middelen zouden effectief kunnen zijn in veel verschillende soorten 
tumoren. Dit geldt mogelijk ook voor sarcomen, waarvoor nu slechts beperkte behan-
delmogelijkheden zijn. In Hoofdstuk 3 wordt het maken en analyseren van een weef-
sel micro-array bestaande uit 18 verschillende typen weke delen tumoren beschreven. 
Membraan aankleuring voor epidermale groeifactor 1 (EGFR; Her1) werd gezien in 
meerdere sarcoom subtypen, o.a. in liposarcomen, leiomyosarcomen, synoviosarcomen, 
maligne perifere zenuwschede tumoren, rhabdomyosarcomen, fibrosarcomen en angi-
osarcomen. Immunohistochemische aankleuring voor epidermale groeifactor 2 (ERBB2; 
Her2Neu) was afwezig in alle sarcoom subtypen. Ondanks het gegeven dat een bepaalde 
groei factor receptor bij immuunhistochemisch onderzoek aanwezig is op de celmem-
braan, hoeft dit niet altijd te betekenen dat de betreffende signaal transductie route 
geactiveerd is, of überhaupt een potentieel doel is voor behandeling. Onze resultaten 
bieden wel de mogelijkheid om het potentiële effect van EGFR remmers in sarcomen te 
gaan bestuderen. Tevens ondersteunt dit de resultaten van eerdere studies waarbij dui-
delijk is geworden dat Her2 geen potentieel doel is om behandeling in sarcomen tegen 
te richten.
Een fase I dosis escalatie studie naar de behandeling met telatinib wordt beschreven in 
Hoofdstuk 4. Telatinib (BAY 57-9352) is een orale tyrosine kinase remmer van VEGFR-2, 
VEGFR-3, PDGFR- β en c-KIT. Deze fase I dosis escalatie studie werd uitgevoerd om de 
veiligheid en verdraagzaamheid van telatinib te onderzoeken. Daarbij werd additioneel 
gekeken naar farmacokinetiek, farmacodynamiek en effectiviteit. Telatinib kon veilig 
worden gegeven zonder veel bijwerkingen tot een dosis van 1500 mg twee keer per dag. 
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Gebaseerd op farmakokinetiek en farmacodynamiek uitkomsten, is telatinib in een dosis 
van 900 mg twee keer per dag de aanbevolen dosis voor toekomstige fase II studies.
Farmacogenetisch onderzoek van telatinib wordt beschreven in Hoofdstuk 5. Dit is een 
onderzoek verricht in een deel van de patiënten die behandeld werden in de fase I studie 
met oraal telatinib. Onze farmacogenetische analyses konden geen associatie aantonen 
tussen relevante genetische polymorfismen en klinische uitkomsten of farmacokinetiek 
kenmerken van telatinib.
Hoofdstuk 6 richt zich op hypertensie en rarefactie, een functionele of structurele ver-
mindering van het aantal kleine capillairen en venulen, tijdens behandeling met telatinib. 
Hypertensie is een bijwerking in anti-angiogenese therapie. Wij verrichtten metingen 
gericht op bloeddruk, endotheel-afhankelijke vasodilatatie (flow-mediated dilatation; 
FMD), endotheel-onafhankelijke vasodilatatie (nitroglycerin-mediated dilatation; NMD), 
aorta pols golf snelheid (aortic pulse wave velocity; PWV), bloed flux in de huid en dicht-
heid van de capillairen tijdens behandeling met telatinib. Wij zagen een significante 
stijging in bloeddruk en PWV, gecombineerd met een significante daling in NMD, FMD, 
blood flux van de huid en dichtheid van de capillairen. Deze studie toont dat de stijging 
van bloeddruk tijdens de behandeling met angiogenese remmers veroorzaakt zou kun-
nen worden door rarefactie, een functionele of structurele vermindering van het aantal 
kleine capillairen en venulen.
Het onderzoek naar onderliggende mechanismen verantwoordelijk voor de hypertensie 
die vaak wordt gezien bij behandeling met bevacizumab (Avastin®), wordt beschreven 
in Hoofdstuk 7. Hypertensie is een vaak voorkomende bijwerking van bevacizumab, een 
monoklonaal antilichaam tegen VEGF, wat kan leiden tot ernstige complicaties. Wij zagen 
een daling in de dichtheid van de capillairen veroorzaakt door behandeling met beva-
cizumab die reversibel is na het stoppen van de bevacizumab therapie. In combinatie 
met de resultaten uit onze eerdere studie met een telatinib bevestigt dit het vermoeden 
dat de geïnduceerde verlaging van de dichtheid van de capillairen een klasse-effect is, 
veroorzaakt door alle VEGF remmers. Onze resultaten impliceren dat rarefactie, een ver-
mindering van het aantal kleine capillairen en venulen, het belangrijkste proces is dat 
ten grondslag ligt aan de hypertensie die wordt gezien bij het gebruik van angiogenese 
remmers. 
In Hoofdstuk 8 wordt een fase I dosis-escalatie studie van sunitinib in combinatie met 
ifosfamide beschreven. Patiënten met vergevorderde of uitgezaaide solide tumoren, 
goede conditie, goede orgaan functie, en geen beschikbare standaard behandeling kon-
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den worden geincludeerd. Continu 1 keer per dag gegeven sunitinib, in oplopende do-
seringen per cohort, werd gecombineerd met 1 van 2 ifosfamide schema’s, namelijk 3 g/
m2/dag1-3 of 1,2 g/m2/dag1-5, intraveneus toegediend, elke 3 weken. Het bijgeven van 
sunitinib beïnvloedde de farmacokinetiek van ifosfamide of van diens metabolieten niet. 
Er werd geen consistente verandering gezien in het aantal circulerende endotheelcellen 
tijdens de behandeling. Sunitinib in een dosis van 12,5 mg per dag gecombineerd met 
ifosfamide 3 g/m2/dag1-3 en sunitinib 12,5 mg/dag in combinatie met ifosfamide 1,2 g/
m2/dag1-5 elke 3 weken ondersteund met granylocyten-groeifactoren (G-CSF) wordt 
goed verdragen door patiënten met vergevorderde solide tumoren en is de aanbevolen 
dosis voor toekomstige fase II studies. Graad 3-4 neutropenie was de meest voorko-
mende bijwerking gezien in 89% van de patiënten (8 van de 9) die werden behandeld 
met de aanbevolen dosis voor toekomstige fase II studies. Neutropenie verliep in bijna 
alle patiënten ongecompliceerd (8 van de 9 patiënten).
Een tweede fase I studie betreffende een nieuw kankercel specifiek middel wordt be-
schreven in Hoofdstuk 9. Het betreft een fase I dosis-escalatie studie met de aurora 
kinase remmer danusertib (PHA-739358) in patiënten met vergevorderde of uitgezaaide 
solide tumoren. Danusertib is een intracellulair werkende pan-aurora kinase remmer. 
Deze dosis-escalatie studie werd uitgevoerd om de veiligheid en verdraagzaamheid van 
danusertib te onderzoeken, en daarnaast te kijken naar farmacokinetiek, biomarkers 
en effectiviteit. De dosis limiterende bijwerking van danusertib is neutropenie, welke 
kortdurend is en meestal ongecompliceerd verloopt, met verder nauwelijks niet-hema-
tologische bijwerkingen. De aanbevolen dosis voor verdere fase II studies was 330 mg/
m2 geïnfundeerd in 6 uur.
Hoofdstuk 10 beschrijft de farmacogenetica van danusertib. Het doel van deze studie 
was mogelijke associaties tussen geselecteerde genetische polymorfismen en farmacoki-
netische of farmacodynamische kenmerken van danusertib te onderzoeken. In patiënten 
met het FMO3 18281AA polymorfisme werd een significant hogere klaring van danuser-
tib gezien, in vergelijking met patiënten die tenminste 1 wildtype allel dragen. Voor de 
varianten in de genen coderende voor de transporters ABCB1 en ABCG2, werd geen as-
sociatie met de klaring van danusertib gezien. Voor varianten in de genen coderend voor 
AURKA, AURKB, RET, FLT4, KDR en FLT3 werd geen associatie met neutropenie gevonden. 
Deze uitkomsten maken het erg onwaarschijnlijk dat de farmacokinetiek en farmacody-
namiek van danusertib beïnvloed wordt door farmacogenetische variaties.
Hoofdstuk 11 geeft de algemene discussie weer en de toekomstperspectieven van de 
kankercel specifieke middelen. De ontwikkeling en registratie van kankercel specifieke 
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middelen gaat opmerkelijk snel. Helaas lijken de meeste kankercel specifieke middelen 
niet zo’n goed effect te hebben als men verwachtte. De hoop was dat wanneer cruciale 
receptoren en signaaltransductie routes konden worden geremd, proliferatie van kan-
kercellen kan worden geblokkeerd en kanker daarmee een chronisch verlopende ziekte 
zou worden. Het feit dat de effectiviteit van de meeste kankercel specifieke middelen 
beperkt is in ongeselecteerde patiënten benadrukt dat verder onderzoek zich o.a. moet 
richten op het selecteren van die subgroepen patiënten die het meeste baat hebben van 
deze middelen. Het onderzoeken van voorspellende receptor polymorfismen of tumor 
subtypen met specifieke overactiviteit van bepaalde signaaltransductie routes kunnen 
helpen om dit doel te bereiken.
De bijwerkingen van deze nieuwe en specifieke middelen kunnen soms zeer ernstig zijn 
en verlopen vaak heel anders dan bij de bekende conventionele chemotherapeutische 
behandeling. Daarom is aanhoudend onderzoek naar nieuwe effectieve anti-kanker mid-
delen, naar bijwerkingen van bekende en nieuwe middelen, en naar manieren om bij-
werkingen te voorkomen of te beperken noodzakelijk. Vele reeds afgeronde klinische 
studies met translationeel onderzoek hebben intussen het inzicht en de ervaring met 
kankercel specifieke middelen vergroot. 
In de komende jaren zal het gebruik van kankercel specifieke middelen ongetwijfeld 
enorm gaan toenemen. De indicaties zullen mogelijk uitbreiden tot bijna elke vorm van 
kanker, in gemetastaseerde en adjuvante situaties, en in combinatie met andere kan-
kercel specifieke middelen of in combinatie met chemotherapie. Vele klinische onder-
zoeken zijn al opgestart met het doel uit te zoeken welke (combinaties van) middelen 
in specifieke patiëntengroepen het grootste te verwachten effect hebben en dus verder 
onderzocht zouden moeten worden. Dit proefschrift beschrijft een klein aantal van vele 
studies die de kennis over kankercel specifieke middelen zal vergroten, over hoe deze 
middelen te gebruiken en aan wie ze voor te schrijven, in de hoop de levensverwachting 






Dit proefschrift is het resultaat van de inspanning en hulp van vele mensen. Als eerste 
wil ik de patiënten bedanken die meegedaan hebben aan deze studies. Zonder hun hulp 
had dit onderzoek nooit verricht kunnen worden.
Ik wil alle mensen van de afdeling oncologie bedanken die mij hebben bijgestaan en 
geholpen. Vydia, Ariënne, Ellie, Marjolein jullie hebben mij in de zoek naar statussen 
en afspraken altijd weer geholpen. Jan, Margret zonder jullie hulp bij de instructie 
en begeleiding van patiënten, het verzamelen van alle monsters en data en de hulp 
met de altijd weer opdoemende SAE’s had ik het nooit gered. Judith, Ellen, Saskia jul-
lie hebben me geholpen om de combinatie van dit onderzoek en mijn opleiding tot 
internist-oncoloog te kunnen combineren. Vincent, Peter-Paul zonder de steun (en de 
drankjes op vrijdag) had ik een hoop vreugde moeten missen de laatste jaren. Hans, je 
bent fantastisch geweest. Je hebt me daar laten gaan waar ik wilde gaan en me altijd 
geholpen. Dank je! Ook mijn beide promotores dank ik hartelijk voor de fantastische 
begeleiding.
Buiten de afdeling oncologie waren er ook velen wiens hulp ik niet had kunnen missen. 
Jos, bedankt voor de goede gesprekken, voor de hulp zelfs tijdens je vakanties en carna-
val. Judith, je hebt me helemaal ingewijd in de wereld van de farmacogenetica. Zonder 
probleem vond je altijd weer de tijd om me te helpen en dingen uit te leggen. Tahar, 
dank je voor alle analyses (soms zelfs in duplo). Ron, je hebt me een hele andere kijk 
gegeven op reviewers, publicaties en editorial boards. Hierbij wil ik natuurlijk ook alle 
andere co-auteurs bedanken voor de vele uren die zij hebben besteed om dit proefschrift 
mogelijk te maken.
Daphne, Elise, Jacq, Hanneke, Ruth, Valeska, de etentjes, high tea, het beachvolleybal, 
het heeft me op de been gehouden. Bianca, Nicole, Yvette zonder die uren praten op 
onze weekenden en gewoon tussendoor was ik allang gestrand. Cindy en Martha, mijn 
paranimfen. Jullie zijn geweldig. Cin, ik hoop dat wel altijd onze verhalen kunnen blijven 
delen en we ooit nog een keer naar de Boney M gaan. Martha, ook jij kent al mijn gehei-
men en hopelijk blijft dit voor altijd. Joost, ik hoop niet dat we nog vaak zullen zeggen: 
’Het is al weer veel te lang geleden’. Ik mis je.
Hierbij moet ik ook mijn mede Veglo bestuursgenoten bedanken voor het feit dat ze 
het al jaren met me uithouden ook tijdens mijn opleidings- en promotie stress. Dit geldt 
waarschijnlijk nog veel meer voor mijn badminton-teamgenoten. Dank jullie dat ik mijn 
agressie af en toe (op de baan) bij jullie kwijt kon. 
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Lieve familie, dank jullie voor alle steun. Helma, je bent de beste schoonzus die ik ooit 
zou kunnen wensen. Geert, Twan misschien mag ik nu af en toe mee een potje squashen? 
Elly, Harry, mijn lieve papa en mama, jullie hebben me gemaakt tot wie ik nu ben. Jullie 
weten zo goed wie ik ben, dat het niet nodig (en onmogelijk) is dat hier te verwoorden.
Jasper, Thomas, Koen, mijn mannetjes, jullie maken de wereld zo mooi.
Ton, jou wil ik het allermeest bedanken, voor je liefde, je motivatie, je hulp om altijd weer 
een oplossing te zoeken. Dank je voor de momenten waarop je zorgde dat ik gewoon 
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